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 A. Summary 
 
A. Summary 
 
Herpesvirus infections are usually asymptomatic or associated with mild 
symptoms. Fatal diseases are seen in immune suppressed and immune 
incompetent individuals. Although herpesviruses are of emerging medical 
importance nowadays an infection only can be controlled by 
chemotherapeutics, which target viral DNA replication and cause negative side 
effects. Essential steps of herpesvirus morphogenesis might indicate new 
targets for interference. 
The export of the 110 nm large herpesvirus nucleocapsid from the cell nucleus 
is a logistic problem, because such a cargo exceeds the size tolerated by the 
nuclear pore complex. Two conserved herpes simplex virus 1 proteins, UL31 
and UL34, form a complex at the inner nuclear membrane and govern nuclear 
egress of herpesvirus nucleocapsids. In mouse cytomegalovirus (MCMV), a 
member of the beta-herpesvirus subfamily, the homologous proteins M53/p38 
and M50/p35 form the nuclear egress complex (NEC). The interaction of these 
proteins is essential for the virus and might serve as a potential drug target.  
Here we describe a saturating random mutagenesis procedure for the UL31 
homologue M53/p38. From a total of 498 individual mutants 72 were reinserted 
into the genome to test virus complementation. The analysis revealed that the 
N- terminus of M53/p38 provides the nuclear localization signal (NLS). The 
M53/p38 binding site for the NEC partner M50/p35 was located to aa 112-137. 
No single aa exchange for alanine could destroy NEC formation but virus 
attenuation revealed a major role for the aa K128, Y129, and L130. Further, the 
lethal phenotype of several insertion and stop mutants indicated the functional 
importance of the C-terminus of the protein, which might serve to construct 
dominant negative mutants. 
The interference of herpesvirus proteins with unknown cellular functions is of 
emerging interest. MCMV nucleocapsid formation is followed by a complex 
process of nucleocapsid transitions through cellular membrane barriers. The re-
organization of the nuclear architecture by viral proteins probably involves the 
interaction with host cell proteins. Here, we found that the NEC of MCMV 
interacts with an important inner nuclear membrane protein complex, the lamin 
B receptor, which controls nuclear membrane stability. Thus, herpesviruses 
might target major cellular principles that govern nuclear integrity. 
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1. The cytomegaloviruses as family members of the herpesviruses 
 
Based on their structural and biological properties the cytomegaloviruses (CMV) 
form the β-subfamily of the herpesviridae. To date more than 120 herpesvirus 
species have been identified in mammals. Herpesviruses possess a large 
double stranded DNA-genome with high coordination capacity, which is 
surrounded by a capsid and an envelope. The genomes of herpesviruses differ 
in size and in GC-content. The GC-content varies between 32% in canine 
herpesvirus and 75% in herpesvirus simiae. Genome size varies between 125 
kbp for Varicella Zoster Virus (VZV) and approximately 230 kbp for 
cytomegaloviruses (HCMV and MCMV, respectively) with a coding capacity of 
approximately 200 proteins (Chee, 1990; Rawlinson, 1996; Varnum, 2004; 
Tang, 2006). The ORFs code for structural components, virus-specific enzymes 
and factors, which are involved in nucleic acid synthesis and nucleotide 
metabolism (Roizman, 2001). Furthermore, a variable number of genes are 
involved in modulation of host defense. 
A characteristic feature of all herpesviruses is the ability to persist lifelong in the 
infected host without inducing chronic symptoms. In this stage, called latency, 
the virus genome persists circular in the cell nucleus and gene expression is 
almost totally abrogated. Latent viruses usually remain undetectable by 
virological means until reactivation occurs. Then, lytic virus-replication is 
frequently accompanied by destruction of the host cell, which leads to 
symptomatic infection of susceptible hosts. 
Based on host range, duration of replication cycle and cell tropism 
Herpesviridae can be further divided into the three subfamilies 
alphaherpesvirinae, betaherpesvirinae and gammaherpesvirinae. (Regenmortel, 
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2004). The α-herpesviruses exhibit a broad host range, a short replication cycle 
and the capacity to establish latency in neuronal cells of sensory ganglia. The 
most prominent members of the α-herpesvirus subfamily are herpes simplex 
virus type 1 and 2 (HSV-1; HSV-2) and varicella zoster-virus (VZV). The name 
of the whole virus family derived from the creeping skin lesions that are caused 
by HSV infection (Greek-herpein= creep). In contrast to the α-herpesvirus 
subfamily the β-herpesviruses are characterized by their restricted host range 
(species specificity) and long replication cycle. The main representatives of this 
subfamily are the cytomegaloviruses which derives its name from its 
characteristic feature that infected cells frequently are enlarged (cytomegalia) 
and exhibit cytoplasmic and nuclear inclusion bodies (owl eyes). Besides 
murine cytomegalovirus (MCMV) and human cytomegalovirus (HCMV) the 
human herpesviruses 6 and 7 (HHV-6, HHV-7) can also be grouped into this 
subfamily. Like β-herpesviruses the γ-herpesviruses also have a restricted host 
range but exhibit replication cycles that vary by species. The γ-herpesviruses 
preferentially infect cells of the lymphatic system, like B- and T-lymphocytes. 
Prominent members of this subfamily are the Epstein-Barr virus (EBV) and the 
human herpesvirus 8 (HHV-8) (Mocarski, 2001; Roizman, 2001). 
 
 
1.1 Biology of CMV infection and host immune defense 
 
After infection of the host the virus spreads in the whole organism by blood 
transport with phagocytotic cells (Stoddart, 1994). CMV can replicate in 
epithelial- and endothelial cells of different organs (e.g. kidney, salivary glands, 
liver, cortex of adrenal glands, lung, intestines, heart, bone marrow and spleen). 
After a mostly asymptomatic primary acute infection CMV persists lifelong in the 
host. Reactivation can be induced by endo- and exogenous stress factors or 
immunosuppression (Krmpotic, 2003; Mocarski, 2001). Cells that carry latent 
virus genomes are presumably undifferentiated dentritic- and myeloid precursor 
cells of the monocyte-macrophage-system (Soderberg-Naucler, 1997; Hahn, 
1998). During the latent phase of infection with the exception of CMV latency-
associated transcripts (CLTs) no further viral genes are expressed within the 
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ie1/ie2- gene region (Kondo, 1996). This prevents exposition of viral antigens to 
the host immune defense. In the animal model it has been shown that MCMV 
infection is predominantly controlled by MHC-class-I restricted CD8+ cytotoxic 
T-lymphocytes (CTLs) immune response (Jonjic; 1990; Reddehase, 1985, 
1988). Until now several CMV-genes have been described interacting with the 
host immune system, thereby modulating and evading host defense (Wagner, 
2002; Thale, 1995; Kleijnen, 1997; Ziegler, 1997; Reusch, 1999; Ziegler, 2000; 
Jones, 1996, 1997; Ahn, 1996, 1997; Hengel, 1999; Menard, 2003; Mocarski, 
2002; Alcami, 2000; Arase, 2002; detailed overview: Koszinowski and Hengel, 
2002; Krmpotic, 2003). 
 
 
1.2 Transmission and clinical relevance of human cytomegalovirus 
(HCMV) 
 
Based on its strict species specificity HCMV only can infect humans. Depending 
on social status and geographic properties between 40-100 % of the adult 
population is infected with this virus (Britt and Alford, 1996; Landolfo, 2003). In 
developing countries these epidemiological numbers can peak up to 100 %. 
The virus can be spread by saliva and mother’s milk but also by virus-
contaminated blood or urine. Furthermore virus transmission by sexual contact 
is possible (Britt and Alford, 1996, Landolfo, 2003). In humans with an intact 
immune system the primary infection is usually asymptomatic although 
mononucleosis and hepatitis can occur. In contrast, HCMV can provoke fatal 
disease in immuno-suppressed-(e.g. AIDS-patients, bone marrow- and organ-
transplanted individuals) and non-immuno-competent individuals (e.g. newborn) 
after primary infection or reactivation from latency (Landolfo, 2003; Mocarski, 
2001). Here, CMV infection can cause retinitis, encephalitis, pneumonitis, 
hepatitis or colitis. During pregnancy intrauterine HCMV infection can cause 
damage to the fetus or abortion. Congenital infection can lead to damage of the 
central nerve system (microcephaly, chorioretinitis), deafness, 
thrombocytopenia, hemolytic anemia or hepatosplenomegaly (Stagno, 1982; 
1986; Boppana, 1992). Congenital infection occurs in 1% of newborns and 
causes symptoms in 15% of infected children. So far, no effective vaccine 
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against HCMV is available. Almost all drugs used against HCMV are nucleoside 
analogues which target the DNA polymerase as a key enzyme for viral DNA 
replication (Coen, 2003). 
 
 
1.3 Mouse cytomegalovirus (MCMV) as animal model for HCMV infection 
 
The strict species specificity of CMV prohibits analysis of HCMV infection in an 
animal model. Therefore, the analysis of the entire spectrum of HCMV infection 
biology needs closely related animal viruses that can serve as laboratory 
models. CMV in mice, rats or guinea pigs provide models. MCMV and HCMV 
are closely related concerning gene homology and both exhibit a high similarity 
of infection-biology and pathogenesis. Therefore, the most frequently used 
animal model to study HCMV infection in vivo is the MCMV infection of mice. As 
described for HCMV the infection with MCMV can be controlled and leads to 
virus-latency in immuno-competent mice (Hudson, 1979). In contrast, infection 
of immuno-suppressed mice results in lethal diseases like pneumonia, hepatitis 
or inflammation of the cortex of adrenal glands (Krmpotic, 2003; Mayo, 1977, 
Reddehase, 1985). Furthermore, it has been shown that MCMV can be 
reactivated from the latent stage (Reddehase, 1994; Krmpotic, 2003). 
Altogether, the MCMV model system enables, by analysis of MCMV-mutants in 
the biological context, the identification of unknown pathogenesis-mechanisms 
of HCMV-infection. 
 
 
2. Structure of cytomegaloviruses 
 
All members of the herpesvirus family share morphological characteristics. 
Mature virions range between 120- and 300 nm in diameter and consist of four 
distinct elements: core, capsid, tegument and envelope (Fig. 1, Roizman, 2001). 
The viral core consists of linear, double stranded DNA, which is surrounded and 
most likely stabilized by a proteinaceous scaffolding matrix. The core is 
encased by a capsid, which is built from 12 pentameric- and 150 hexameric 
capsomers, arranged in a T=16 icosohedral lattice forming the protein shell and 
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ranges between 100-110 nm in diameter. Both, core and capsid form the 
nucleocapsid. Nucleocapsids are embedded into the tegument that consists of 
an amorphous electron-dense matrix of 20 to 30 different proteins. The 
tegument is presumed to be involved in early gene transcription after virus 
entry. Capsid and tegument are enveloped by a lipid bilayer that originates from 
the host cell. Virus encoded spike-like glycoproteins are embedded into the 
envelope. These allow virus attachment to host cell receptor structures and are 
responsible for virion-host cell membrane fusion during virus entry (Mocarski, 
2006). 
 
 
 
 
 
 
 
 
Figure 1. Structure of a herpesvirus virion. (Left) Electron micrograph of a herpes simple 
virus type 2 (HSV-2). The virion is approximately 180 nm in diameter. (Right) Schematic 
diagram of a herpesvirus virion showing the lipid envelope that is studded with at least 10 
glycoproteins originating from virus. The tegument comprises at least 15 viral proteins and the 
linear double-stranded genome is encased by an icosahedral capsid. Adapted from Flint 
(Principles of virology), first edition, 2000. 
 
During human CMV infection besides intact virions non-infectious virus particles 
are also built. These structures designated as “dense bodies” are located in the 
cytoplasm of the infected cell and possess neither viral DNA nor capsid but 
consist mainly of viral tegument protein pp65 (Irmiere, 1983). Furthermore, to a 
minor extent non infectious enveloped virus particles are built that possess a 
capsid but no viral genome. In contrast to HCMV the murine cytomegalovirus 
(MCMV) forms no “dense bodies” but virions with multiple capsids (Chong, 
1981). 
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3. Replication of cytomegaloviruses 
 
Like for all herpesviruses the replication cycle of HCMV and MCMV is strictly 
regulated. CMV entry into host cell starts with adsorption of the virion on the cell 
surface (Fig. 2). This is mediated by interaction of viral glycoproteins to their 
corresponding surface receptors and leads to fusion of virus- and host 
membranes and delivery of the nucleocapsid to the cytoplasm of the host cells 
(Spear, 2003, 2004). HCMV is estimated to carry 20 viral integral membrane 
proteins (Mokarski, 2006). Five glycoproteins, gB, gH, gL, gM and gN are 
broadly conserved among the herpesvirus family. For most human 
herpesviruses cell surface proteoglycans like heparan-sulfate have been shown 
to play a role for initial contact with the cell, e.g. in alpha- (HSV-1, VZV), beta- 
(HCMV, HHV-6A, HHV-6B, HHV-7) and gammaherpesvirus (KSHV/HHV-8) 
subfamilies (Spear, 2003, 2004). Consistently, herpesviruses often exhibit a 
broad cell tropism for virus attachment- and entry steps. After virus entry 
nucleocapsids are transported to the nuclear pores, followed by release of the 
viral DNA to the nucleus and its circularization (Dohner, 2004; Smith, 2002; 
Welte, 2004). Viral gene expression is regulated in cascades. Three phases of 
gene expression are distinguished: immediate early (IE)-, early (E)- and late (L)-
gene expression (Mocarski, 2001). The immediate early gene expression is 
initiated as soon as the viral genome enters the nucleus of the permissive cell. 
For the transcription of IE genes no de novo synthesis of viral proteins is 
needed. Parts of the transcripts have been suggested to originate from previous 
infections and to be transferred to the new host by viral tegument proteins 
(Bresnahan, 2000). IE proteins regulate the induction of early (E) genes 
expression (Mocarski, 1996). Early gene activation occurs mainly on the 
transcriptional level and expressed proteins are necessary for replication of the 
viral genome. For herpesvirus DNA replication two potential mechanisms are 
discussed. One model suggests analogous to bacteriophage lambda the 
replication of DNA as rolling circle (Boehmer, 1997, 2003). More recently, a 
recombination-dependent branching mechanism analogous to T-even 
bacteriophage replication was suggested (Wilkinson, 2003, 2004; Jackson, 
2003). The start of DNA replication defines initiation of the late (L) phase. In this 
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period of infection predominantly structural proteins are expressed, which are 
components of the virion or involved in virus assembly. DNA replication results 
in production of multi-genomic length concatemeric intermediates, which are 
cleaved down to genome length units during packaging into capsids (McVoy, 
1994; Mocarski, 2001; Bogner, 2002; Schynts, 2003). It is suggested that 
nucleocapsids are actively transported in the nucleus and unify with a set of 
primary tegument proteins at the inner nuclear membrane (INM) (Forest, 2005; 
Klupp, 2006; Kotsakis, 2001; Wolfstein, 2006; Baldick, 1996). 
Nucleocapsid export involves a complex process of nucleocapsid transitions 
through cellular membranes. This egress mechanism of the nucleocapsid out of 
the nucleus and acquisition of the viral envelope is discussed controversially. 
The single envelope theory assumes that the viral envelope corresponds to the 
outer nuclear membrane (ONM) and is already acquired at the stage of capsid 
egress from the nucleus (Wild, 2005; Leuzinger, 2005). The de- and re-
envelopment model assumes that viral nucleocapsids acquire a first envelope 
by budding through the inner nuclear membrane (Fig. 2 and 4). Then 
nucleocapsids bud from the inner nuclear membrane (INM) into the space 
between INM and outer nuclear membrane (ONM). This process is termed 
primary envelopment. Next, viral particles fuse with the outer leaflet of the 
nuclear membrane or ER, thereby loosing their primary envelope. Naked, 
premature virions are then released to the cytoplasm where a second 
tegumentation step and transport of the virions to the trans-Golgi-network takes 
place. Viral envelope proteins are assumed to be processed during transition 
through ER and the trans-Golgi-network (Enquist, 1998; Mettenleiter, 2002, 
2004; Gershon, 1994). A secondary envelopment occurs at a not yet clearly 
defined compartment. It has been suggested that the second envelopment of 
the virions occurs after transit through the trans-Golgi-network by fusion with 
Golgi-derived vesicles that traverse through the cytoplasm to the plasma 
membrane of the cell, where the mature virions are released into the extra-
cellular space by exocytosis (Gershon, 1994; Skepper, 2001; Mettenleiter, 
2002, 2004, 2006). 
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Figure 2. Herpesvirus replication. 
Viral envelope glycoproteins mediate 
attachment and fusion with the cellular 
membrane. This leads to release of 
capsid encased viral DNA (red 
hexagons) into the cytoplasm and 
capsid transport to the nucleus. Next, 
viral DNA enters the nucleus by 
transfer through the nuclear pore-
complex and circularises. 
Transcription of viral genes is 
regulated in a timed, cascaded 
fashion. Immediate early (IE) proteins 
(orange) exhibit mainly regulatory 
functions and are responsible for 
induction of ´early´ (E) gene 
expression. E-proteins are necessary 
for viral replication (green). Late viral 
proteins (L, blue) are involved in late 
maturation events, e.g. capsid 
formation, DNA- packaging, and 
egress. Nucleocapsids bud through 
the nuclear envelope by enveloping- 
and de-enveloping events and 
traverse the cytoplasm to the trans-
golgi-network, where virions mature. 
Mature virions reach the plasma 
membrane of the cell by exocytosis 
and are released to the extra-cellular 
space. Adapted from Coen, 2003. 
 
Transport through the nuclear envelope of the cell poses a major logistic 
problem during herpesvirus morphogenesis. 
 
 
4. The nuclear envelope 
 
The nuclear envelope (NE) separates the cytoplasm from the nucleoplasm (see 
also reviews: D´Angelo, 2006; Gruenbaum, 2005; Foisner, 2001). It is 
composed of four domains: the outer nuclear membrane (ONM), the inner 
nuclear membrane (INM), the perinuclear space and the nuclear lamina (Fig. 3). 
The outer nuclear membrane is continuous with the rough endoplasmic 
reticulum (rER) and studded with ribosomes (D´Angelo, 2006). ONM and ER 
protein contents are similar in composition. Furthermore, the outer nuclear 
membrane provides attachment sites for structural elements of the cytoplasm. 
The perinuclear space is located between the outer- and the inner nuclear 
membrane and is continuous with the ER lumen, which enables molecules to 
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passively diffuse between the two compartments. The inner nuclear membrane 
harbors a unique set of membrane-associated- and integral proteins that link 
the nuclear membranes with nuclear lamina (NL) and chromatin (Ch) (Foisner, 
2001; Chu, 1998). INM and outer nuclear membrane fuse at sites where nuclear 
pore complexes (NPC) span the nuclear envelope. NPCs are large protein 
assemblies with a estimated complex mass of around 125 MDa in metazoa. 
They are mediators of nucleo-cytoplasmic trafficking of soluble macromolecules 
(for review see: Tran, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic diagram of the nuclear envelope showing nuclear membranes, 
nuclear pore complex, nuclear lamina and chromatin structures. Integral INM proteins, 
associated proteins and their topology are depicted: Lamin B receptor (LBR/ p58) as complex, 
Emerin, MAN1 and lamina-associated polypeptides (LAPs), heterochromatin protein-1 (HP1), 
barrier-to-autointegration factor (BAF), A- and B-type lamins and HA95. Adapted from Foisner, 
2001. 
 
The nuclear lamina of higher eukaryotes underlines the INM and composes a 
dense meshwork of intermediate filaments made of lamin proteins and lamin 
associated proteins. The lamina, which has a depth of 20-80 nm provides a 
skeletal framework and attachment sites for chromatin and is therefore essential 
for nuclear integrity. 
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4.1 The lamin proteins 
 
Lamins are type-V-intermediate filament proteins that consist of a globular 
amino-terminal ´head´ domain, a long α-helical coiled coil ´rod´ domain and a 
globular carboxy-terminal ´tail´ domain. The ´rod´ domain mediates lamin 
dimerisation. Head-to-tail polymerization and assembly of higher order is 
mediated by head- and tail domains (Herrmann, 2003). Based on their 
biochemical properties and behavior during mitotic events nuclear lamins are 
grouped in A- and B-type lamins (Moir, 2000). A-type lamins (A, C, A∆10 and 
C2) are widely expressed in differentiated cells (D´Angelo, 2006). They arise 
from a single gene (LMNA) by alternative-spliced mRNA. Human lamins A and 
C are identical for their N-terminal 566 amino acids but possess different C-
terminal endings (Muchir, 2004). Mature A-type lamins are obtained by initial C-
terminal isoprenylation of prelamin A, which is then endoproteolytically cleaved 
by a metalloproteinase. Lamins C and C2 remain unmodified (Weber, 1989; 
Leung, 2001). The A-type lamins are presumably incorporated into the nuclear 
lamina at later time points of post mitotic nuclear assembly than B-type lamins. 
The B-type lamins are lamin-B1 and B2, which are encoded by the 
corresponding LMNB1- and LMNB2 genes. During development B-type lamins 
are expressed in all somatic cells (Muchir, 2004). Post-translational 
isoprenylation enables B-type lamins to attach to the INM during interphase and 
to remain attached to INM during mitotic disassembly of the NE (Gruenbaum, 
2005). Although A-and B-type lamins are stable components of the nucleus it is 
unclear how they are organized. During telophase and early G1 phase lamins 
are mobile and have a half-life of about 30 min. Due to lamin polymerization in 
interphase lamins are almost immobile and have a prolonged half-life of 3 hours 
(Moir, 2000). The dynamic properties are regulated by lamin-binding proteins 
and post-translational modification (e.g. phosphorylation by cellular or viral 
kinases or de-phosphorylation). Several human diseases, like striated muscle 
diseases (e.g. Emery-Dreifuss muscular dystrophy), lipodystrophy syndromes, 
peripheral neuropathies (e.g. Charot-Marie-Tooth disorders) or premature aging 
syndromes (e.g. Hutchinson-Gilford progenia) can be linked to mutations in 
lamin A- and C-genes (Muchir, 2004; Sullivan, 1999; Wilkie, 2006). 
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4.2 Proteins and protein complexes interacting with lamins 
 
Lamins bind in vitro to a number of INM proteins, including LBR (lamin B 
receptor-complex), emerin, MAN1, lamina-associated polypeptides-1 and –2β 
(LAP1, LAP2β) and nesprin-1α (Foisner, 2001; Zastrow, 2004) (Fig. 3). They 
also bind chromatin proteins (histone H2A or H2B dimers), soluble lamina-
associated polypeptide-2α (LAP2α), actin, barrier-to-autointegration factor 
(BAF), sterol-response-element-binding protein (SREBP), retinoblastoma 
protein (RB), Kruppel-like protein (MOK2) and presumably also to components 
of the RNA-polymerase-II-dependent transcription- and DNA-replication 
complexes (for review see Muchir, 2004; Schirmer, 2005; Gruenbaum, 2005). It 
is suggested that lamins and lamina associated proteins are functionally 
involved in chromatin organization, nuclear integrity, spacing of the NPCs and 
reassembly of nuclear components after mitotic events (D´Angelo, 2006). 
Moreover, multiprotein complexes that connect the nucleoskeleton and the 
cytoskeleton are proposed to be anchored by lamins via nesprins, UNC-83 and-
84 or ZYG-12 (Zhen, 2002; Malone, 2003; Gruenbaum, 2005; Wilhelmsen, 
2006). DNA replication and RNA polymerase II- dependent transcription is 
affected by alteration of nuclear lamin organization (Spann, 2002). 
 
 
4.2.1 The lamin B receptor-complex (LBR or p58) 
 
One of the best characterized lamin- and chromatin-binding membrane proteins 
is the human lamin B receptor (LBR) or p58 (Fig. 3). LBR is widely expressed in 
cells of higher eukaryotes and the human gene has recently been characterized 
(Schuler, 1994). The LBR or p58 is a 615-amino acid protein, which comprises 
a nucleoplasmic N-terminal domain of about 210 amino acids and a 
hydrophobic carboxy-terminal domain with eight putative transmembrane 
segments that integrate LBR into the INM (Chu, 1998; Worman, 1990; Ye and 
Worman, 1994). The membrane spanning domain of LBR has a sterol-
reductase activity and therefore may participate in steroid metabolism (Holmer, 
1998; Schuler, 1994). The N-terminal part contains phosphorylation sites for 
Cdc2 kinase and protein kinase A as well as arginine-serine (RS) motives that 
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were proposed to mediate protein-protein interactions between components of 
the splicing machinery (Courvalin, 1992; Simos, 1992;). LBR in vitro and in vivo 
binds to B-type lamins. This interaction remains stable during mitosis, when the 
nuclear envelope is fragmented and the lamina is depolymerized (Meier, 1994; 
Margalit, 2005). In vitro LBR binds to double stranded (ds) DNA and to histone 
H3-H4 tetramers. Furthermore, LBR interacts with chromatin-associated protein 
HA95 and heterochromatin protein-1 (HP1), which is suggested to mediate 
gene silencing (review: Chu, 1998; Foisner, 2001; Gruenbaum, 2005). Like for 
lamins, mutations in LBR are linked to human diseases, e.g. Pelger-Huet 
anomaly (PHA) (for review: Gruenbaum, 2005; Muchir, 2004). During 
interphase LBR is arranged as a multimeric complex with nuclear A- and B-type 
lamins, with a LBR kinase of 150 kDa (p150) that phosphorylates LBR and LBR 
associated proteins (p32), with an integral membrane polypeptide p18 of 
unknown function and with p32 (Simos, 1994; Nikolakaki, 1996, Deb, 1996). 
The p32 protein localizes in the mitochondrial matrix as well as in the nucleus, it 
has an acidic iso-electric point and forms homo-trimers that build a channel-like 
structure (Jiang, 1999; Sunayama, 2004; Muta, 1997). p32 has been associated 
with apoptosis and regulation of RNA splicing (Sunayama, 2004) and with 
splicing factor 2 (SF2) (Krainer, 1991). It is also recruited by viral functions 
although its function is not clear. The p32-protein interacts with the human 
immunodeficiency virus type 1 (HIV-1) trans-activator Rev that is required for 
viral replication (Luo, 1994). It was also shown that p32 interacts with 
adenovirus core protein V (Matthews, 1998) and represses adenovirus major 
late transcription (Öhrmalm, 2006). It interacts with herpesvirus saimiri open 
reading frame 73 gene (Hall, 2002). Recently, it has been shown that human 
cytomegalovirus kinase UL97 binds p32. The complex is then transferred to the 
nuclear envelope, where it interacts with LBR and associated lamins (Marschall, 
2005). Another LBR associated protein, the heterochromatin protein-1 (HP1) is 
also attacked by the viral machinery. HP1 binds LBR and interacts with histone 
1 (H1) and cross-links the NE with the chromatin (Daujat, 2005). The human 
polyomavirus agnoprotein interacts with HP1 and is responsible for HP1 
dissociation from the LBR and perturbation of the NE, which enables 
poliomavirus virions to egress from the nucleus (Okada, 2005). 
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4.2.2 LEM-domain proteins and BAF complexes 
 
The LEM domain, a motif of about 40 residues, is a characteristic feature of 
inner nuclear membrane proteins Emerin, LAP2 proteins, MAN1 and LEM2 (Fig. 
3). All LEM domain proteins interact with A- and/or B-type lamins in vitro. 
Moreover, these proteins have been shown to directly bind BAF (barrier to 
autointegration factor) (Lee, 2001, Shumaker, 2001; Lin, 2000; Furukawa, 1999; 
Segura-Totten, 2002, Chu, 1998; Mansharamani, 2004). LEM domain proteins 
are variable in length but, with the exceptions of MAN1 and LEM2, represent 
type II integral membrane proteins with a single membrane spanning domain 
close to the carboxy-terminus (Chu, 1998). MAN1 and LEM2 have two trans-
membrane segments (Lin, 2000; Brachner, 2005). The trans-membrane region 
is flanked by a nucleoplasmic domain that is responsible for lamin binding and 
amino-terminal by the LEM domain, which is responsible for chromatin binding 
(Chu, 1998; Muchir, 2004). Chromatin binding occurs not directly by LEM 
domain but is mediated by BAF (Margalit, 2005; Tifft, 2006). BAF is a conserved 
10 kDa protein that forms dimers and can be phoshorylated. These dimers bind 
LEM domain proteins and also to dsDNA, histone 3 (H3), histone 1.1, lamin A 
and transcriptional regulators (Bengtsson, 2006; Montes De Oca, 2005). LEM 
domain proteins can interact with other members of the protein family (e.g. 
MAN1 and emerin; Mansharamani, 2004). LEM domain proteins and the LBR 
complex are inter-connected by lamins and by HP1 and BAF with the 
chromatin. They form a network that is based on the integrity of lamin filaments 
and of the chromatin organization during interphase and mitosis (Gruenbaum, 
2005). But lamins, BAF and a number of LEM domain proteins (e.g. LAP2α) are 
also present in the nucleus as soluble proteins and involved in cell-cycle 
regulation, replication and transcription (Furukawa, 2003; Vlcek, 2002; 
Haraguchi, 2001, Dechat, 2004). Moreover, these proteins presumably have a 
scaffolding function for multi-protein complexes (Gruenbaum, 2005). MAN1 has 
been shown directly to bind to receptor-regulated SMAD proteins (R-SMAD) 
and other members of the TGFβ superfamily and to be involved in signal 
transduction (Osada, 2003; Dijke, 2004; Worman, 2005). Again, like for lamins 
or the LBR complex, mutations in LEM domain proteins can be linked to severe 
 
 - 14 - 
 
 B. Introduction 
 
disease, e.g. X-linked Emery-Dreifuss muscular dystrophy, which is caused by 
mutations in emerin (Muchir, 2004; Holaska, 2006). Recently, it has been 
shown that emerin is necessary for HIV-1 infection. HIV-1 cDNA associated with 
emerin in vivo. Furthermore, the LEM-domain protein with associated BAF was 
essential for cDNA integration into chromatin (Jacque, 2006). 
 
 
5. The egress of herpesvirus capsids from the nucleus 
 
The packaging of unit-length viral genomic DNA into pre-formed capsids takes 
place in the nucleus of the infected cell. Afterwards, the nucleocapsids have to 
leave the nucleus to access the cytosol where the mature virions are formed. 
The mechanism of this process, coined as nuclear egress, is to date intensively 
discussed (Mettenleiter, 2006; Klupp, 2006; Wild, 2005; Leuzinger, 2005). With 
more than 100 nm in diameter the size of a herpesvirus capsid exceeds the size 
tolerated by the nuclear pore complex (NPC), which mediates transport 
between nucleus and cytoplasm. One model suggests enlargement of the 
nuclear pores upon herpesvirus infection. Accordingly, capsids can use 
enlarged nuclear pores as a gateway for access to the cytoplasmic 
compartment (Wild, 2005; Leuzinger, 2005). Another, more accepted, model 
suggests that export of herpesvirus nucleocapsids requires a different strategy 
to penetrate the nuclear envelope: the budding of herpesvirus nucleocapsids 
through the nuclear envelope (Fig. 2, 4; Mettenleiter, 2002, 2004, 2006). In 
support for the second theory for HCMV or MCMV infected cells local nuclear 
membrane duplications and patches of wrapped viral capsids have been 
observed by ultra-structural analysis (Radsak, 1991; Rupp et al., manuscript in 
preparation). However, for capsids the inner nuclear membrane (INM) is not 
simply accessible, since it is stabilized by the nuclear lamina layer (NL). The 
nuclear lamina constitutes an orthogonal filamentous protein meshwork with a 
depth of 20-80 nm (Fig. 3). This lamina layer is only dissolved during mitosis 
due to lamin phosphorylation by specific cellular kinases (Gerace, 1980; 
Ottaviano, 1985; Otto, 2001; Peter, 1990; Dessey, 1988; Buendia, 2001). 
Virus maturation events are controlled by multi-protein assemblies which 
require the interaction of a number of viral and cellular proteins. For MCMV-
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infection it has been proposed that cellular protein kinase C is induced and 
recruited to the nuclear membrane. This is accompanied by phosphorylation of 
lamin B (Muranyi, 2002). Recently, the same has been confirmed for HSV-1 
infection. It was suggested that modification of the nuclear lamina promotes the 
budding event of the herpesvirus nucleocapsids (Park, 2006). But also other 
viral encoded protein kinases like UL13 and Us3 from HSV-1 or the UL13 
homologue BGLF4 from EBV have been linked to modulation of cellular 
activities and late virus maturation events (Kato, 2005, 2006; Kawaguchi, 2003; 
Klupp, 2001; Gershburg, 2006). 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Herpesvirus assembly and egress from the nucleus. Demonstrated by a diagram 
is the de-and re-enveloping model of herpesvirus nuclear egress. Viral gene products involved 
in specific egress reactions are indicated. Reactions are illustrated by corresponding electron 
micrographs of cells infected by α-herpesvirus pseudorabies virus (PrV). The nucleocapsid 
initially acquires an envelope by budding through the inner nuclear membrane. The enveloped 
nucleocapsid next fuses with the outer nuclear membrane and is released to the cytoplasm. In 
the cytoplasm the viral nucleocapsid acquires more tegument proteins and is transported to the 
trans-golgi-network. The final viral envelope is acquired upon budding of tegument associated 
capsid into a late compartment of the secretory pathway. Bar= 150 nm. Adapted from Flint 
(Principles of virology), first edition, 2000; and Mettenleiter, 2002, 2005, 2006. 
 
The HCMV UL97 gene is homologous to protein kinases of other α-, β- and γ –
herpesviruses (Chee, 1989; Rawlinson, 1997; Wagner, 2000). The UL97 gene 
product function has been linked to nuclear egress inasmuch as a UL97 
deletion mutation causes a 100-fold decrease in viral yield (Prichard, 1999; 
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Krosky, 2003; Azzeh, 2006; Prichard, 2005). Moreover, HCMV UL97 kinase is 
recruited by the cellular protein p32 to the nuclear envelope. This is thought to 
accumulate the p32-UL97 complex at the lamin B receptor complex for lamin 
phosphorylation (Marschall, 2005). 
 
 
5.1 The nuclear egress complex (NEC) 
 
Gene products involved in herpesvirus morphogenesis are often essential for 
viral growth. Studies in alpha-herpesviruses have shown that two conserved 
viral proteins, the prototypic UL31- and the UL34 gene products play a major 
role during primary envelopment (Klupp, 2000; Fuchs, 2002; Reynolds, 2001, 
2002; Roller, 2000; Neubauer, 2002). In the gamma-herpesvirus EBV the 
BFRF1 and BFLF2 gene products (Farina, 2000, 2005; Gonnella, 2005; Lake, 
2004) and in the beta-herpesvirus mouse cytomegalovirus (MCMV) the 
products of the M53- and M50 genes (Bubeck, 2004; Muranyi, 2002; Lötzerich, 
2006) or HCMV gene products UL53 and UL50 (Dal Monte, 2002, Marshall, 
2006) have this function. In MCMV both genes, the UL31 homologue M53/p38 
and the UL34 homologue M50/p35 are located within the same HindIII fragment 
H of the 230 kbp MCMV genome (Fig. 5). 
 
 
 
 
 
 
 
Figure 5. Schematic diagram of the M50/p35 and M53/p38 localization within the MCMV 
genome. (Top line) Hind III cleavage map of the 230-kb MCMV genome. (Second line) Position 
and transcriptional direction of M50/ p35 and M53/p38 within the HindIII fragment H. 
 
The UL34 and related proteins are type II membrane proteins, which circulate in 
the contiguous membranes of ER and INM (UL34, M50, UL50, BFRF1) unless 
the nuclear protein UL31 or UL31 related proteins (M53, UL53, BFLF2) arrest 
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them in the INM. Apparently the complex formation by the two proteins, coined 
the nuclear egress complex (NEC), is pivotal for nuclear egress of herpesviral 
nucleocapsids (Ye, 2000; Roller; 2000; Klupp, 2000; Gonnella, 2005; Farina, 
2005; Bubeck, 2004). 
The NEC executes this task by interacting with mostly unknown cellular protein 
partners, which already reside in or are recruited to the INM. For instance, HSV-
1 nuclear egress proteins UL31 and UL34 have been reported to bind lamins A 
and C in vitro. In addition, isolated expression of both proteins redistributed 
lamins A/C from the nuclear envelope to the nucleoplasmic compartment 
(Reynolds, 2003). Moreover, both HSV-1 NEC proteins are suggested to be 
involved in chromatin re-organization (Simpson-Holley, 2004). In MCMV 
infected cells M50/p35 recruits its viral interaction partner M53/p38 and cellular 
PKC to the INM (Muranyi, 2002). As described for MCMV and HSV-1 
recruitment of the protein kinase C to the NE is accompanied by 
phosphorylation of lamins and alterations of the nuclear lamina (Muranyi, 2002; 
Park, 2006). These interactions are thought to displace the rigid nuclear lamina 
for nucleocapsid budding (Farina, 2005; Gonnella, 2005; Muranyi, 2002; 
Bubeck, 2004). 
The MCMV-NEC (Fig. 6) interacts with further viral proteins. Nuclear M53/p38 
binds to M94, which is a MCMV-primary tegument protein that is associated 
with virus capsids (Ruzsics, unpublished observation). In addition, M51, another 
tegument associated protein was identified as an interaction partner of M53/p38 
by yeast two hybrid analysis (Fossum and Haas, unpublished data). Thus, 
M53/p38 might be an adaptor protein that links nucleocapsids and nuclear 
egress sites. 
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Figure 6. Proposed working model for egress of MCMV capsids from the nucleus-the 
MCMV-nuclear egress complex (NEC). (1) M50/p35 reaches the INM (inner nuclear 
membrane) of the nucleus by ER-diffusion and interacts with its viral NEC partner M53/p38. (2) 
The nucleocapsids acquire first tegument proteins. (3) The M50-M53 complex probably 
mediates nucleocapsid recruitment to the INM due to interaction of M53/p38 with capsid 
associated primary tegument. Viral MCMV-NEC proteins might also bind to several cellular 
proteins and presumably are involved in de-stabilization of the nuclear lamina or chromatin re-
organization. (4) Nucleocapsids bud into the nuclear envelope (NE) and are released to the 
cytoplasm after de- and re-envelopment steps. ER (endoplasmic reticulum); NPC (nuclear pore 
complex); La (lamina). 
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6. Aims and concepts 
 
The major aim of this work was to collect functional information about M53/p38 
that can be associated with the MCMV nuclear egress machinery. At the 
starting point of this work it was known that cellular PKC is recruited to the 
nuclear envelope upon MCMV infection resulting in phosphorylation of cellular 
lamins and destabilization of the lamina. M50/p35 and M53/p38 were assumed 
to be involved in this process (Muranyi, 2002). M50/p35 binds M53/p38 and this 
binding is essential for productive MCMV infection (Bubeck, 2004). In absence 
of any detailed structural and functional information for the detailed analysis of 
M50/p35 a random Tn7-based mutagenesis procedure at single gene level was 
established and combined with the BAC-technology. This approach enabled a 
comprehensive gene analysis of the isolated viral gene and of the gene in the 
viral context and the binding site in M50/p35 for M53/p38 was identified 
(Bubeck, 2004). However, efficiency of the random mutagenesis was poor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Analysis of the essential MCMV gene M53. (I) In vitro Tn7 based linker scanning 
mutagenesis of M53, DNA analysis of the transposon-inserted gene, transfection of mutated 
plasmids into eukaryotic cells and biochemical or cell biological assays upon isolated gene 
expression. (II) Re-insertion of mutated plasmids into the viral genome. (III) Virus reconstitution. 
Adapted from Bubeck, 2004. 
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Therefore, the first aim of this project was to establish an improved random Tn7 
based linker scanning mutagenesis (Biery, 2000) for M53/p38. As the first 
mutational analysis of a herpesvirus UL31 family member, for the MCMV M53 
gene a library of M53 insertion mutants was generated. A representative set of 
M53 mutants was re-inserted into the ∆M53-MCMV-BAC for functional analysis 
in the genomic context (Fig. 7). 
 
The interaction motives of UL34- and UL31-homologues are conserved among 
herpesviruses and prototypic UL31- and the UL34 gene products play a major 
role during primary envelopment (Klupp, 2000; Fuchs, 2002; Reynolds, 2001, 
2002; Roller, 2000; Neubauer, 2002). Thus, a next aim of this project was to 
characterize the interaction of M53/p38 with M50/p35 and to localize the 
sequence required for M50/p35 binding. 
 
A further aim of this work was to study the interaction of NEC proteins M50/p35 
and M53/p38 with proteins of the cellular nuclear envelope. Since nuclear 
egress is intensively discussed but to date not well characterized, this may help 
to elucidate ongoing viral- and cellular processes. It has been described for 
different viruses that nuclear egress presumably is induced by interaction of 
viral proteins with cellular components of the NE (Marschall, 2005; Okada, 
2005). Using pull-down assays after co-expression of the NEC proteins several 
cellular interaction partners of M50/35 and M53/p38 could be identified, which 
are mainly members of the LBR complex. 
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1. Material 
 
1.1 Devices 
 
Bacterial shaker (ISF-1-W) Kühner, Adolf AG, Birs-
felden, CH 
Bio-photometer      Eppendorf, Hamburg, D 
Centrifuges  AvantiTM J-20xp   Beckman Coulter  
      GmbH, Krefeld, D 
L8-55M ultracentrifuge Beckman Coulter GmbH, 
Krefeld, D 
Multifuge 3S-R Heraeus Instruments, 
Gera, D 
Biofuge Stratos  Heraeus Instruments, 
Gera, D 
   Centrifuge 5417 R   Eppendorf, Hamburg, D 
Confocal microscopes Leica DM IRB  Leica, Bensheim, D 
    Zeiss Axiovert 200M Zeiss, Jena, D 
Fluorescence microscope (1x71)    Olympus, Hamburg, D 
Developing-machine Optimax TR  MS Laborgeräte, 
Wiesloch, D 
Gel drying system (model 583)    Bio-Rad, Munich, D 
Gel air dryer       Bio-Rad, Munich, D 
Gene PulserTM      Bio-Rad, Munich, D 
Gradient former model 150 Gibco BRL, Gaithers-burg, 
MD, USA 
Incubator (B5050E)  Heraeus Instruments, 
Gera, D 
Incubator (BB16CU)  Heraeus Instruments, 
Gera, D 
Light-microscope (Axiovert 25)  Zeiss Carl AG, Goettin-
gen, D 
Mini-Protean 3 Cell      Bio-Rad, Munich, D 
PCR systems T Gradient     Biometra, Goettingen, D 
GeneAmp®PCR system  Applied Biosystems, 9700
     New Jersey, USA 
PerfectBlueTMVertical electrophoresis system  Peqlab, Erlangen, D 
Photo documentation apparatus (Eagle Eye)  Bio-Rad, Munich, D 
Roler mixer SRT      Stuart, Staffordshire, UK 
Semi-dry-transfer cell (Trans-blot-SD)   Bio-Rad, Munich, D 
Sonifier 450       Branson, Danbury, GB 
Sonifier-bath SONOREX SUPER RK 103H  Bandelin, Berlin, D 
Thermo shaker 5436     Eppendorf, Hamburg, D 
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Vortex-mixer  Bender/Hobein AG, 
Zurich, CH 
Water bath F10      Julabo, Seelbach, D 
 
 
1.2 Consumables 
 
Cell culture dishes 60x 15mm (20 cm2)  Becton Dickinson,  
      Heidelberg, D 
100x 20mm (55 cm2)  Becton Dickinson, 
Heidelberg, D 
   150x 20mm (145 cm2)  Sarstedt, Nümbrecht, D 
Cell culture plates (6-, 12-, 24-, 48-, 96 well)  Becton Dickinson, 
Heidelberg, D  
Cell scratcher (25-, 39 cm)    Costar, Bodenheim, D 
Chemiluminescence film (HyperfilmTMECL) Amersham Biosciences, 
Freiburg, D 
Cuvettes Condensor cuvettes (2 mm)  Bio-Rad, Munich, D 
Unique cuvettes  Brand, Wertheim, D 
Dishes (ø 9 cm for agar plates)  Grainer, Frickenhausen, D 
Eppendorf reaction tubes (1.5 ml & 2 ml)  Eppendorf, Hamburg, D 
Falcon reaction tubes (15 ml & 50 ml)  Becton Dickinson, 
Heidelberg, D 
Hybond-P membrane Amersham Biosciences, 
Freiburg, D 
Spin cup colums and tubes (HandeeTM)   Pierce, Rockford, USA 
Ultracentrifugation tubes (25x89 mm) Beckman Coulter GmbH 
Krefeld, D 
Whatman paper (Blotting paper)  Macherey & Nagel, 
Düren, D 
X-ray films (Biomax MR film)  Kodak, New Haven, CT, 
USA 
 
 
1.3 Reagents 
 
β-Mercaptoethanol      Sigma, Deisenhofen, D 
1 kb-DNA ladder New England Biolabs, 
Frankfurt/Main, D 
Acetic acid       Merck, Darmstadt, D 
Agarose       Invitrogen, Karlsruhe, D 
Agar  Becton Dickinson, 
Heidelberg, D 
Ammonium persulfate (APS)    Sigma, Deisenhofen, D 
Ampicillin       Sigma, Deisenhofen, D 
AmpliTaq DNA Polymerase  Applied Biosystems, New 
Jersey, USA 
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Bacto tryptone Difco Lab., Detroit, USA 
Bromphenolblue Serva, Heidelberg, D 
Carboxy-methyl cellulose     Sigma, Deisenhofen, D 
Chloramphenicol      Sigma, Deisenhofen, D 
D-desthio biotin solution (10x)    IBA, Göttingen, D 
Di-methyl sulfoxide (DMSO)    Merck, Darmstadt, D 
Di-thio threitol (DTT)     Roth, Karlsruhe, D 
Dulbecco´s modified Eagle medium (DMEM)  Gibco, NY, USA 
ECL plus Western Blot detection system Amersham Biosciences, 
Freiburg, D 
Ethylene diamine-tetra acetic acid (EDTA)  Fluka, New-Ulm, D 
“Expand High Fidelity PCR System” Polymerase Roche Diagnostics, 
Mannheim, D 
Fetal calf serum (FCS)     Invitrogen, Karlsruhe, D 
Glycerin Carl Roth GmbH & Co, 
Karlsruhe, D 
Glycine Carl Roth GmbH & Co, 
Karlsruhe, D 
HA-matrix (3F10, immobilized)  Roche Diagnostics, 
Mannheim, D 
HA-peptide (YPYDVPDYA)  Roche Diagnostics, 
Mannheim, D 
Hydrochloric acid (HCl)     Merck, Darmstadt, D 
Isopropanol       Merck, Darmstadt, D 
Kanamycin       Sigma, Deisenhofen, D 
L-Glutamine       Invitrogen, Karlsruhe, D 
Methanol Carl Roth GmbH & Co, 
Karlsruhe, D 
M-Per-mammalian protein lysis buffer Pierce, Rockford, USA 
Newborn calf serum (NCS)  Invitrogen, Karlsruhe, D 
Nonidet P-40 (NP40)  ICN-Biomedicals Inc. 
Ohio, USA 
N, N, N´, N´-Tetra-methyl-ethylene-diamine   Sigma, Deisenhofen, D 
(TEMED) 
Optiprep       Sigma, Deisenhofen, D 
Para-formaldehyde (PFA)     Merck, Darmstadt, D 
Penicillin Gibco/BRL, Life Lab., 
Paisley, Scotland 
Penicillin-Streptomycin     Invitrogen, Karlsruhe, D 
Phenol/Chloroform (Roti-Phenol/C/I) Carl Roth GmbH & Co, 
Karlsruhe, D 
Phenol-red Serva, Heidelberg, D 
Phenyl-methyl-sulfon fluoride (PMSF) Sigma, Deisenhofen, D 
Phosphono acetic acid (PAA) Sigma, Deisenhofen, D 
Potassium chloride      Merck, Darmstadt, D 
Potassium hydrogen phosphate    Merck, Darmstadt, D 
Pro-mixTM (L-[35S] in vitro cell labeling mix) Amersham, Freiburg, D 
Protease inhibitor cocktail (PIC) Roche Diagnostics, 
Mannheim, D 
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Protein A sepharose (CL-4B) Pharmacia/LKB, Uppsala, 
S 
Protein G sepharose (Fast Flow) Pharmacia/LKB, Uppsala, 
S 
Restriction enzymes and buffers Biolabs, Frankfurt/Main, D 
RNase A Roche Diagnostics, 
Mannheim, D 
Rotiphorese gel 30 Carl Roth GmbH & Co, 
Karlsruhe, D 
RPMI 1640  Invitrogen, Karlsruhe, D 
RPMI –Met/Cys Invitrogen, Karlsruhe, D 
Shrimp alkaline phosphatase (SAP) Roche Diagnostics, 
Mannheim, D 
Skim milk powder  Merck, Darmstadt, D 
Sodium dodecyl sulfate (SDS) Carl Roth GmbH & Co, 
Karlsruhe, D 
Sodium acetate Merck, Darmstadt, D 
Sodium chloride Merck, Darmstadt, D 
Sodium di-hydrogen phosphate Merck, Darmstadt, D 
Sodium hydrogen carbonate Merck, Darmstadt, D 
Sodium hydroxide Merck, Darmstadt, D 
Strep Tactin regeneration buffer    IBA, Göttingen, D 
Strep Tactin sepharose     IBA, Göttingen, D 
(D+) Sucrose Carl Roth GmbH & Co, 
Karlsruhe, D 
Superfect       Quiagen, Hilden, D 
T4-DNA ligase  New England Biolabs, 
Frankfurt/Main, D 
Teleostier gelatine       Sigma, Deisenhofen, D 
Tris Carl Roth GmbH & Co, 
Karlsruhe, D  
Triton-X-100 Carl Roth GmbH & Co, 
Karlsruhe, D 
Trypsin/EDTA Gibco/BRL, Life Lab., 
Paisley, Scotland  
Tween 20 Merck, Darmstadt, D 
Yeast extract Becton Dickinson, 
Heidelberg, D 
Zeocin Invitrogen, Karlsruhe, D 
 
 
1.4 Commercial kits 
 
ECLPLUS Western Blot Detection System  Amersham Biosciences, 
Freiburg, D 
Flag®M purification kit  Sigma, Saint Louis, USA 
GFX Micro Plasmid Prep Kit  Amersham Biosciences, 
Freiburg, D 
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GFX PCR DNA and Gel Band Purification Kit Amersham Biosciences, 
Freiburg, D 
ImmobilonTMWestern Chemiluminescent HRP Millipore, Billerica, MA,  
Substrate USA 
MBS-mammalian transfection kit Stratagene, Cedar Creek, 
USA 
M-Per-mammalian protein extraction kit Pierce, Rockford, USA 
NucleoBond PC100  Macherey-Nagel, Düren, 
D 
Plasmid-Midi-Kit      Quiagen, Hilden, D 
QIAquick PCR Purification Kit    Quiagen, Hilden, D 
SilverQuestTMSilver Staining Kit    Invitrogen, Karlsruhe, D 
 
 
1.5 Oligonucleotide-peptides 
 
The used oligonucleotide peptides for cloning and sequencing were produced 
by Metabion, Martinsried, Munich, D and have a purity of at least 95%. Used 
primers are listed in the attachment. 
 
 
1.6 Plasmids 
 
1.6.1 Commercially available and published plasmids 
 
Litmus28:       NEB, Frankfurt a.M., D 
pACYC177:       NEB, Frankfurt a.M., D 
pCP20:       Cherepanov, 1995 
pCR3:        Invitrogen, Karlsruhe, D 
pEGFPN1:  Clontech, Mountain View, 
CA, USA 
pGPS-4:       NEB, Frankfurt a.M., D 
pOriR6K-zeo-ie:      Bubeck, 2004 
pOriR6K-zeo-ie-M50:     Bubeck, 2004 
pSMfr3:       Wagner, 1999 
pSMfr3-∆M50:      Bubeck, 2004 
pST76K:       Posfai, 1997 
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1.6.2 Plasmids constructed over the project 
 
1.6.2.1 M53/p38 expression plasmids 
 
pCR3-M53: The M53 ORF was amplified from the Hind III fragment of the 
wtMCMV-BAC thereby using AB6-02 and AB7-02 primers and cloned into pCR3 
using KpnI and BamHI resulting in pCR3-M53 (Bubeck, 2004). 
 
pLit28-M53: For the linker scanning mutagenesis procedure the M53 ORF was 
cloned from pCR3-M53 (Bubeck, 2004) into Litmus28 (NEB, Frankfurt a.M., D) 
using KpnI and XbaI generating pLit28-M53. 
 
pM53-EGFPN1, pM53-s106-EGFPN1, pM53-s137-EGFPN1 and pM53-s168-
EGFPN1: The M53-green fluorescent protein (GFP) fusion proteins were 
generated as follows. The wt- and mutant M53 ORF were amplified by PCR 
using primers AB6-SpAs and AB7-02. The PCR products were inserted into 
BamHI and SpeI digested Litmus28 (NEB, Frankfurt a.M., D). Then the sub-
cloned wt and mutant M53 fragments were isolated by SpeI and PmeI digestion 
and inserted into NheI and SmaI treated pEGFPN1 (Clontech, Mountain View, 
CA, USA). 
 
 
1.6.2.2 pOriR6k-zeo-ie derived plasmids 
 
pM53-∆16-106: The NLS sequence was removed from the pM53-∆16-106NLS 
by AgeI digestion and re-ligation generated the pM53-∆16-106 construct 
carrying only the 16-106 deletion. 
 
pM53-∆16-106NLS: To generate the N-terminal M53 deletion mutants lacking 
aa16 to 106, the pOriR6K-zeo-ie-M53 was amplified by inverse touch down 
PCR (Padgett, 1996) using 5´-SapI-delN and 3´-Ndel-SapI primers which 
carried an NLS coding sequence derived from the SV40 large T antigen. The 
PCR product was treated with SapI and re-ligated generating the pM53-∆16-
106NLS construct in which the deleted sequence was replaced with the SV40 
NLS. 
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pM53-∆16-136NLS: The N-terminal M53 deletion mutant lacking aa16 to 136 
was generated by insertion of the NLS21 and NLS22 annealed synthetic 
oligonucleotides into the AgeI and BspHI treated pM53-∆16-106NLS resulting in 
pM53-∆16-136NLS. 
 
pOriR6K-zeo-ie-FlagM53: The pOriR6K-zeo-ie-FlagM53 used for pull down 
analysis of cellular interaction partners of the M53-M50 complex, was 
constructed as follows. Synthetic oligonucleotides Flag1 and Flag2 were 
annealed and inserted into KpnI and EarI digested pOriR6K-zeo-ie-M53 
resulting in pOriR6K-zeo-ie-FlagM53. 
 
pOriR6K-zeo-ie-HAM50: The pOriR6K-zeo-ie-HAM50, used for pull down 
analysis of cellular interaction partners of the M53-M50 complex, was kindly 
provided by A. Bubeck, LMU, unpublished. 
 
pOriR6K-zeo-ie-M53: 
 
Figure 8. Schematic 
representation of M53 
inserted into the expression 
vector pO6R6k-zeo-ie. 
Indicated the M53 ORF 
(orange), in blue the bacterial 
regulation elements (zeocin 
resistance gene and oriR6K) 
and in green elements for 
eukaryotic expression and 
insertion into the BAC genome 
(PCMV, BGHpA and FRT). 
 
 
 
 
The M53 ORF was cloned into pOriR6K-zeo-ie rescue vector (Bubeck, 2004) 
from pCR3-M53 (Bubeck, 2004) using KpnI and NotI resulting in pOriR6K-zeo-
ie-M53 (Fig. 8) which was used due to its FRT-site as wt M53 rescue and 
expression vector in this study. 
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pOriR6K-zeo-ie-STM50: The pOriR6K-zeo-ie-STM50, used for pull down 
analysis, was constructed as follows. Synthetic oligonucleotides ieST1 and 
ieST2 were annealed and inserted into pOriR6K-zeo-ie by ApaI and XhoI 
resulting in pOriR6K-zeo-ie-ST. The M50 ORF was amplified by AB6-02 and 
M50Strep primers and cloned into pOriR6K-zeo-ie-ST by KpnI and XhoI. 
 
M53-point mutants (Alanine-screening; L112A, H116A, F119A, P123A, D124A, 
L125A, E126A, K128A, Y129A, L130A, M133A, I137A, YL129,130A, KYL128-
130A, ∆108-136A): Point mutations were introduced into the M53 ORF by 
mutated overlapping primers (see supplementary table for primer list) as 
follows. The M53 ORF was amplified by PCR using AB6-02 and reverse 
mutagenesis primers as well as AB7-02 and forward mutagenesis primers, 
thereby generating 5´- and 3´-M53 fragments, appropriately. The 5´-fragments 
were digested with KpnI/SapI, and 3´-fragments with SapI/MluI and then 
inserted into the KpnI and MluI treated pOriR6K-zeo-ie-M53 in a one step 
reaction. 
 
 
1.6.2.3 Plasmid with temperature sensitive origin of replication (Ts) 
 
pST76K-S4: The pST76K-S4 vector was generated by inserting a Tn7-based 
mini-transposon carrying the KpnI/SacI fragment of pGPS-4 (NEB, Frankfurt 
a.M., D) into pST76K (Posfai, 1997) thereby creating a new transposon donor 
vector with a temperature sensitive origin of replication. 
 
 
1.6.2.4 MCMV-BACs 
 
The ∆M53-and ∆M50-BACs were generated on the basis of pSM3fr-16FRT17, 
which served as wt MCMV-BAC in this study (Bubic, 2004). The ∆M50-BAC 
was generated as described previously (Bubeck, 2004). For generation of the 
∆M53-BAC first a linear recombination fragment carrying a kanamycin 
resistance marker was generated by PCR on pACYC177 template (NEB) by 
using 5´-M53del and 3´-M53del primers (see supplementary table for primer 
list). Next, the M53-ORF (nucleotide positions 78461 to 79459 of MCMV strain 
Smith, according to Rawlinson (Rawlinson, 1996)) was deleted from pSM3fr-
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16FRT17 by ET recombination in E. coli using this linear recombination 
fragment as described previously (Wagner, 2004). All mutant MCMV BACs 
were generated by Flp mediated insertion of pOriR6K-zeo-ie derived expression 
plasmids into pSMfr3-∆M50 or pSMfr3-∆M53 (Bubeck, 2004; Lötzerich, 2006, 
table 1). 
 
BAC-backbone Inserted plasmid Resulting mutant BAC 
pSMfr-∆M53 pOriR6K-zeo-ie-M53 pM53E 
pSMfr-∆M53 pM53-∆16-106NLS pM53-∆16-106NLSE 
pSMfr-∆M53 pM53-∆16-106 pM53-∆16-106E 
pSMfr-∆M53 pM53-∆16-136NLS pM53-∆16-136NLSE 
pSMfr-∆M53 pM53-L112A pM53-L112AE 
pSMfr-∆M53 pM53-H116A pM53-H116AE 
pSMfr-∆M53 pM53-F119A pM53-F119AE 
pSMfr-∆M53 pM53-P123A pM53-P123AE 
pSMfr-∆M53 pM53-D124A pM53-D124AE 
pSMfr-∆M53 pM53-L125A pM53-L125AE 
pSMfr-∆M53 pM53-E126A pM53-E126AE 
pSMfr-∆M53 pM53-K128A pM53-K128AE 
pSMfr-∆M53 pM53-Y129A pM53-Y129AE 
pSMfr-∆M53 pM53-L130A pM53-L130AE 
pSMfr-∆M53 pM53-M133A pM53-M133AE 
pSMfr-∆M53 pM53-I137A pM53-I137AE 
pSMfr-∆M53 pM53-YL129,130A pM53-YL129,130AE 
pSMfr-∆M53 pM53-KYL128-130A pM53-KYL128-130AE 
pSMfr-∆M53 pM53-∆108-136A pM53-∆108-136AE 
pSMfr-∆M53 pOriR6K-zeo-ie-M53s106 pM53-s106E 
pSMfr-∆M53 pOriR6K-zeo-ie-M53s137 pM53-s137E 
pSMfr-∆M53 pOriR6K-zeo-ie-M53s168 pM53-s168E 
pSMfr-∆M53 pOriR6K-zeo-ie-M53s185 pM53-s185E 
pSMfr-∆M53 pOriR6K-zeo-ie-M53s233 pM53-s233E 
pSMfr-∆M53 pOriR6K-zeo-ie-M53s290 pM53-s290E 
pSMfr-∆M53 pOriR6K-zeo-ie-M53s309 pM53-s309E 
pSMfr-∆M53 pOriR6K-zeo-ie-M53s313 pM53-s313E 
pSMfr-∆M53 pOriR6K-zeo-ie-M53iX 
(in total 46 insertion 
mutants; see results 4., 
Fig. 21) 
pM53-iXE 
pSMfr-∆M50 pOriR6K-zeo-ie-STM50 pSTM50E 
 
Table 1. BACs constructed during this study. 
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1.7 Bacterial strains 
 
DH10B (Invitrogen, Karlsruhe, D): F- mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80lacZ∆M15 ∆lacX74 recA1 araD139 ∆(ara, leu)7697 galU galKλ- rpsL nupG 
 
Pir1 (Invitrogen, Karlsruhe, D): F- ∆lac169 rpoS (Am) robA1 creC510 hsdR514 
endA recA1 uidA (∆MluΙ)::pir-116 
 
 
1.8 Cells 
 
293   Adenovirus transformed human kidney-carcinoma cells 
(ATCC CRL 1573) 
 
M2-10B4  Stroma-cell-line from bone marrow of BALB/c-mouse 
   (ATCC CRL 1972) 
 
NIH3T3  Contact inhibited murine fibroblasts of NIH Swiss-mouse 
   (ATCC CRL 1658) 
 
MEF Murine embryonal fibroblasts of BALB/c-mouse (Serrano, 
1997) 
 
 
1.8.1 Cell culture reagents 
 
All cell culture reagents were received from Invitrogen (Gibco). 
 
1.8.1.1 Basal media 
 
DMEM (+ 4500 mg/L-glucose; L-glutamine; L-pyruvate) 
RPMI 1640 (+ L-glutamine) 
RPMI 1640 (+ L-glutamine, - L-cystine; - L-methionine) 
 
 
1.8.1.2 Supplements and sera 
 
D-PBS (-CaCl2; -MgCl2) 
L-glutamine (200 mM; 100x) 
NEAS (non essential amino acids; 100x) 
Penicillin-streptomycin-sulfate (100 IU/ml and 0.1 mg/ml) 
Sodium bicarbonate (7.5%) 
Trypsine/EDTA (0.5 g/l Trypsine; 0.2 g/l EDTA; 0.85 g/l NaCl) 
Foetal bovine sera (FCS) 
Newborn calf sera (NCS) 
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1.9 Viruses 
 
The MCMV wild type (wt) and mutant viruses used in this study were derived 
from the bacterial artificial chromosomes (BACs) pSM3fr (Wagner, 1999), 
pSMfr3-∆M50 (Bubeck, 2004) and pSMfr3-∆M53 (Lötzerich, 2006) and 
constructed BACs, summarized in table 1. For virus reconstitution, BAC-DNA 
was transfected into MEF (see 2.4.2).  
 
 
1.10 Antibodies 
 
1.10.1 Primary antibodies 
 
1.10.1.1 Rabbit polyclonal antisera 
 
Anti M50/p35  Muranyi, 2002 
Anti Histone 3  Santa Cruz, California, 
USA 
Anti Histone 4  Santa Cruz, California, 
USA 
 
1.10.1.2 Rabbit monoclonal antibodies 
 
Anti Lamin B receptor (LBR)    Biomol, Hamurg, D 
Anti Histone H3      Biomol, Hamburg, D 
Anti Histone H4      Biomol, Hamburg, D 
 
1.10.1.3 Mouse monoclonal antibodies 
 
CROMA 101 - pp89 (IE)  provided by S. Jonjic, 
University of Rijeka, 
Rijeka, Croatia 
Anti HP1α       Biomol, Hamburg, D 
Anti Histone H1  Santa Cruz, California, 
USA 
Anti Histone H1.0      Abcam, Cambridge, UK 
 
1.10.1.4 Rat polyclonal antisera 
 
Anti M53/p38  Eurogentec, Seraing, 
Belgium 
Anti M86  Eurogentec, Seraing, 
Belgium 
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1.10.1.5 Goat polyclonal antisera 
 
Anti p32  Santa Cruz, California, 
USA 
Anti Lamin B1  Santa Cruz, California, 
USA 
Anti Lamin A/C  Santa Cruz, California, 
USA 
Anti HP1α  Santa Cruz, California, 
USA 
Anti MAN1  Santa Cruz, California, 
USA 
Anti Emerin  Santa Cruz, California, 
USA 
Anti LAP2  Santa Cruz, California, 
USA 
 
 
1.10.2 Secondary antibodies 
 
All secondary antibodies used in this study were pre-adsorbed to ensure 
minimal cross-reaction with serum proteins of other species. 
 
1.10.2.1 FITC-conjugates 
 
Donkey anti-rabbit IgG     Dianova, Hamburg, D 
Donkey anti-mouse IgG     Dianova, Hamburg, D 
Donkey anti-rat IgG      Dianova, Hamburg, D 
Donkey anti-goat IgG     Dianova, Hamburg, D 
 
1.10.2.2 Texas-Red-conjugates 
 
Donkey anti-rabbit IgG     Dianova, Hamburg, D 
Donkey anti-mouse IgG     Dianova, Hamburg, D 
Donkey anti-rat IgG      Dianova, Hamburg, D 
Donkey anti-goat IgG     Dianova, Hamburg, D 
 
1.10.2.3 Alexa-488-conjugates 
 
Goat anti-mouse IgG  Mo Bi Tec, Goettingen, D 
Goat anti-rabbit IgG  Mo Bi Tec, Goettingen, D 
Goat anti-rat IgG  Mo Bi Tec, Goettingen, D 
 
1.10.2.4 Alexa-633-conjugates 
 
Goat anti-mouse IgG  Mo Bi Tec, Goettingen, D 
Goat anti-rabbit IgG  Mo Bi Tec, Goettingen, D 
Goat anti-rat IgG  Mo Bi Tec, Goettingen, D 
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1.10.2.5 Peroxidase (Pox)-conjugates 
 
Donkey anti-rabbit IgG     Dianova, Hamburg, D 
Goat anti-mouse IgG     Dianova, Hamburg, D 
Goat ant-rat IgG      Dianova, Hamburg, D 
Donkey anti-goat IgG     Dianova, Hamburg, D 
 
 
2. Methods 
 
2.1 Isolation and purification of nucleic acids 
 
2.1.1 Small scale isolation of plasmid DNA 
 
LB medium       LB-zeo medium 
10 g Bacto tryptone      10 g Bacto tryptone 
5 g yeast extract      5 g yeast extract 
10 g NaCl       10 g NaCl 
add ddH2O to 1l      add ddH2O to 1l 
sterilize at 1210C for 2.5 h  sterilize at 1210C  
for 2.5 h 
 
LB agar       LB-zeo agar 
7.5 g agar in 500 ml LB medium 7.5 g agar in 500 ml LB- 
sterilize at 1210C for 2.5 h zeo medium 
  sterilize at 1210C  
for 2.5 h 
 
Antibiotics 
Zeocin: 30 µg/ml 
Kanamycin: 50 µg/ml 
Chloramphenicol: 25 µg/ml 
Ampicillin: 100 µg/ml 
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Solution I (resuspension buffer; Amersham)  100 mM Tris/HCl, pH 7.5 
10 mM EDTA, 
400 µg/ml RNase I 
 
Solution II (lysis buffer; Amersham)   0.2 M NaOH 
        1% (w/v) SDS 
 
Solution III (neutralization buffer; Amersham)  2.5 M KOAc 
        2.5 M HOAc 
 
Additional requirements: Wash buffer (Amersham) and ddH2O. 
 
 
Bacteria were cultivated at 370C (or at 300C for Ts plasmids, see 1.6.2.3) on LB- 
or LB-zeo agar plates over night (ON) using appropriate antibiotics for selection 
of the plasmids of interest. Isolated colonies were picked and 3 ml LB- or LB-
zeo medium (if zeocin was recommended for selection) supplemented with 
appropriate antibiotics were inoculated. The cultures were incubated over night 
(ON) at 370C (or at 300C for propagation of Ts plasmids) in a bacteria shaker 
agitating at 180 rpm. 
For small scale isolation of plasmids the GFX-Micro Plasmid Kit (Amersham) 
was used. 2 ml of bacterial suspension was pelleted in an Eppendorf reaction 
tube and the pellet was resuspended in 300 µl of solution I. For alkaline lysis 
300 µl of solution II was added. Addition of 600 µl solution III then led to 
precipitation of SDS, chromosomal DNA and protein content. After 
centrifugation at 14.000 rpm for 5 min in an Eppendorf centrifuge 5415C the 
supernatant was transferred to glasfiber-matrix columns of the GFX Micro 
Plasmid Prep Kit (Amersham). Next the columns were centrifuged at 14.000 
rpm for 1 min and after addition of 400 µl wash buffer (Amersham) this 
centrifugation step was repeated. To elute the plasmid-DNA which is bound to 
the columns 50-100 µl of ddH2O was added to the columns, incubated at room 
temperature (RT) for 1 min followed by centrifugation at 14.000 rpm for 2 min. 5 
µl of the DNA preparation were analyzed by restriction pattern analysis. 
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2.1.2 Large scale isolation of plasmid DNA 
 
P1-resuspension buffer (Qiagen)    50 mM Tris/HCl, pH 8.0 
        10 mM EDTA 
        100 µg/ml RNase A 
 
P2-lysis buffer (Qiagen)     1% (w/v) SDS 
        200 mM NaOH 
 
P3-neutralisation buffer (Qiagen)    3 M KOAc 
        pH 5.5 with acetic acid 
 
QBT-equilibration buffer (Qiagen)   750 mM NaCl 
        50 mM MOPS 
        15% (v/v) EtOH 
0.15% (w/v) Triton-X-100 
        pH 7.0 
 
QC-wash buffer (Qiagen)     1 M NaCl 
        50 mM MOPS 
        15% (v/v) EtOH 
        pH 7.0 
 
QF-elution buffer (Qiagen)     50 mM Tris/HCl, pH 8.5 
        1.25 M NaCl 
        15% (v/v) EtOH 
 
Ion-exchange columns (Qiagen)  Qiagen-tip 500 
 
Additional requirements: Isopropanol, 70% EtOH and ddH2O. 
 
 
250 ml LB- or LB-zeo medium (if zeocin was recommended for selection) were 
supplemented with appropriate antibiotics (see 2.1.1), inoculated with 5 ml of 
over night bacterial culture of one bacterial clone and incubated at 370C (or at 
300C for propagation of Ts plasmids) over night on a bacteria shaker at 180 
rpm. 
For isolation of up to 500 µg of plasmid-DNA the Qiagen Plasmid Midi Kit was 
used. Bacteria were pelleted (15 min; 6000 rpm; 40C; GS-3 rotor, Sorvall) and 
resuspendet in 10 ml buffer P1. Afterwards 10 ml of buffer P2 was added and 
lysed for 5 min at room temperature (RT). After addition of 10 ml neutralizing 
buffer P3 and incubation for 20 min on ice, SDS, proteins and chromosomal 
DNA was removed by centrifugation (30 min; 13.000 rpm; 40C; SS-34 rotor, 
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Sorvall). An Ion exchange column Qiagen-tip 500 was equilibrated with 10 ml 
buffer QBT and applied with the filtered cleared supernatant from the previous 
centrifugation step, thereby allowing the supernatant to enter the resin by 
gravity flow. The columns were next washed twice with buffer QC and plasmid-
DNA was eluted with 15 ml buffer QF. Eluted DNA was afterwards precipitated 
with 10.5 ml isopropanol and centrifuged for 30 min at 40C and 12.000 rpm in a 
SS-34 rotor. The DNA-pellet was washed with 70% ethanol, air-dried and 
dissolved in up to 500 µl ddH2O. 
 
 
2.1.3 Small scale isolation of BAC-DNA 
 
P1-resuspension buffer (Qiagen)    50 mM Tris/HCl, pH 8.0 
        10 mM EDTA 
        100 µg/ml RNase A 
 
P2-lysis buffer (Qiagen)     200 mM NaOH 
1% (w/v) SDS 
 
P3-neutralisation buffer (Qiagen)    3 M KAc 
        pH 5.5 with acetic acid 
 
Additional requirements: Phenol/chloroform/isoamyl alcohol (25:24:1), 
Isopropanol, 70% EtOH and TE-buffer (supplemented with 10 µg/ml RNase A). 
 
The CMV BAC-DNA has a size of over 230 kbp. In order to avoid damage of the 
BAC-DNA during preparation the probes should neither being harshly shaked 
nor vortexed. It was also recommended to use cut pipette-tips. 10 ml LB-media 
supplemented with appropriate antibiotics (see 2.1.1) were inoculated with one 
bacterial colony and incubated over night at 370C. The bacterial suspension 
was transferred to a 15 ml Falcon reaction tube and centrifuged in a Heraeus-
centrifuge (5 min; 3500 rpm). For bacterial resuspension and -lysis and for 
neutralization of the lysate buffers P1-P3 from the Qiagen Plasmid Midi Kit were 
used. 
The bacterial pellet was resuspended in 300 µl P1 (Qiagen) and transferred to a 
2 ml Eppendorf reaction tube. For alkaline lysis 300 µl P2 (Qiagen). After an 
incubation for 5 min at RT SDS, chromosomal DNA and protein contents were 
precipitated due to addition of 300 µl P3 (Qiagen) and an incubation on ice for 
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10 min. After centrifugation in an Eppendorf centrifuge 5415C (14.000 rpm; 10 
min; RT) the supernatant was carefully transferred to a new 2 ml Eppendorf 
reaction tube. DNA was extracted by addition of approximately 1 ml 
phenol/chloroform/isoamyl alcohol (25:24:1), which accumulates DNA in the 
upper watery phase after an additional 5 min centrifugation step at 14.000 rpm. 
Next, the watery phase was transferred to a new 2 ml Eppendorf reaction tube 
and DNA was precipitated by addition of 1 ml isopropanol followed by 
centrifugation (14.000 rpm; 20 min; 40C). After a washing step with 1 ml of 70% 
ethanol the DNA pellet was air dried and resuspended in 100 µl TE-buffer 
(supplemented with 10 µg/ml RNase A). For the following restriction pattern 
analysis normally 45 µl of the isolated BAC-DNA was used. 
 
 
2.1.4 Large scale isolation of BAC-DNA 
 
S1-resuspension buffer (Macherey and Nagel)  50 mM Tris/HCl, pH 8.0 
        10 mM EDTA 
        100 µg/ml RNase A 
 
S2-lysis buffer (Macherey and Nagel)   200 mM NaOH 
1% (w/v) SDS 
 
S3-neutralization buffer (Macherey and Nagel)  2.8 M KAc 
        pH 5.1 
 
N2-equilibration buffer (Macherey and Nagel)  100 mM Tris 
        900 mM KCl 
        15% (v/v) EtOH 
0.15% (w/v) Triton-X-100 
        pH 6.3 with H3PO4
 
N3-wash buffer (Macherey and Nagel)   100 mM Tris 
        1.15 M KCl 
        15% (v/v) EtOH 
        pH 6.3 with H3PO4
 
N5-elution buffer (Macherey and Nagel)   100 mM Tris 
        1 M KCl 
        15% (v/v) EtOH 
        pH 8.5 with H3PO4
 
Additional requirements: Isopropanol, 70% EtOH and TE-buffer (10 mM 
Tris/HCl, 1 mM EDTA, pH 8.0). 
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For large scale isolation of BAC-DNA the Nucleobond-AX 100 Kit from 
Macherey and Nagel was used. For pipetting of BAC-DNA it was recommended 
to use cut pipette tips to minimize shear forces that can damage the large BAC-
DNA molecules. 200 ml LB-media supplemented with appropriate antibiotics 
(see 2.1.1) were inoculated with 5 ml bacterial pre-culture and incubated over 
night at 370C in a bacteria shaker at 180 rpm. Bacteria were pelleted by 
centrifugation (6000 rpm; 15 min; GS-3 rotor). Next, the bacterial pellet was 
resuspended in 8 ml S1 buffer (Macherey and Nagel). For alkaline lysis 8 ml S2 
buffer (Macherey and Nagel) was added to the bacterial suspension. After an 
incubation for 5 min at RT SDS, chromosomal DNA and protein contents were 
precipitated due to addition of 8 ml S3 buffer (Macherey and Nagel) and an 
incubation on ice for 10 min. Next, the bacterial lysate was cleared by filtration 
and applied to the equilibrated adsorption cartridge. Afterwards, a total volume 
of 12 ml of N3-washing buffer was applied to the cartridge in three steps and 
BAC-DNA was eluted twice by addition of 2x 2.5 ml buffer N5 that was pre-
warmed to 500C. DNA was precipitated with isopropanol, washed with 70% 
ethanol and finally the air dried BAC-DNA pellet was dissolved in 150 µl TE-
buffer for 2 hours at 370C or ON at 40C and stored at 40C. 
 
 
2.1.5 Determination of DNA concentration and purity of the isolated DNA 
 
In order to determine concentration and purity of the isolated DNA the optical 
density (OD) at 260 nm and at 280 nm was determined using an Eppendorf 
spectrophotometer. 1 OD260 unit equals 50 µg/ml double-stranded DNA or 38 
µg/ml single-stranded DNA or RNA. The measured OD260 allowed the 
calculation of nucleic acid concentration of the sample. Absorption at 280 nm 
indicated the presence of protein contamination, because aromatic amino acids 
absorb strongly at 280 nm. The ratio between the two readings at OD260 nm and 
OD280 nm allowed an estimation about DNA sample purity. In the best case this 
ratio should range between 1.8 and 2. 
 
 - 39 - 
 
 C. Material and methods 
 
2.2 Analysis and cloning of DNA 
 
2.2.1 Restriction digest of DNA 
 
Restriction endonucleases  New England Biolabs, 
Schwalbach, D 
 
10x restriction buffer  New England Biolabs, 
Schwalbach, D 
 
Restriction of DNA was performed with commercial restriction endonucleases in 
the recommended buffer systems. For restriction pattern analysis of plasmids, 5 
µl of a small scale plasmid preparation were used, which corresponds to 
approximately 0.5-1 µg of DNA. Regularly the restriction was performed in a 
total volume of 40 µl for 1-2 hours according to the instructions of the 
manufacturer thereby adding to 0.5-1 µg of DNA 20 units of the restriction 
enzyme, 4 µl of the recommended 10x buffer, 4 µl of 10x BSA (if necessary) 
and ddH2O. 
For analysis of BAC-DNA the restriction digest was performed in a total volume 
of 70 µl, adding 7 µl of the recommended 10x reaction buffer, 7 µl of 10x BSA, 
40 units of the respective restriction endonuclease and ddH2O to 45 µl of a 
small scale BAC-DNA preparation. BAC-DNA digests were incubated 4 hours or 
over night according to the instructions of the manufacturer. For restriction 
pattern analysis of large scale DNA preparations of either plasmids or BACs 1.5 
µg of DNA were digested in a total volume of 40-70 µl. 
 
 
2.2.2 Dephosphorylation of DNA 
 
To avoid re-circulation of cleaved, linearized vector DNA after restriction digest, 
the 5´-terminal phosphate groups from DNA fragments were dephosphorylated 
by alkaline phosphatase treatment (SAP, “shrimp alkaline phosphatase”; NEB). 
SAP (1 unit/pmol DNA) was directly added after the restriction digest and 
incubated for one hour at 370C. Afterwards, SAP was heat-inactivated at 750C 
for 20 min. 
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2.2.3 Amplification of DNA by Polymerase Chain Reaction (PCR) 
 
Oligonucleotides Metabion, Martinsried, D 
 
Template       10-100 ng matrix-DNA 
 
Polymerase AmpliTag DNA 
Polymerase 
(Applied Biosystems, New 
Jersey, USA) 
 
10x reaction buffer containing 15 mM MgCl2  GeneAmp 10x PCR buffer 
(Applied Biosystems, New 
Jersey, USA) 
 
Desoxynucleotides PCR Nucleotide Mix  
(10 mM; Roche, 
Mannheim, D) 
 
The Polymerase Chain Reaction is a tool for in vitro amplification of defined 
DNA sequences. The standard PCR reaction for a fast screening of generated 
random transposon insertion mutants was performed with DNA as a template at 
a concentration of 10 ng-100 ng in a total reaction volume of 50 µl and following 
conditions: 
 
Reaction: 
10 ng-100 ng      template-DNA 
400 nM (each)      oligonucleotide-primer 
10 µM (each)      dNTP-mix 
0.1 vol.  10x GeneAmp PCR buffer 
containing 15 mM MgCl2
10 units  AmpliTag DNA 
Polymerase 
0.1 vol.       DMSO (if needed) 
 
Temperature-cycles: 
• one cycle for 5 min at 940C 
• 25 repeating cycles with 
 30 sec at 940C 
 45 sec at appropriate hybridization-temperature 
 45 sec elongation-time at 720C 
• 7 min at 720C 
 
For cloning purposes the amplification of coding sequences longer than 1000 
bp was performed by means of the Expand High Fidelity PCR system (Roche). 
The High Fidelity Polymerase of this kit possesses a prove-reading activity and 
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is therefore more precise. Using a touch down program the PCR was performed 
in a total reaction volume of 100 µl under following conditions: 
 
Reaction: 
10 ng-100 ng      template-DNA 
400 nM (each)      oligonucleotide-primer 
60 µM (each)      dNTP-mix 
0.1 vol.  10x Expand HF reaction 
buffer containing 15 mM 
MgCl2 
3.5 units  Expand High Fidelity PCR 
system Polymerase 
0.1 vol.       DMSO (if needed) 
 
Temperature-cycles: 
• one cycle for 5 min at 950C 
• 35 repeating cycles with 
30 sec at 940C 
1 min at hybridization-temperatures dropping down per cycle from 620C 
to 500C 
1 min 30 sec elongation time at 680C 
• 6 min at 680C 
 
Polymerase Chain Reaction was performed using a thermo-cycler 
GeneAmp®PCR system 9700 (Applied Biosystems, New Jersey, USA). For 
calculation of the hybridizing-temperature (TH) of a primer the following formula 
was applied: 
 
TH (0C)= 60+ [(G+C)x 41/Ntnumber]- (600/Ntnumber) 
 
Here G+C corresponds to the number of cytosines and guanidins in the primer 
sequence and Ntnumber  to the length of the oligonucleotide primer.  
10 µl of the PCR reaction were tested for amplification on a 0.8% TAE/agarose 
gel. For purification of the amplified DNA the remaining 90 µl of the PCR 
reaction were applied on a 1% TAE/agarose gel and the respective band was 
cut out and purified using the GFXTM Gel Extraction and DNA Purification Kit 
(Amersham; see 2.2.4). 
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2.2.3 Agarose gel electrophoresis 
 
Agarose  Invitrogen, Karlsruhe, D 
 
1x TAE       40 mM Tris-acetate 
(electrophoresis buffer)     1 mM EDTA 
 
1x TBE       90 mM Tris 
(electrophoresis buffer BAC-DNA)   90 mM boric acid 
        1 mM EDTA, pH 8.3 
 
Ethidiumbromide stock solution    10 mg/ml in TAE 
 
5x DNA loading buffer     40% (w/v) sucrose 
        0.05% (w/v) brom- 
        phenolblue 
0.1 % (w/v) SDS 
1 mM EDTA, pH 8.0 
 
DNA length standard 1 kb “ladder”, 1 µg/ml 
(Gibco/BRL, Eggenstein, 
D) 
 
DNA fragments obtained by restriction enzyme digests or PCR reaction were 
separated and analyzed by agarose gel electrophoresis. Depending on the 
expected fragment size the digested plasmid DNA or PCR amplicon was 
separated in a 0.6-1% (w/v) TAE/agarose gel while digested BAC-DNA always 
was separated in a 0.8% TBE/agarose gel. 
The agarose was dissolved due to heating in an appropriate volume 1x TAE- or 
TBE buffer and cooled down to 560C. Afterwards 1 µg/ml ethidium bromide was 
added and the agarose was poured to a horizontal gel chamber. After setting of 
the agarose the gel was overlaid with 1x TAE- or TBE buffer and loaded with 
DNA-length-standard and probes that were supplemented with loading buffer. 
Separation was performed at constant voltage of 5 V/cm for ½ hour to one hour. 
For separation of BAC-DNA a constant voltage of 70 V for 14-16 hours was 
used. After electrophoresis DNA was visualized by UV-light using an Eagle-Eye 
imaging system. 
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2.2.4 Isolation of DNA fragments from agarose-gels 
 
Gel-extraction-system GFXTM gel extraction- and 
DNA purification kit 
(Pharmacia/LKB, Uppsala, 
S) 
 
If separated DNA fragments had to be used for further cloning steps, the 
respective DNA bands were cut from the gel and purified by means of the 
GFXTM gel extraction- and DNA purification kit (Pharmacia) following the 
instructions of the manufacturer. To prevent UV-light induced DNA damage, 
weak UV light was applied for DNA visualization while cutting. The content of 
eluted DNA was determined photometrically or estimated on a 1% TAE/agarose 
gel by means of the DNA length standard. 
 
 
2.2.5 Annealing of synthetic oligonucleotides 
 
For insertion of short DNA fragments into a vector, complementary 
oligonucleotides were synthesized (Metabion) and annealed to form a double 
stranded DNA fragment. Oligonucleotides were flanked by suitable overhangs 
as usually obtained after restriction enzyme cuts to allow the insertion into a 
respectively cut vector. Two complementary oligonucleotides were mixed to a 
concentration of about 40 µM each, incubated at 750C for 5 min and cooled 
down to RT for 30 min. 1 µl of the annealed oligonucleotides, neat and diluted 
1/50, were added to separate ligation reactions containing 100 ng of an 
adequately cut and purified vector fragment. 
 
 
2.2.6 Ligation of DNA fragments 
 
DNA-fragments were ligated by means of the T4-DNA ligase (NEB) with a molar 
ratio of 1:4 between the vector (100 ng) and the insert. Ligation was performed 
in a total volume of 10 µl by mixing 400 units of T4-DNA ligase (2 µl), 1 µl of the 
respective 10x T4 ligase reaction buffer, DNA fragments and ddH2O. The 
reaction was incubated over night (ON) at 160C for “blunt”-end DNA fragments 
or at RT for 1 hour for overlapping (“sticky”)-end DNA fragments. 
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2.2.7 Transformation of recombinant DNA 
 
2.2.7.1 Preparation of electro-competent bacteria 
 
Glycerol-solutions  15% glycerol (w/v) in H2O 
10% glycerol (w/v) in H2O 
 
All preparation steps were performed on ice or at 40C, using pre-cooled pipettes 
and solutions. For production of electro competent bacteria 400 ml LB-media (if 
necessary supplemented with antibiotics) were inoculated with 2 ml of an over-
night bacteria culture and incubated at 370C or at 300C to an OD600 of about 0.5 
(after 2-4 hours of cultivation). Afterwards, the bacteria culture was put on ice 
and pelleted at 5000 rpm and 40C for 10 min. To remove salt and medium 
components the bacteria pellet was washed twice by resuspension in 100 ml 
ddH2O followed by two steps of resuspension in 15% glycerol and subsequently 
four times pelleting at 5000 rpm and 40C for 10 min. Afterwards the pellet was 
resuspended in 1.5 ml of 10% glycerol and 60 µl aliquots in Eppendorf reaction 
tubes were snap frozen in liquid nitrogen and stored at –800C. 
 
 
2.2.7.2 Transformation of electrocompetent bacteria 
 
SOC medium      20 g/l Bacto tryptone 
5 g/l yeast extract 
        0.5 g/l NaCl 
        2.5 mM KCl 
        10 mM MgCl2
        20 mM glucose 
 
The electroporation technique is based on the fact that by a short electric 
impulse (10 µs) of high field energy (∼12.5 kV per cm) the permeability of the 
bacteria cell wall is increased which leads to an uptake of DNA molecules. To 
introduce plasmids into electrocompetent bacteria 2 µl of ligation mix were 
added to 60 µl of electrocompetent bacteria and transferred to a pre-cooled 
transformation cuvette (0,2 µm in diameter; BioRad). Next, the bacteria were 
pulsed with 2.5 kV, 200 Ω and 25 µF (Gene Pulser II; BioRad). Immediately 
after the pulse 1 ml of SOC medium was added and the bacteria were 
transferred to a 1.5 ml Eppendorf reaction tube for incubation at 370C or 300C. 
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After one hour 50-200 µl of bacteria culture were plated on pre-warmed agar 
plates supplemented with appropriate antibiotics and incubated at 370C or 430C 
over night. 
 
 
2.2.8 Linker scanning mutagenesis of the M53 ORF 
 
GPSTM-LS Linker-Scanning System  NEB, Frankfurt 
a.M., D 
 
For the mutagenesis procedure the M53 ORF was cloned from pCR3-M53 
(Bubeck, 2004) into Litmus28 (NEB, Frankfurt a.M., D) using KpnI and XbaI 
generating pL-M53 which was used as target vector for the transposon 
mutagenesis. pST76K-S4, a new transposon donor vector with a temperature 
sensitive origin of replication, was generated by inserting the mini-transposon 
carrying the KpnI/SacI fragment of pGPS-4 (NEB) into pST76K (Posfai, 2004). 
pLit28-M53 was subjected to in vitro random transposon insertion mutagenesis 
using TnsABC*-transposase (NEB) and pST76K-S4 (see 1.6.2.3) as donor 
according to the manufacturer instructions. The following setting was used: 
 
Donor  1 µl 
Target     1 µl 
10x GPS Buffer    2 µl 
ddH2O       14 µl 
TnsABC* Transposase   1 µl 
 
After incubation of 10 min at 370C which is needed for the assembly reaction 
1µl of Start-B Solution was added (300mM MgAc). During an incubation time of 
one hour at 370C the strand transfer reaction was performed. Afterwards the 
transposase was heat-inactivated at 750C for 10 min, put on ice for 5 min and 
the reaction-mix was precipitated by addition of 2 µl NaAc (3M NaAc, pH 5.2) 
and 100 µl 100% EtOH and incubation for 15 min at –800C. The resulting DNA-
pellet was dissolved in 5-10 µl ddH2O. E. coli DH10B cells (Invitrogen) were 
transformed by 2 µl of the transposition mixture and insertion mutants were 
selected by chloramphenicol and ampicilin at 430C to remove both the intact 
acceptor and donor plasmids. Plasmid DNA was prepared from this primary 
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pool of insertion mutants and the 1084 bp KpnI/NsiI fragments containing the 
M53 ORF and the randomly inserted mini-transposons were isolated and re-
cloned into KpnI/NsiI treated pOriR6K-zeo-ie rescue plasmid. Recombinants 
containing the M53 ORF with the mini-transposon insertions were selected by 
chloramphenicol and zeocin. Plasmid DNA was prepared from this secondary 
pool of insertion mutants and the mini-transposon was removed by PmeI 
digestion and re-ligation generating a pOriR6K-zeo-ie-M53mut insertion library, 
which was maintained in E. coli PIR1 (Invitrogen). Insertion sites were identified 
for selected clones by PCR screening and sequencing as described previously 
(Bubeck, 2004; Fig. 9). 
The in vitro transposition reaction was also performed with a linearized 
KpnI/NotI-M53-fragment which was obtained by restriction of pOriR6K-zeo-ie-
M53. Here instead of 60 min the strand transfer reaction was prolonged to 100 
min. After heat-inactivation of the transposase the KpnI/NotI-M53-fragment was 
re-ligated for two hours at 160C with the KpnI/NotI-digested pOriR6K-zeo-ie 
followed by precipitation. 
 
 
 
 
Figure 9. General principle of a 
random mutagenesis of an 
essential viral gene. In a first step 
the viral gene of interest (gray box) 
is sub-cloned into a rescue plasmid 
(rescue) containing one FRT site 
(open box with gray triangle). This 
plasmid is subjected to an in vitro 
Tn7-based random mutagenesis 
procedure, leading to a mutant 
library with 15 bp-insertions (black 
box) into the target plasmid. This 
mutant library is transformed into 
E.coli (open boxes) and single 
clones are screened by PCR for 
insertions into the gene of interest. 
Adapted from Bubeck, 2004. 
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2.3 Cells and viruses 
 
2.3.1 Tissue culture 
 
2.3.1.1 Cultivation of cells 
 
Cell line Basic medium Additives Split/interval. 
MEF DMEM 10% FCS, 0,6% (w/v) Pen., 1,3% (w/v) Strep 1:3/3-4 days 
M2-10B4 RPMI 10% FCS, 0,6% (w/v) Pen., 1,3% (w/v) Strep 1:6 /3-4 days 
293 DMEM 10% FCS, 0,6% (w/v) Pen., 1,3% (w/v) Strep., 
0,3 mg/ml Q 
1:12/4 days 
NIH-3T3 DMEM 5% NCS, 0,6% (w/v) Pen., 1,3% (w/v) Strep. 1:6/3-4 days 
 
Table 2. Cell lines used during this work. List of Cell lines and culture media, prepared from 
the commercial available basic media and additives. In the last column the dilution of the cells 
for each split and the split interval is indicated. 
 
All cell lines were cultivated on culture dishes in an incubator at 370C, 5% CO2 
and 95% relative humidity. Cells were split every 3-6 days in a ratio between 1:2 
to 1:12 (see table 2). In order to split confluent cells the medium was removed, 
cells were washed with 2-10 ml PBS and detached from the bottom of the 
culture dish by a treatment with few drops of trypsine/EDTA for 1-2 min at RT. 
Detached cells were resuspended in fresh medium thereby inactivating the 
trypsine. A pertinent amount was transferred to a new culture dish with fresh 
medium. NIH 3T3 murine fibroblast (ATCC CRL 1658), M2-10B4, a bone 
marrow stromal cell line (ATCC CRL 1972), human 293 cells (ATCC CRL 
1573), and mouse embryonic fibroblasts (MEF) were propagated as described 
previously (Menard, 2003). 
 
 
2.3.1.2 Freezing and thawing of eukaryotic cells 
 
Freezing medium      10% (v/v) DMSO 
        40% (v/v) FCS 
        in DMEM medium 
 
For freezing cells were detached from the culture dish by trypsine treatment, 
centrifuged (Haereus) at 315x g for 5 min and resuspended at a concentration 
of 5x 106 to 1x 107 cells in freezing medium. This suspension was aliquoted to 
pre-cooled CryotubesTM (Nunc), which were cautiously cooled down to –800C 
and after 48-72 hours transferred for long terms storage to liquid nitrogen. 
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Cells were thawed at 370C in a water bath and as soon as possible 
supplemented with 10 ml of appropriate medium to dilute toxic DMSO. After 
centrifugation at 315x g for 5 min (Heraeus) cells were resuspended in fresh 
culture medium and transferred to culture dishes. 
 
 
2.3.2 Working with MCMV 
 
2.3.2.1 Generation of recombinant MCMV-BACs 
 
The ∆M53-BAC was generated on the basis of pSM3fr-16FRT17 (Bubic, 2004). 
A linear recombination fragment carrying a kanamycin resistance marker was 
generated by PCR on pACYC177 template (NEB) by using 5´-M53del and 3´-
M53del primers. The M53-ORF (nucleotide positions 78461 to 79459 of MCMV 
strain Smith, according to Rawlinson (Rawlinson, 1996)) was deleted from 
pSM3fr-16FRT17 by ET recombination in E. coli using this linear recombination 
fragment as described previously (Wagner, 2004). The wt and mutant rescue 
plasmids were inserted into the ∆M53-BAC at the FRT site as described 
previously (Bubeck, 2004). Here mutagenesis was performed in the RecA-
recombinase negative E.coli-strain DH10B by means of the pCP20 plasmid 
which carries the FLP-recombinase, an ampicillin resistance-cassette and a 
temperature-sensitive (Ts) origin of replication (ori). This origin causes a low 
copy number per bacteria and replicates at 300C. For FLP mediated 
recombination, bacteria were kept for 15 min under non-selective conditions. 
Afterwards, 150 µl of bacteria were plated on Cam/Zeo plates and cultured at 
430C. At non permissive temperature of more than 370C the pCP20 plasmid got 
lost (Fig. 10). On the following day single colonies were picked for small scale 
BAC-DNA preparation in order to test for single recombination events. 
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Figure 10. Re-insertion of 
mutated plasmids into the viral 
genome. To re-insert the gene 
mutants into the viral genome the 
respective MCMV-BAC and a FLP 
recombinase expressing plasmid 
(FLP) are maintained in E.coli. 
Subsequently, the rescue plasmids 
are transformed into E.coli. FLP 
recombinase mediates site-
specific recombination between 
the FRT sites and unifys the BAC 
and the rescue plasmid. Selection 
with chloramphenicol and zeocin 
identifies BACs with the inserted 
rescue plasmid carrying the 
mutated gene of interest. Adapted 
from Bubeck, 2004. 
 
 
2.3.2.2 Reconstitution of recombinant MCMV-BACs to virus 
 
The wt and mutant MCMV-BACs were reconstituted to virus by transfection of 
semi-confluent MEF on 6 cm dishes with 1.5 µg of purified BAC-DNA by means 
of Superfect® transfection reagent (Quiagen, see 2.4.2). Thereby BAC-DNA 
was added up to 150 µl with media (without supplements) and mixed gently. 
After addition of 10 µl Superfect® transfection reagent and mixing the solution 
was incubated at RT for 10-15 min. Afterwards the probes were added up to 1 
ml with supplemented medium, transferred to PBS-washed cells and incubated 
in an incubator for 2.5-3.5 hours. After incubation the Superfect/DNA mixture 
was removed from the cells and replaced by fresh culture media. Always two 
independent BAC clones were transfected in two replicates. 24 hours after 
transfection cells were re-plated onto 10 cm dishes and then re-fed weekly. 
Cultures were inspected during six weeks after transfection (Fig. 11). As control 
pM53E DNA was transfected and a reconstitution experiment was considered 
valid when pM53E DNA derived virus plaques occurred during the second week 
post transfection. 
The wild type (wt) MCMV Smith strain was recovered from pSM3fr-BAC 
(Wagner, 1999). All mutant viruses were derived from the pSM3fr-16FRT17-
BAC carrying an FRT site between the genes m16 and m17. Growth properties 
of the 16FRT17 MCMV are identical to the (wt) MCMV both in vitro and in vivo 
 
 - 50 - 
 
 C. Material and methods 
 
(Bubic, 2004). Reconstituted viruses were propagated on M2-10B4 cells 
(Menard, 2003) and titrated on MEF by a plaque assay (Reddehase, 1985). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Virus-reconstitution. BAC-DNA was isolated and transfected into eukaryotic cells 
for virus-reconstitution and cells were screened for viral plaques. Adapted from Bubeck, 2004. 
 
 
2.3.2.3 MCMV virus stock preparation 
 
VSB (Virus Standard Buffer)    0.05 M Tris/HCl 
        0.012 M KCl 
0.005 M EDTA 
        pH 7.8 with HCl 
 
For a high titer virus stock preparation M2-10B4-cells were cultured on 12-30 
dishes (14 cm) and at a confluency of 80% each dish was infected with around 
1 ml of reconstituted virus supernatant from lysed 10 cm culture dishes. 
Alternatively, at a confluency of 30% cells were infected with an MOI of 0.1. 
After 3-5 days, when cells showed up an overall cytopathic effect, the virus-cell 
suspension was harvested and transferred to sterile 250 ml centrifugation 
beaker. All following steps of virus stock preparation were performed on ice or 
in centrifuges cooled to 40C. Next, the harvested virus-cell suspension was 
centrifuged at 5400x g (Beckmann; AvantiTM J-20xp; JLA 16-250) for 15 min to 
separate free virus particles which remained in the supernatant from cells and 
cell-associated virus particles in the pellet. For isolation of the cell-associated 
virions the pellet was resuspended in 5 ml of DMEM and homogenized in a 
glass homogenisator (douncer; 20 strokes). Afterwards, cell debris was 
removed by a second centrifugation step at 17.400x g (Beckmann; AvantiTM J-
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20xp; JA 25-50) for 10 min. To concentrate viral particles, supernatants from 
both steps were combined and centrifuged at 25.000x g (Beckmann; AvantiTM J-
20xp; JLA 16-250) for three hours. Next, the pellet was resuspended in 4 ml of 
VSB medium and homogenized with a douncer (20 strokes). Afterwards virus 
homogenate was carefully loaded on a 10 ml sucrose cushion of 15% sucrose 
in VSB (SW28 ultracenrifugation tube). After an ultracentrifugation step of one 
hour at 30.000x g (Beckman, SW28) the pellet of purified viral particles was 
resuspended in 1-2 ml VSB medium and aliquoted to 60 µl aliquots which were 
snap frozen in liquid nitrogen and stored at –800C. 
 
 
2.3.2.4 Growth curves 
 
The growth kinetics of different mutant viruses were compared to each other 
and wt MCMV in multi-step growth conditions. NIH3T3 fibroblasts were grown 
on 12 well plates (Nunc) one day before the start of the experiment to obtain 
cell numbers around 3x10  per well for the day of infection. Cells were infected 
with a MOI of 0.1 in a volume of 1 ml. In order to allow virus adsorption infected 
cells were incubated for 1 hour at 37 C in an incubator. Afterwards the 
infectious supernatant was exchanged by 1 ml of supplemented medium. After 
infection supernatant was collected from cells every day over a period of 7 
days, stored at –80 C and virus titer was determined by plaque assay. Samples 
were taken in duplicates for each day.
5
0
0
 
 
2.3.2.5 MCMV titer determination by plaque assay 
 
Carboxymethyl cellulose containing 3.75 g carboxymethyl 
medium (500 ml) cellulose (Sigma) 
388 ml ddH2O 
to be autoclaved 
        5 ml L-glutamine 
5 ml penicillin/ 
streptomycin (0.6% (w/v) 
Pen.; 1.3% (w/v) Strep) 
        25 ml FCS 
        50 ml 10x MEM 
        2.5 ml NEAS 
24.7 ml NaHCO3 (7.5%) 
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For determination of MCMV virus titers MEF were cultured on 48 well plates. At 
a confluency of 100% the medium of each well was replaced by 400 µl of serial 
diluted virus suspension (normally 10-2 to 10-7 in supplemented DMEM). 
Titrations were done in duplicates. After one hour of incubation in a CO2-
incubator to allow virus adsorption, infectious supernatant was removed and 
cells were overlaid with carboxymethylcellulose containing medium to avoid 
virus spread. After 4-5 days plaques were counted and virus titer was 
determined by means of the following equation: 
 
Virus titer (PFU/ml)= 
counted plaques x dilution factor / vol. of virus dilution (0.4 ml) 
 
 
 
2.4 Analysis of proteins 
 
2.4.1 Transfection of eukaryotic cells using calciumphosphate-precipitation 
 
CaCl2        0.25 M 
 
2x HEBS       16 g/l NaCl 
        0.72 g/l KCl 
0.25 g/l Na2HPO4x2H2O 
        10 g/l HEPES 
        2 g/l glucose 
        pH 7.05 with NaOH, 
        sterile filtered 
 
For transient transfection of eukaryotic cells by calciumphosphate-precipitation 
cells should have a confluency of 50-70% (Sambrook, 2001). 7 µg (for 6 cm 
dishes; 14 µg-10 cm; 28 µg-14 cm) of plasmid-DNA was transferred to a 15 ml 
Falcon reaction tube and supplemented with 250 µl CaCl2 solution (500 µl for 
14 µg; 1000 µl for 28 µg). While mixing permanently 250 µl of 2x HEBS buffer 
was dropped to the probe (500 µl for 14 µg; 1000 µl for 28 µg). After an 
incubation at RT for 15 min the mixture was supplemented with 3 ml (for 6 cm 
dishes; 6 ml-10 cm; 12 ml-14 cm) of pre-warmed medium and transferred to 
PBS washed cells. Cells were incubated with this mixture over night. For longer 
incubation times than 24 hours the medium had to be exchanged. This was the 
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method of use for transient transfection of 293 cells. Expressed proteins were 
analyzed 24 hours after transient transfection. 
 
 
2.4.2 Transfection of eukaryotic cells using Superfect® transfection reagent 
 
For transient transfection of eukaryotic cells by Superfect® transfection reagent 
(Quiagen) semi-confluent NIH3T3- or MEF cells on a 6 cm dish were 
transfected with a total of 7 µg of plasmid-DNA. DNA, 150 µl serum free DMEM 
and 15 µl Superfect® transfection reagent were mixed and incubated at RT for 
15 min. Afterwards, the mixture was supplemented with 1 ml of pre-warmed 
medium and transferred to PBS washed cells. After 2.5-3.5 hours the 
transfection mixture was exchanged to pre-warmed, supplemented medium. 
Expressed proteins were analyzed 24-48 hours after transient transfection. 
 
 
2.4.3 Protein extraction from eukaryotic cells 
 
All steps of protein extraction, preparation of nuclei and pull down assays were 
performed on ice. With exception of total lysis buffer all buffers were 
supplemented with 1x PIC (Roche) to stabilize proteins. 
 
 
2.4.3.1 Protein extraction from eukaryotic cells using total lysis buffer 
 
Total lysis buffer      62.5 mM Tris, pH 6.8 
2% (v/v) SDS 
10% (v/v) glycerol 
6M Urea 
5% (v/v) β-mercapto-
ethanol 
0.01% (w/v) bromo-
phenolblue 
0.01% (w/v) phenolred 
 
For protein extraction cells were scratched from a 6-10 cm dish by a cell 
scratcher 24 hours after transfection or infection, transferred to a 15 ml Falcon 
reaction tube and pelleted at 310x g (1200 rpm, Heraeus-centrifuge) for 5 min at 
RT. The cell pellet was next resuspended in 1 ml PBS, transferred to a 1.5 ml 
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Eppendorf reaction tube, pelleted at 830x g (2800 rpm, 5417-R-centrifuge) for 5 
min at RT and resuspended in up to 350 µl of total lysis buffer. Normally, 10-20 
µl of total protein extract was analyzed by SDS-PAGE (see 2.4.8) and Western 
Blot (see 2.4.9). Alternatively, for analysis of infected cells, total lysis buffer was 
added directly to the cell culture dish and lysis was performed for 10 min on ice. 
 
 
2.4.3.2 Protein extraction from eukaryotic cells using IP lysis buffer 
 
IP lysis buffer 150 mM NaCl 
20 mM Tris, pH 8.0 
        1% Triton-X-100 
 
PIC (Protease inhibitor cocktail ,100x) Complete Mini (Roche, D) 
 
For analysis of protein-protein interaction 1/20 of the 1 ml PBS-cell suspension 
was transferred to a new 1.5 ml Eppendorf reaction tube, pelleted at 830x g 
(2800 rpm, 5417-R-centrifuge) for 5 min at RT and resuspended in 50 µl of total 
lysis buffer to determine total protein load by SDS-PAGE and Western Blot. The 
rest of cell suspension was pelleted at 830x g (2800 rpm, 5417-R-centrifuge) for 
5 min at RT and lysis was performed with 1 ml of IP lysis buffer for 30 min on 
ice. Next, cell debris was pelleted at 20.800x g (14.000 rpm, 5417-R-centrifuge) 
for 30 min at 40C and supernatant was transferred to a new 1.5 ml Eppendorf 
reaction tube. 
 
 
2.4.3.3 Protein extraction from eukaryotic cells using high salt lysis buffer 
 
High salt lysis buffer  450 mM NaCl 
20 mM Tris, pH 8.0 
        1% Triton-X-100 
 
DNase Benzonase®Nuclease, 25 
U/µl (Novagen, Madison, 
WI, USA) 
 
PIC (Protease inhibitor cocktail ,100x)   Complete Mini (Roche, D) 
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For analysis of cellular interaction partners of M53/p38 and M50/p35 instead of 
the IP lysis buffer a high salt lysis buffer was used. Lysis was performed 90 min 
on ice in presence of 125 U Benzonase®Nuclease. In addition, total cell lysates 
were supplemented with 250 U Benzonase®Nuclease. Afterwards HA-or Flag-
tag pull down was performed (see 2.4.6 and 2.4.7). 
 
 
2.4.3.4 Preparation of nuclear extracts 
 
Hypotonic buffer      10 mM HEPES, pH 7.9 
        10 mM KCl 
        1.5 mM MgCl2
 
Lysis buffer M-Per® mammalian 
protein extraction reagent 
(Pierce, Rockford, USA) 
 
For preparation of nuclear extracts 293 cells were scratched from a 10 cm dish 
by a cell scratcher 24 hours after transfection, transferred to a 15 ml Falcon 
reaction tube and pelleted at 310x g (1200 rpm, Heraeus-centrifuge) for 5 min at 
RT. Next, the cell pellet was resuspended in 1 ml PBS and transferred to a 1.5 
ml Eppendorf reaction tube. 1/20 of the 1 ml PBS-cell suspension was 
transferred to a new 1.5 ml Eppendorf reaction tube, pelleted at 830x g (2800 
rpm, 5417-R-centrifuge) for 5 min at RT and resuspended in 50 µl of total lysis 
buffer to determine total protein load by SDS-PAGE (see 2.4.8) and Western 
Blot (see 2.4.9). The rest of cell suspension was collected by centrifugation at 
830x g (2800 rpm, 5417-R-centrifuge) for 5 min at RT and the cell pellet next 
was resuspended in 600 µl hypotonic buffer. After incubation on ice for 10 min, 
cells were lysed by three repeated sonication steps of five seconds. The nuclei 
were collected by centrifugation at 20.800x g (14.000 rpm, 5417-R-centrifuge) 
for 30 min at 40C and treated with up to 400 µl M-Per® mammalian protein 
extraction reagent. 
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2.4.4 Metabolic labeling of proteins and co-immunoprecipitation 
 
Starvation medium Bio WhittakerTM RPMI 
1640 
 with L-glutamine, without 
L-cystine or L-methionine 
(Cambrex, Verviers, 
Belgium) 
 
[35S]-cystine and methionine Promix L-[35S]-in vitro cell labeling 
mix; 14.3 mCi/ml 
(Amersham, Freiburg; D) 
 
Protein A-sepharose  CL-4B (Amersham, 
Uppsala; S); 50% 
suspension, 5x washed in 
washing-buffer B, stored 
in buffer D 
 
Protein G-sepharose 4 fast flow (Amersham, 
Uppsala; S); 50% 
suspension, 5x washed in 
washing-buffer B, stored 
in buffer D 
 
Buffer B  1 mM Tris, pH 8.0 
  150 mM NaCl 
2 mM EDTA 
0.1 % Triton-X-100 
 
Buffer D       10 mM Tris, pH 8.0 
 
PIC (Protease inhibitor cocktail ,100x)   Complete Mini (Roche, D) 
 
Sub-confluent 293 cells on 6 cm dishes were co-transfected with pOriR6K-zeo-
ie-M53 or pOriR6k-zeo-ie-M53mut with 3.5 µg of pOriR6K-zeo-ie-M50 or 
pOriR6K-zeo-ie vector (Bubeck, 2004) by Ca2PO4 precipitation (see 2.4.1). 
Twenty-four hours after transfection cells were washed once with pre-warmed 
(370C) PBS and starvation medium and incubated for 40 min in an incubator 
with 4 ml/dish of starvation medium. Newly synthesized proteins were labeled 
by adding of warm (370C) labeling medium (starvation medium supplemented 
with 300 µCi/ml 35S-methionine and cystine mixture; Promix, Amersham) for 
one hour. The cells were lysed on an ice-chilled metal plate by adding of 
1ml/dish of IP lysis buffer (supplemented with 1x PIC; see 2.5.3.2), lysates were 
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transferred to an Eppendorf reaction tube, centrifuged at 40C for 15 min 
(12.000x g, Eppendorf centrifuge) and 900 µl of supernatant were transferred to 
a new Eppendorf reaction tube without disturbing the pellet. Next, pre-
absorption was performed at 40C for 60 min on an roll incubator by adding of 50 
µl of protein A- or G-sepharose to the cleared lysate. After centrifugation at RT 
for 2 min (12.000x g) the co-immunoprecipitation was carried out as described 
previously (Bubeck, 2004). To 900 µl pre-absorbed lysate 5 µl of an M50/p35 
specific polyclonal rabbit antiserum (Muranyi, 2002) was added and incubated 
at 40C on a roll incubator for 60 min followed by addition of 50 µl Protein-A 
Sepharose (Amersham) and incubation at 40C on a roll incubator for 45 min to 
precipitate the M50/p35 specific-complexes. M53/p38 was precipitated on 50 µl 
Protein-G Sepharose beads (Amersham) with 5 µl of a specific rat polyclonal 
antiserum raised against a synthetic peptide representing the 15 N-terminal 
amino acids of M53/p38 (Bubeck, 2004). Afterwards the mixture was 
centrifuged for 2 min at RT (12.000x g) and the beads with bound proteins were 
washed five times with IP lysis buffer (supplemented with 1 x PIC) to remove 
unspecific bound proteins followed by a final washing step with buffer D 
(supplemented with 1 x PIC) to reduce the salt content. Beads were taken up in 
50 µl of 2x sample buffer and boiled at 950C for five min to elute the proteins. 
After centrifugation for 2 min at RT (12.000x g) eluted proteins in the 
supernatant were analyzed by SDS-PAGE (see 2.4.8). 
 
 
2.4.5 Strep-tag pull down assay 
 
Buffer W (Washing buffer)     150 mM NaCl 
        100 mM Tris/HCl,  
pH 8.0 
        1 mM EDTA 
 
Buffer E (Elution buffer)     150 mM NaCl 
100 mM Tris/HCl,  
pH 8.0 
        1 mM EDTA 
2.5 mM desthiobiotin (IBA, 
Göttingen, D) 
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Strep-Tactin® Sepharose 50% suspension in 150 
mM NaCl, 100 mM 
Tris/HCl, pH 8.0, 1 mM 
EDTA, Strep-Tactin, 5 
mg/ml covalently coupled 
to Sepharose 4FF beads 
(IBA, Göttingen, D) 
 
Sub-confluent 293 cells on 6 cm dishes were co-transfected with 3.5 µg of the 
construct pOriR6K-zeo-ie-STM50 expressing Strep II-tagged M50/p35 and 3.5 
µg of plasmid pOriR6K-zeo-ie-M53 or pOriR6k-zeo-ie-M53mut by Ca2PO4 
precipitation (see 2.4.1). Twenty-four hours after transfection the cells were 
washed with PBS, scratched from the plates and re-suspended in PBS. 5% of 
the cell suspension was lysed directly in total lysis buffer (62.5mM Tris, pH 6.8; 
2% SDS [v/v];10% glycerol [v/v]; 6M Urea; 5% β-mercaptoethanol [v/v]; 0.01% 
bromophenolblue [w/v]; 0.01% phenolred [w/v]) and the samples were 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE, see 2.4.8) and analyzed by Western Blot (see 2.4.9) to determine the 
total protein load. The rest of the cell suspension was collected by centrifugation 
and pellets were lysed in hypotonic buffer (10 mM HEPES, pH 7.9; 10 mM KCl; 
1.5 mM MgCl2) by sonication. 
The nuclei were collected by centrifugation at 20.800x g (14.000 rpm, 5417-R-
centrifuge) for 30 min at 40C, treated with up to 400 µl M-Per® mammalian 
protein extraction reagent (Pierce; see 2.5.3.4) and transferred to a HandeeTM 
Spin cup column (Pierce). Next, 100 µl Strep-Tactin Sepharose (IBA) was 
added to pull down Strep II-tagged M50/p35 complexes and incubated for 1 
hour at 40C on a roll incubator. The Strep II-tag is a short peptide (8 amino 
acids; WSHPQFEK), which binds with high selectivity to Strep-Tactin, an 
engineered streptavidin. After a centrifugation step at 20.800x g (14.000 rpm, 
5417-R-centrifuge) for 2 min pulled down protein complexes were washed five 
times with 400 µl of buffer W and centrifuged at 20.800x g (14.000 rpm, 5417-R-
centrifuge) for 1 min at 40C. Protein complexes were eluted from the HandeeTM 
Spin cup column (Pierce) to a new 1.5 ml Eppendorf reaction tube by addition of 
100 µl desthiobiotin supplemented buffer E to the Strep-Tactin Sepharose 
(IBA), incubation for 20 min and centrifugation for 2 min at 20.800x g at 40C. 50 
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 µl of eluted samples were separated by SDS-PAGE and analyzed by Western 
Blot (see 2.4.8 and 2.4.9). 
 
 
2.4.6 HA-tag pull down assay 
 
Anti-HA Affinity Matrix  50% suspension in PBS, 
clone 3F10, rat IgG1, 3.5 
mg/ml, covalently coupled 
to agarose beads (Roche, 
Mannheim, D) 
 
HA peptide  1 mg/ml, YPYDVPDYA, 
recognized by Anti-HA 
clones 3F10 and 12CA5 
(Roche, Mannheim, D) 
 
For analysis of cellular interaction partners of M50/p35 alone or in complex with 
M53/p38 sub-confluent 293 cells on 10 cm dishes were transfected with 7 µg of 
the construct pOriR6K-zeo-ie-HAM50 expressing HA-tagged M50/p35 or co-
transfected with 7 µg of plasmid pOriR6K-zeo-ie-M53 by Ca2PO4 precipitation 
(see 2.4.1). Twenty-four hours after transfection the cells were washed with 
PBS, scratched from the plates and re-suspended in PBS. 5% of the cell 
suspension was lysed directly in total lysis buffer and the samples were 
separated by SDS-PAGE (see 2.4.8) and analyzed by Western Blot (see 2.4.9) 
to determine the total protein load. The rest of the cell suspension was lysed in 
1 ml high salt lysis buffer (see 2.4.3.3). Afterwards 100 µl of Anti-HA Affinity 
Matrix (Roche) was added to 1 ml lysate and incubated for 90 min at 40C on a 
roll incubator. Next, The HA matrix was pelleted at 20.800x g (14.000 rpm, 
5417-R-centrifuge) for 2 min and supernatant was removed. The matrix was 
then washed five times with high salt lysis buffer and once with 10 mM Tris, pH 
7.6. After a final centrifugation step at 20.800x g (14.000 rpm, 5417-R-
centrifuge) for 2 min the low salt buffer was totally removed and proteins were 
eluted by addition of 100 µl 2x SDS sample buffer. 50 µl of eluted sample was 
separated by SDS-PAGE and analyzed by Western Blot. Alternatively, up to 
100 µl of eluted sample was analyzed by SDS-PAGE and silver staining. 
Furthermore, proteins were eluted also under non-denaturating conditions by 
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addition of 100 µl HA peptide (1 mg/ml) and analyzed by SDS-PAGE and 
Western Blot or silver staining (see 2.4.8-2.4.10). 
 
 
2.4.7 Flag-tag pull down assay 
 
Anti-Flag M2 Affinity Matrix  50% suspension in 
glycerol, clone M2, murine 
IgG1, covalently coupled 
to agarose beads (Sigma, 
Saint Louis, Missouri, 
USA) 
 
Flag peptide 5 µg/µl (3x peptide 
solution), 
MDYKDHDGDYKDHDIDY
KDDDDK, recognized by 
Anti-Flag M2 monoclonal 
antibody (Sigma, Saint 
Louis, Missouri, USA) 
 
Buffer W (Washing buffer)     150 mM NaCl 
        50 mM Tris/HCl, pH 7.4 
 
For analysis of cellular interaction partners of M50/p35 alone or in complex with 
M53/p38 sub-confluent 293 cells on 10 cm dishes were transfected with 7 µg of 
the construct pOriR6K-zeo-ie-FlagM53 expressing Flag-tagged M53/p38 or co-
transfected with 7 µg of plasmid pOriR6K-zeo-ie-M50 by Ca2PO4 precipitation 
(see 2.4.1). Probes were treated and analyzed as described for the HA pull 
down assay (see 2.4.6) thereby using 60-100 µl of Anti-Flag M2 affinity resin, 
buffer W (150 mM NaCl; 50 mM Tris/HCl, pH 7.4) for washing and 2x SDS 
sample buffer or alternatively 100 µl of 200 ng/µl Flag peptide for protein 
elution. 
 
 
2.4.8 SDS-PAGE 
 
Acrylamid-solution      29.2% (w/v) acrylamid 
(RotiphoreseGel 30) 0.8% (w/v) N, N-methylen-
bisacrylamid (Carl Roth 
GmbH & Co, Karlsruhe, 
D) 
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APS solution  10% (w/v) APS 
(ammonium persulfate) in 
ddH2O 
 
 
N, N, N`, N`,-tetra-methyl-ethylene-diamine Sigma, Deisenhofen, D 
(TEMED) 
 
SDS solution  20% (w/v) in ddH2O 
 
4x Upper-Tris stacking gel buffer  0.5 M Tris 
  0.4% (v/v) SDS 
 pH 6.8 
 
4x Lower-Tris separating gel buffer 1.5 M Tris 
  0.4% (v/v) SDS 
 pH 8.8 
 
Electrophoresis buffer (Laemmli) 50 mM Tris 
 0.4 M glycine 
0.1 % (w/v) SDS 
 
2x SDS sample buffer     400 mM Tris, pH 8.8 
        2 M Sucrose 
        10 mM EDTA, pH 8.0 
        0,02% BPB  
50 mM DTT (freshly 
added) 
4% (v/v) SDS (freshly 
added) 
 
4x SDS sample buffer 800 mM Tris/HCl, pH 8.8 
2 M Sucrose 
        20 mM EDTA, pH 8.0 
        0.04% BPB 
100 mM DTT (freshly 
added) 
8% (v/v) SDS (freshly 
added) 
 
Gel fixation buffer      40% (v/v) MetOH 
10% (v/v) acetic acid  
in ddH2O 
 
Molecular weight marker  1 µl [14C]-methylated  
(for metabolic labeled proteins) proteins (14.3 kDa-200 
kDa), 0.37-3.7 Mbq/mg 
(10-100 µCi/mg) protein, 
1.85 kBq/ml (5 µCi/ml), 
Amersham, Freiburg, D 
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SDS-PAGE standards 10 µl of prestained SDS-
PAGE standard; low 
range (BioRad, Munich, 
D) or PageRulerTM 
Prestained Protein Ladder 
(Fermentas, St.-Leon-Rot, 
D) 
 
For separation of metabolic labeled proteins denaturating 11.5-13.5% SDS 
gradient gels were poured by means of a gradient mixer from a ready to use, 
gas-stabilized, watery acrylamide stock solution with bisacrylamide. All gels 
were prepared by means of 4x Lower-Tris buffer (pH 8.8) in the separating gel 
and 4x Upper-Tris buffer (pH 6.8) in the stacking gel in presence of 0.4% SDS. 
After polymerization of the separation- and stacking gel the gel was fixed in the 
electrophoresis apparatus and overlaid with electrophoresis buffer. Protein 
probes were taken up in up to 50 µl of 2x SB and boiled for five min at 950C 
before gel-loading. Proteins were separated at constant 20 mA for 20-24 hours. 
Afterwards the gel was fixated (see 2.4.10) for 45 min and vacuum-dried at 
800C for 2 hours (BioRad gel drying system). Last, the gel was exposed against 
a X-ray film (Kodak, Biomax MR film, New Haven, CT, USA) at –800C for 1-7 
days. 
For analysis of proteins by Western Blot normally 10 µl of total cell lysates 
(1:100 of probe) or up to 50 µl of samples after pull down assay were separated 
by 10-15% SDS-PAGE using a Minigel-system (BioRad, Richmond, USA). 
Percentage of the SDS-gel thereby was chosen according to the expected 
molecular weight of the analyzed protein and the desired resolution. Proteins 
were separated at constant 160 V for 60-75 min. 
 
 
2.4.9 Western Blot 
 
Blotting buffer      25 mM Tris 
        190 mM glycine 
        20% methanol 
 
TBS-T       150 mM NaCl 
        10 mM Tris/HCl, pH 8.0 
0.02% Tween 20 (freshly 
added) 
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Detection-kits  ECLPLUS Western Blot 
Detection System 
(Amersham, Freiburg, D)  
and ImmobilonTM Western 
Chemi-luminescent HRP 
Substrate (Millipore, 
Billerica, MA, USA) 
 
 
2.4.9.1 Sandwich construction 
 
After SDS-PAGE proteins from the gel were transferred to a Hybond-P-PVDF-
membrane (Amersham, Freiburg, D) which was activated 5 min by methanol 
and equilibrated in blotting buffer. For this procedure the gel was placed on the 
activated membrane and both together were placed between three layers of 
Whatman paper above and below that were soaked in blotting buffer. Next, the 
sandwich was transferred to a “Semidry-Blotting”-apparatus (BioRad, Freiburg, 
D) and blotting was performed for 40 min at constant 18 V and RT. 
 
 
2.4.9.2 Detection of blotted proteins 
 
For immunodetection of proteins, first the blotted PVDF-membrane was 
incubated over night at 40C with 5% (w/v) nonfat milk powder in TBS-T to block 
unspecific binding sites. Next, the membrane was incubated at RT for one hour 
with primary antibody that was diluted 1:300-1:2000 in TBS-T. Afterwards the 
membrane was washed in ∼100 ml TBS-T for at least 90 min thereby 
exchanging the washing buffer every 20 min. The PVDF-membrane was then 
incubated for one hour at RT with horseradish peroxidase-conjugated 
secondary antibody which was usually diluted 1:7500 in TBS-T and afterwards 
washed again for at least 90 min with TBS-T thereby exchanging the washing 
buffer every 20 min. For detection of the proteins the peroxidase coupled to the 
secondary antibody was traced by chemiluminescent-detection by means of 
either the ECLPLUS Western Blot Detection System (Amersham, Freiburg, D) or 
the ImmobilonTM Western Chemiluminescent HRP Substrate (Millipore, Billerica, 
MA, USA) thereby following the instructions of the manufacturers. Afterwards, 
for detection of the reaction the membrane was exposed to a 
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chemiluminescence film (HyperfilmTM ECL, Amersham, Freiburg, D) for one sec 
up to one hour. 
 
 
2.4.10 Silver-staining 
 
Fixative       40% (v/v) ethanol 
        10% (v/v) acetic acid 
made with ddH2O 
 
PerfectBlueTMVertical electrophoresis system  Peqlab, Erlangen, D 
 
SilverQuestTMSilver Staining Kit Invitrogen, Karlsruhe, D 
 
For analysis of cellular interaction partners of M50/p35 alone or in complex with 
M53/p38 sub-confluent 293 cells on 10 cm dishes were transfected with 7 µg of 
the construct pOriR6K-zeo-ie-FlagM53 expressing Flag-tagged M53/p38 or co-
transfected with 7 µg of plasmid pOriR6K-zeo-ie-M50 by Ca2PO4 precipitation 
(see 2.4.1). In addition, cells were transfected with 7 µg of the construct 
pOriR6K-zeo-ie-HAM50 expressing HA-tagged M50/p35 or co-transfected with 
7 µg of plasmid pOriR6K-zeo-ie-M53. Alternatively, 293 cells were co-
transfected with both pOriR6K-zeo-ie-HAM50 and pOriR6K-zeo-ie-FlagM53. 
Cell lysis was performed as described above (see 2.4.3.3), thereby using high 
salt lysis buffer. HA-tag pull down and Flag-tag pull down were performed as 
described above (see 2.4.6 and 2.4.7) and proteins were eluted by addition 
either of 2x SDS-sample buffer to the matrix or by the respective peptide. Up to 
60 µl of eluted protein samples were separated by SDS-PAGE (see 2.4.8) with 
a PerfectBlueTMVertical electrophoresis system (Peqlab, Erlangen, D) on a 8-
16% gradient gel at constant 30 mA for 4 hours. Afterwards the gel was fixated 
in 100 ml fixative over night and silver staining was performed according to the 
instructions of the manufacturer. Last, the gel was air dried for 80 min by means 
of a air gel dryer (BioRad, Munich, D). 
 
 
 
 
 
 - 65 - 
 
 C. Material and methods 
 
2.4.11 Confocal laser scanning microscopy 
 
PBS        137 mM NaCl 
        2.7 mM KCl 
        4.3 mM Na2HPO4
        1.4 mM KH2PO4
        pH 7.5 
 
Fixative  3% (w/v) para-
formaldehyde in PBS 
(freshly prepared or 
thawed) 
 
Quench-solution 50 mM NH4Cl 
 20 mM glycine in PBS 
 
Permeabilization buffer 0.2% (v/v) Triton-X-100 in 
PBS 
 
Blocking buffer 0.2% (v/v) teleostier-
gelatine in PBS (Sigma, 
Deisenhofen) 
 
Embedding media  Histogel, (Linaris, 
Bettingen a. Main, D) 
 
 
In order to visualize the intracellular localization of wt- and mutant M53/p38, 
M50/p35 and cellular interaction partners of the viral proteins, double-
immunofluorescence-stainings were performed and localization was determined 
by means of a confocal laser scanning microscope. If not indicated all steps of 
the procedure were performed at RT. 
NIH 3T3 cells were grown on 12 well plates on glass cover slips and transfected 
(see 2.4.2) or infected at a confluency of 60-80%. After 24 hours cells were 
washed twice with 2 ml/well PBS and fixated for 20 min with 1 ml/well of 3% 
para-formaldehyde/PBS (Muranyi, 2002). After two additional washings with 2 
ml/well PBS cells were quenched for 20 min by addition of 1 ml/well 
NH4Cl/glycine-solution and again washed twice 2 ml/well with PBS. Afterwards 
cells were permeabilized by incubation with 1 ml/well of 0.2% Triton-X-100/PBS 
for 10 min, washed three times with 2 ml/well PBS and stabilized by incubation 
in 1 ml/well of 0.2% teleostier-gelatine/PBS for 10 min. Next, cells were 
incubated for 45 min with primary antibodies which were diluted 1:2000 in PBS, 
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washed four times with 2 ml/well PBS and stabilized again for 10 min by 
incubation in 1 ml/well of 0.2% teleostier-gelatine/PBS. Afterwards an 
incubation for 45 min in the dark with FITC- or Texas Red-conjugated 
secondary antibody followed, which was diluted 1:75 in PBS for FITC- and 
1:150 in PBS for Texas Red- conjugated antibody. Last, cells were washed two 
times with 2 ml/well PBS, embedded with “Histogel” (Linaris) on a cover slip 
and analyzed at the confocal microscope (Leica). 
Wt and mutant M53/p38 was visualized with the specific polyclonal rat 
antiserum as primary antibody (Eurogentec) and fluorescein-conjugated goat 
anti-rat IgG (Dianova) as secondary antibody. M50/p35 was visualized with 
polyclonal rabbit antiserum as primary antibody (Muranyi, 2002) and Texas-red-
conjugated donkey anti-rabbit IgG (Dianova) as secondary antibody. 
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1. M53/p38 is expressed with late kinetics and is essential for MCMV 
replication 
 
1.1 Optimization of M53/p38 detection by Western-blot analysis 
 
The optimal virus load for the detection of M53/p38 in infection experiments was 
determined on NIH 3T3 cells infected with wt MCMV at different multiplicity of 
infection (MOI) of 0.1, 0.2, 0.5 and 1.0. 24 hours post infection total cell lysates 
were prepared and proteins were separated by SDS-PAGE. Cell lysates from 
uninfected NIH 3T3 cells or transfected with pOriR6K-ie-zeo-M53 were 
analyzed as negative- or positive controls, respectively. Furthermore, a lysate 
from wt MCMV infected NIH 3T3 cells served as positive control. M53/p38 
signals were visualized by Western-blot using rat antiserum specific to the N-
terminal 15 amino acids (aa) of the M53/p38 ORF at a dilution of 1:2000 
(Bubeck, 2004). The M53/p38 specific signal at 38 kDa was detectable in 
analyzed infected and transfected probes but was missing in uninfected NIH 
3T3 cells. The strongest M53/p38 signal was detectable for the lysate from NIH 
3T3 cells infected at an MOI of 0.5 (Fig. 12, lane 6). As a second the same 
probes were analyzed by SDS-PAGE and Western-blot and probed at a dilution 
of 1:2000 with rabbit antiserum specific for the late MCMV protein M50/p35 
which has a predicted molecular weight of 35 kDa and interacts with M53/p38. 
In accordance with the results for M53/p38 the strongest M50/p35 signal was 
detectable for the lysate from NIH 3T3 cells infected at an MOI of 0.5 (Fig. 12, 
lane 6). Therefore, for all further infection experiments an MOI of 0.5 was used. 
 
 
 
 
 
 
 
 - 68 - 
 
 D. Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Determination of proper MOI for infection experiments. NIH 3T3 fibroblasts were 
infected at different MOI with wt MCMV and cell lysates were prepared 24 hours after infection 
(lanes 4-7). As controls NIH 3T3 cells were mock transfected (lane 3) or transfeted with 
pOriR6k-ie-M53 (M53) and cell lysate was prepared 24 hours post transfection (lane 1). 
Additionally, already tested wt MCMV lysate was probed as expression control (lane 2). 
Proteins were separated by SDS-PAGE and M53/p38 and M50/p35 signals were visualized by 
Western blot using specific antisera. 
 
 
1.2 Determination of the expression kinetics of M53/p38 
 
M50/p35 follows early-late expression kinetics upon MCMV infection (Bubeck, 
2004). Therefore, we wanted to know, if the same is true for M53/p38. The 
expression kinetics of M53/p38 was determined on NIH 3T3 cells infected with 
wt MCMV at an MOI of 0.5. Cell lysates were prepared at different times after 
infection and proteins were separated by SDS-PAGE. M53/p38 signals were 
visualized by Western-blot using rat antiserum specific to the N-terminal 15 
amino acids (aa) of the M53/p38 ORF (Bubeck, 2004). The M53/p38 specific 38 
kDa band became detectable at 18 hours post-infection (Fig. 13A, lane 4). 
M53/p38 gradually accumulated at later time points (Fig. 13A, lane 5-6) with a 
maximum of 36 hours after infection. 
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Figure 13A. Expression kinetics of M53/p38. NIH 3T3 fibroblasts were infected with wt 
MCMV and cell lysates were prepared at indicated time points (hours) after infection (lanes 2-7). 
As a control NIH 3T3 cells were transfected with pOriR6k-ie-M53 (M53) and cell lysate was 
prepared 24 hours post transfection (lane 1). Proteins were separated by SDS-PAGE and the 
M53/p38 signal was visualized by Western blot using specific rat antiserum. 
 
To confirm that M53/p38 is a true late protein, the DNA replication was blocked 
in infected cells by addition of 300 µg/ml phosphono-acetic acid (PAA; Sigma) 
to prevent the expression of late MCMV genes (Gold, 2002). M53/p38 was 
clearly detectable 24 hours after infection in the untreated cells (Fig. 13B, lane 
3) whereas PAA treatment abolished expression of the protein (Fig. 13B, lane 
6). In the controls the expression of the major capsid protein (M86), another late 
gene product, was blocked by PAA treatment while the expression of the 
immediate-early gene product pp89 was not affected. Therefore, M53/p38 
expression follows late kinetics. 
 
B 
Figure 13B. Expression 
kinetics of M53/p38. NIH 3T3 
fibroblasts were infected with wt 
MCMV in the absence or in 
presence of phosphono-acetic 
acid (PAA), (lanes 1-3 and 4-6, 
respectively). Cell lysates were 
prepared from infected cells at 
indicated time points (hours) 
after infection. Proteins were 
separated by SDS-PAGE and 
signals for M53/p38, M86 and 
pp89 were visualized by 
Western blots using specific 
antisera. 
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1.3 M50/p35 and M53/p38 co-locate to the nuclear membrane 
 
M53/p38 is diffusely distributed in the nucleus of transfected 293 endothelial 
cells expressing only M53/p38, whereas isolated M50/p35 is found in nuclear 
and ER membranes (Muranyi, 2002). After co-expression of both proteins, 
M53/p38 is redistributed to the nuclear envelope. Since human 293 cells can 
not be productively infected by MCMV a different cell system had to be used to 
study the sub-cellular localization of M53/p38 and M50/p35 after transfection or 
infection. To this end, NIH 3T3 fibroblasts were transfected either with wt 
M53/p38 or wt M50/p35. Sub-cellular localization of wt M53/p38 or wt M50/p35 
was analyzed by confocal microscopy after indirect immunofluorescence 
staining with specific antisera (Fig. 14A). Used antisera and secondary 
antibodies showed no cross-reactivity to cellular proteins in mock transfected 
NIH 3T3 fibroblasts (Fig. 14A, first horizontal row). After isolated expression of 
wt M53/p38 (Fig. 14A, M53) the typical diffuse nuclear staining pattern was 
detectable. There was no cross-reactivity of the anti-M50 sera to M53/p38 (Fig. 
14A, second horizontal row). 
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Figure 14A. Sub-cellular localization 
of M53/p38 and M50/p35. NIH 3T3 cells 
were mock transfected, transfected with 
either wt M53 or with wt M50/p35. Single 
transfected cells were stained with rat 
specific antiserum against M53/p38 and 
co-stained with rabbit specific antiserum 
against M50/p35. For detection of M53 a 
fluorescein-conjugated secondary 
antibody was used (green). For detection 
of M50 a Texas red coupled secondary 
antibody was used (red). No cross-
reactivity of the sera could be detected. 
lated expressed M50/p35 was found in nuclear and ER membranes as 
scribed for 293 cells. The specific anti-M53 sera did not cross-react with wt 
50/p35 (Fig. 14A, third horizontal row). Next, sub-cellular localization of wt 
53/p38 or wt M50/p35 after co-expression of both proteins and infection of 
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NIH 3T3 cells was analyzed by confocal microscopy after indirect 
immunofluorescence staining. The phenomenon described for transfection of 
293 cells was also detectable after transfection and infection of NIH3T3 
fibroblasts with MCMV (Fig. 14B). Co-expression of M50/p35 and M53/p38 
changed the distribution of M53/p38 to the nuclear envelope. Additionally to 
these findings, 24 hours after infection or transfection of NIH3T3 cells M50/p35 
localized consistently in peri-nuclear structures (Fig. 14B, second vertical row). 
Furthermore, performing indirect immunofluorescence staining 24 hours after 
infection of cells with MCMV, in contrast to transfected cells, M53/p38 is also 
detectable in these structures co-localized with M50/p35 (Fig. 14B, second 
horizontal row). In infected cells the morphology of the NEC positive peri-
nuclear structures was not characteristic for an ER staining. 
 
B 
 
 
 
 
 
 
 
 
Figure 14B. Subcellular localization of M53/p38 and M50/p35. NIH 3T3 cells were either co-
transfected with M53/p38 and M50/p35 or infected with wt MCMV (C3X) at an MOI of 0.5. 
Transfected or infected cells were stained with rat specific antiserum against M53/p38 and co-
stained with rabbit specific antiserum against M50/p35. For detection of M53 a fluorescein-
conjugated secondary antibody was used (green). For detection of M50 a Texas red coupled 
secondary antibody was used (red). 
 
 
1.4 M50/p35 directly binds to M53/p38 
 
M50/p35 directly binds to M53/p38 and the binding region of M50/p35 is 
essential for MCMV growth (Bubeck, 2004). We predicted that the binding 
region of M53/p38 to M50/p35 should also represent an essential function. 
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In order to set up a system to test binding of M53/p38 to M50/p35, 293 cells 
were either mock transfected, transfected with pM53 or pM50, expressing 
wtM53 or wtM50, respectively, or co-transfected with pM53 and pM50. Cell 
lysates were prepared and co-immunoprecipitation was performed. Half of the 
lysates were precipitated with specific rabbit anti-M50/p35 sera and protein A-
sepharose (Amersham; Fig. 15, lanes 1-4). The other half was precipitated with 
specific rat anti-M53/p38 sera and protein G-sepharose (Amersham; Fig. 15; 
lanes 5-8). Using anti-M50/p35 sera M50/p35 was precipitated indicated by a 
specific band at 35 kDa (Fig. 15, lane 3). M53/p38 could be clearly co-
precipitated indicated by a specific band at 38 kDa (Fig. 15, lane 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Co-immunoprecipitation of M53/p38 and M50/p35. Plasmids expressing M53/p38 
(lane 2,5) or M50/p35 (lane 3,7) were transfected into 293 cells. In parallel wt M53 was co-
transfected with wt M50/p35 (lanes 4 and 6). Cells were radioactively labeled and probes were 
either precipitated with protein-A sepharose using anti-M50/p35 specific rabbit serum (lanes 1-
4) or with anti-M53/p38 specific rat serum on protein-G sepharose (lanes 5-8). Samples were 
analyzed by SDS-PAGE followed by autoradiography. 
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For lysates of mock- or pM53 transfected cells no specific bands could be 
detected (Fig. 15, lanes 1, 2). Using anti-M53/p38 sera from rat M53/p38 was 
weakly precipitated (Fig. 15, lane 5). M50/p35 also weakly co-precipitated 
together with M53/p38 (Fig. 15, lane 6). No specific bands were detectable for 
controls “mock” and “M50” (Fig. 15, lanes 7, 8). Using anti-M53/p38 sera and 
protein G-sepharose the intensity of the specific signals was weaker compared 
to signal intensity after anti-M50/p35 immunoprecipitation. Thus, in all further 
co-immunoprecipitation experiments the specific anti-M50/p35 together with 
protein A-sepharose were used to detect the M50/p35-M53/p38 complex. 
As an alternative method to radioactive co-immunoprecipitation a non-
radioactive pull down assay was tested. pM50ST expressing Strep-II tagged 
M50/p35 was co-expressed with wt and mutant M53/p38 constructs. 
To test specificity of this assay, 293 cells were either mock transfected, 
transfected with pM50, expressing wt M50/p35 or transfected with pM50ST, 
expressing M50ST. Furthermore, pM50ST or pM50 were co-transfected with 
pM53, expressing wt M53/p38. As controls for protein load- and expression total 
cell lysates were separated by SDS-PAGE and subjected to Western-blot 
analysis using M53/p38- or M50/p35 specific antiserum (Fig.16, T, upper- and 
middle panel). The specific M53-band at 38 kDa became detectable only for the 
co-transfected probes (Fig. 16, upper panel, T, lanes 3, 5). The specific M50-
band at 35 kDa became detectable in the transfected- and co-transfected 
probes but was missing in the mock control (Fig. 16, middle panel, T, lanes 2, 3, 
4, 5). Using the Strep-II tag pull down assay only proteins bound to M50 should 
be recovered by Strep-Tactin sepharose beads from lysates of 293 cells. Next, 
bound proteins were eluted from the beads by desthiobiotin, separated by SDS-
PAGE and subjected to Western-blot analysis using M53/p38 specific 
antiserum. As predicted, the specific 38 kDa band of M53/p38 was only 
detectable in the lysate of 293 cells co-transfected with pM50ST and pM53 (Fig. 
16, B, lane 3) but not in the cell lysate of 293 cells co-transfected with pM50 and 
pM53 (Fig. 16, B, lane 5). Furthermore, no unspecific signals were detectable in 
mock control or probes M50ST and M50 (Fig. 16, B, lanes 1, 2, 4), indicating 
high specificity of this assay. This convinced us that the tagged M50/p35 protein 
had kept the properties of wt M50/p35 with regard to M53/p38 binding. 
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Therefore, for further experiments this pull down assay was used to confirm the 
results obtained by co-localization- and immunoprecipitation experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Pull down assay of M53/p38 with Strep tagged M50/p35. Wt M50/p35 or M50ST 
were transfected into 293 cells. In parallel wt M53 was co-transfected either with M50ST or wt 
M50/p35 into 293 cells. Total cell lysates were analyzed to test the protein expression by 
Western blot using specific antiserum against M53/p38 (upper panel, M53, total protein-T) or 
against M50/p35 (middle panel, M50, total protein-T). Proteins complexed with M50ST were 
precipitated by Strep-Tactin Sepharose. Desthiobiotin eluates were analyzed by SDS-PAGE 
and blotted on membranes. Wt M53/p38 protein was detected by Western blot with M53/p38 
specific antiserum (lower panel, M53, bound protein-B). 
 
 
1.5 The M53 ORF is essential for viral growth and infectivity can be 
reconstituted by ectopic re-insertion of the wild-type M53 gene into the 
M53 deletion genome 
 
1.5.1 Deletion of endogenous M53/p38 leads to loss of functionality of MCMV-
infection 
 
M53/p38 can be co-precipitated with M50/p35, indicating functional interaction 
between both gene products (Bubeck, 2004). Inactivation of genes homologous 
to M50 and M53 in α-herpesviruses severely affects viral growth in cell culture 
(Reynolds 2001, Fuchs 2002). Deletion of UL31 or UL34 from HSV-1 genome 
severely reduces the viral growth but the genes are not strictly essential (Liang, 
2004). In contrast, the M50 gene is essential for virus reconstitution in MCMV 
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and involved in the egress of the MCMV capsid from the nucleus (Bubeck, 
2004). To test essentiality of M53/p38 for MCMV replication, the M53 ORF was 
deleted from the MCMV-BAC using ET recombination in E. coli. The construct 
was tested for infectivity by transfection into MEFs and NIH3T3 cells. No 
infectious virus could be reconstituted by transfection of m16/17FRT-∆M53 
BAC, thus the M53 ORF is essential for virus reconstitution from genomic 
BACs. 
 
 
1.5.2 Ectopic expression of M53 reverts the null-phenotype of the ∆M53-MCMV-
BAC 
 
The null-phenotype of m16/17FRT-∆M53-BAC was reverted in order to ensure 
that the inability to gain infectious virus after transfection of m16/17FRT-∆M53-
BAC was solely due to the deletion of the M53 gene. By using the rescue 
plasmid pOriR6K-ie-zeo carrying an FRT site (Bubeck, 2004) the M53 ORF was 
re-inserted into the m16/17FRT-∆M53-BAC at its FRT site in Flp expressing E. 
coli. The Flp recombinase directs the site specific recombination between the 
FRT sites located on the rescue plasmid and the BAC (for construction 
principles see material and methods: 1.6.2.4, 2.3.2.1 and (Bubeck, 2004)). 
The rescue inserted the M53 ORF into the deletion BAC at the position between 
genes m16 and m17 resulting in pM53E-BAC. The predicted genome sequence 
of pM53E-BAC was confirmed by restriction pattern analysis (Fig. 17A) and 
sequencing at the position of the predicted genetic changes. Transfection of 
MEF cells with pM53E-BAC DNA resulted in viral progeny (M53E-MCMV). 
However, the growth of M53E-MCMV was slightly attenuated compared to the 
BAC derived wt virus. Under multi-step growth conditions the ectopic 
expression of the M53 gene in M53E-MCMV resulted in moderately (0.7 log) 
lower end-titers five days post-infection compared to the parental BAC-derived 
MCMV (Fig. 17B). 
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Figure 17. Ectopic rescue of the M53 deletion mutant. (A) Restriction analysis of ∆M53-
BAC, C3x-BAC and pM53E-BAC. Respective BAC-DNA was analyzed by NotI-restriction and 
DNA was separated on a BAC-TBE-agarose gel. Single insertion of pM53 into the ∆M53-BAC is 
accompanied by an additional band at around 11 kb. Multiple insertions can be determined by 
an additional band at 3.5 kb. (B) Growth kinetics of the viruses derived from pSMfr3 (wt) or 
pM53E (M53E) were determined on NIH 3T3 cells. Sub-confluent cultures were infected with 
the respective viruses. Supernatants of the infected cells were harvested on the indicated days 
and the infectious progeny was quantified by plaque assay. 
 
Attenuation of M53E-MCMV compared to the wt MCMV was observed in four 
independent experiments and may be due to the altered expression kinetics of 
ectopic M53/p38 from a late gene to a gene controlled by the immediate early 
(ie) promoter of HCMV and expressed throughout the replication cycle. Clearly, 
the M53 gene is essential for MCMV growth and the M53 null phenotype can be 
reverted by ectopic expression of the M53 ORF. These findings could be 
confirmed by a trans-complementation assay. A trans-complemented M53 
deletion virus was unable to produce viral progeny under non-complementing 
conditions (Lötzerich, 2006). 
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2. Construction of an insertion mutant library of the M53 ORF and analysis 
of the mutants in the context of the MCMV genome 
 
In the comprehensive mutant library for the M50 gene the efficiency of the in 
vitro transposon mediated mutagenesis was only 10% (Bubeck, 2004). We 
wanted to improve the efficiency of the in vitro transposition reaction in order to 
generate a comprehensive library of M53 insertion mutants. 
Donor: 20 ng 
Target: 80 ng 
pGPS4/ 
Litmus 28 
pST76k-S4/ 
Litmus 28 
pST76k-S4/ 
Litmus 28-M53 
pST76k-S4/ 
pOriR6kie-M53 
Selection marker Amp/ Cm Amp/ Cm Amp/ Cm Zeo/ Cm 
Bacteria host 
strain 
DH10B DH10B DH10B Pir 
Permissive 
temperature 
370C 430C 430C 430C 
Transposition/ 
reaction 
3550 6750 7920 1500 
 
Table 3. Transposon donor- and acceptor combinations used in this study. 
 
Different strategies for Tn7-based transposon mediated mutagenesis were 
tested (table 3). Since pGPS4 (NEB) and our rescue vector pOriR6K-ie-zeo-
M53 carry the same origins of replication this transposon donor-acceptor 
combination could not be used for mutagenesis. Therefore, the M53 ORF was 
first sub-cloned into the Litmus 28 vector which served as acceptor for Tn7-
based transposon mediated mutagenesis. In addition we constructed a new 
transposon donor plasmid pST76K-S4, which based on pGPS4 (NEB) and 
carries the Tn7 derived mini-transposon and a conditional origin of replication to 
allow donor plasmid elimination after the transposition reaction at non-
permissive temperature (Posfai, 1997). Furthermore, the origins of replication of 
pST76K-S4 and pOriR6K-ie-zeo-M53 are different, which enabled to use this 
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transposon donor-acceptor combination. Using the new transposon donor 
plasmid pST76k-S4 for in vitro transposition in combination with Litmus 28 
(NEB) the number of colony forming transpositions in one reaction was 
improved 90% compared to pGPS4 and Litmus 28, which were used for the 
transposon mediated mutagenesis of M50/p35 (Bubeck, 2004). Furthermore, 
using pST76k-S4 in combination with Litmus 28-M53 (pLitM53) the efficiency of 
transposition was even higher. In contrast by using the rescue plasmid 
pOriR6K-ie-zeo-M53 as transposon acceptor plasmid in combination with 
pST76k-S4, the efficiency of transpositions dropped by 80% compared to 
Litmus 28-M53 as acceptor. 
Restriction analysis of pOriR6K-ie-zeo-M53 after in vitro transposition revealed, 
that the Tn7 derived mini-transposon was inserted randomly into the rescue 
vector but preferentially inserted into the vector backbone and not into the M53-
ORF (Fig. 18A and B). Using pLitM53 and pST76k-S4 for in vitro transposition 
could increase the number of inserted Tn7 derived mini-transposon into the 
M53-ORF to 30% (Fig. 18C). A transposition into linearized M53 was not useful 
due to site specific preference of inserted transposon. Therefore, as the most 
effective transposon donor-acceptor combination, for transposon mediated 
mutagenesis of M53/p38 the transposon donor vector pST76k-S4 and the 
acceptor pLitM53 were used. Next, after in vitro transposition acceptor plasmids 
carrying the mini-transposon were selected and purified as a pool (for principle 
see Fig. 18E). 
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Figure 18A-D. Construction of an insertion mutant library of the M53 ORF. (A-D) 
Restriction analysis of M53-mutant libraries. (A) Different DNA preparations of poriR6k-ie-
zeoM53 after transposition with pST76k-S4 were analyzed by NotI-restriction. As control wt M53 
in poriR6k-ie-zeo was analyzed. The transposon inserted at various sites of the construct. (B) 
KpnI/NotI restriction of these DNA preparations revealed that the transposon preferentially 
inserted into the vector but not into the M53-ORF (black arrowheads for M53 insertion). (C) 
Different DNA preparations of pLit-M53 after transposition with pST76k-S4 were analyzed by 
KpnI/XbaI-restriction, As control wt M53 cloned to pLit was analyzed (black arrowheads for M53 
insertion).(D) After transposon mutagenesis in pLit-M53 the library was purified as a pool and 
sub-cloned into pOriR6k-ie-zeo. Different DNA preparations of poriR6k-ie-zeoM53TnL were 
analyzed by KpnI/NotI-restriction(black arrowheads for M53 insertion). 
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 Figure 18E. Principle of random 
transposon insertion mutagenesis. In a 
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first step in vitro transposon reaction was 
performed with pLit-M53 and pST76k-S4. 
Next, acceptor plasmids pM53Tn carrying 
the mini-transposon were selected and 
purified as a pool. In a third step M53-ORF 
which is increased in size due to 
transposon insertion was cloned by 
KpnI/NsiI to pOriR6k-ie-zeo resulting in 
M53mutTn. Removal of the Tn7-based 
transposon by PmeI restriction and 
religation resulted in 5 aa insertions in the 
M53-ORF. From a library of 28,000 
pOriR6K-ie-zeo-M53 mutants 986 
independent clones were screened by 
PCR and 498 plasmids with an insertion in 
the M53 ORF were sequenced. 
 
lection for M53 ORF with inserted transposon and increased in size due to 
e inserted transposon, was achieved by isolation of the ORF and insertion into 
e rescue plasmid pOriR6K-ie-zeo (Fig. 18D). PmeI digestion then removed 
e mini-transposon and subsequent re-ligation resulted in insertion of 5 aa or of 
stop codon into the coding sequence. This provided a library of 28,000 
riR6K-ie-zeo-M53 mutants. From this library 986 independent random clones 
re screened by PCR and 498 plasmids with an insertion in the M53 ORF 
re sequenced. Depending on the primary insertion site in the codons, both 
ad through- and truncation mutants were found, some at the very same amino 
id position (Fig. 19). 
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Figure 19. Analysis of 498 M53 insertion mutants. Displayed is the amino acid sequence of 
M53/p38. Arrowheads indicate transposon insertion sites. Three arrowheads indicate more than 
three insertions at the same position of the M53-ORF; Two arrowheads represent two insertions 
leading to the introduction of 5 aa into the M53 ORF. One arrowhead indicates transposon 
insertion at one site of the M53-ORF. Underlined parts of the M53 amino acid sequence indicate 
the conserved regions described in Fig.20. Red letters indicate aa which are strictly conserved 
in β-herpesvirus. 
 
 
From this set a total of 46 in frame insertion mutants representing a distribution 
of about one insertion per 10-15 aa and 8 stop mutants were selected for the 
complementation assays and were re-inserted one by one into the m16/17FRT-
∆M53-BAC (Re-insertion principle see figure 10).
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3. Alignment of the aa-sequence of a total of 36 members of the UL31 
family indicates conserved and not-conserved regions 
 
 
 
 
 
 
 
 
 
 
Figure 20. Analysis of M53 insertion mutants by ectopic cis-complementation of ∆M53-
BAC. Sequence comparison of the M53/p38 homologues. The amino acid sequence of 
M53/p38 was aligned to all 36 UL31 family members by use of the Vector NTI Align X program 
(Invitrogen) via the BLOSUM 62 similarity matrix. The depicted similarity plot was calculated 
using a 5-aa window size and with scores for identity and strong and weak similarities of 1.0, 
0.5 and 0.2, respectively. The x-axis represents the number of the amino acids of the 
consensus sequence. Conserved regions one to four (CR1-4) are indicated below the diagram. 
 
Using the AlignX program (Invitrogen) the aa-sequence of a total of 36 
members of the UL31 family (www.sanger.ac.uk/Software/Pfam, accession 
number PF02718; (Bateman, 2004)) were aligned (Fig. 20). The average 
similarity between beta-herpesvirus UL31 members is 47.5% and 25.1% within 
the whole family. However, the homology is not equally distributed along the 
sequences. A variable N-terminal and a conserved region including the central 
and C-terminal 2/3 of the proteins were identified with a similarity of 84.6% 
among the beta-herpesviruses and 44% for the whole family. Furthermore, 
when the entire UL31 family was aligned, the similarity plot indicated four peaks 
along the conserved region, which may reflect strictly conserved domains and 
were assigned as conserved regions one to four (CR1-CR4). We assumed that, 
according to the sequence conservation, lethal mutations should accumulate in 
the conserved central and C-terminal regions (corresponding to aa 115-333 of 
M53/p38) rather than in the N-terminal variable region (corresponding to aa 1-
114 of M53/p38). We expected to find the binding site(s) for M50/p35 within one 
of the four conserved regions. 
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4. Ability of the selected M53-mutant set to rescue the M53 null 
phenotype: Confirmation of the in silico predicted sequence homology 
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Figure 21. M53 mutants and their ability to rescue virus growth of the ∆M53 genome. 
Displayed is the amino acid sequence of M53/p38. Arrowheads indicate transposon insertion 
sites. Open arrowheads indicate insertions leading to a stop codon; filled arrowheads represent 
insertions leading to the introduction of 5 aa into the M53 ORF. Light green arrowheads indicate 
mutants that rescued the ∆M53 phenotype. Black arrowheads indicate those mutants that were 
not able to rescue the ∆M53 phenotype. Underlined parts of the M53 amino acid sequence 
indicate the conserved regions described in Fig.20. 
 
First, the ability of the selected mutant set to rescue the M53 null phenotype 
was tested. To this end, M53 mutants were re-inserted into the ∆M53-MCMV-
BAC, which was then transfected into MEF (reconstitution principle see figure 
11). The results of the virus reconstitution screen are summarized in figure 21. 
All in frame insertions within the N-terminal part of the M53 ORF (aa 1-114) 
gave rise to viral progeny. In contrast, 32 out of 37 insertion mutants in the 
central- and C-terminal domains had a lethal phenotype. The clusters of lethal 
mutants are interspersed by single viable insertion mutants. The 14 viable 
 
 - 84 - 
 
 D. Results 
 
insertion mutants showed viral plaques comparable to the MCMV-M53E virus. A 
set of 8 truncation mutants was chosen to test the essentiality of the four 
conserved sequence clusters. All truncation mutants turned out to be non-
functional. Altogether, loss-of-function-mutants accumulated in the conserved 
central- and C-terminal part of M53/p38. The less conserved N-terminal domain 
tolerated a number of insertions suggesting that this domain has a less stringent 
function. 
 
 
5. The N-terminal 1/3 of M53/p38 contains a nuclear localization signal 
 
Within the non-conserved N-terminal region of M53/p38 two overlapping 
bipartite nuclear localization sequences (NLS) are predicted at aa 24-41. In 
order to test this, the N-terminal domain of the wt M53 protein from aa 16-106 
was deleted thereby creating mutant M53-∆16-106. The very N-terminal 15 aa 
were kept as target sequence for the M53/p38 peptide specific antibody 
(Bubeck, 2004). After insertion into m16/17FRT-∆M53-BAC the M53-∆16-106 
was not able to rescue the null phenotype of the genome (Fig. 22). After 
transfection of NIH 3T3 cells with pOriR6K-ie-zeo expressing the M53-∆16-106 
cytoplasmic staining was observed instead of the diffuse nuclear staining typical 
for wt M53/p38 (Fig. 22). To prove that the loss of function of the M53-∆16-106 
mutant was due to protein miss-location we inserted the 9aa NLS from the 
SV40 large T antigen into M53-∆16-106 to create M53-∆16-106NLS. The 
heterologous NLS restored the correct nuclear localization of the protein (Fig. 
22). The existence of an NLS within the N-terminal part of M53/p38, was tested 
by a fusion between aa 1-106 of M53/p38 and the EGFP ORF. NIH 3T3 cells 
expressing EGFP showed fluorescent protein in both cytoplasm and nucleus 
whereas the M53/1-106-EGFP fusion construct was restricted to the nucleus. 
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Figure 22. Functional analysis of N-terminal deletion mutants of M53. (A) Schematic 
representation of the different deletion constructs. The epitope for the anti-M53/p38 serum is 
indicated by a star at the very N-terminus of the diagrams. The variable sequences are 
represented by open boxes. The conserved regions are shown as shaded boxes. The deleted 
sequences are indicated by a line. The inserted SV40-NLS is indicated by a crossed box. The 
EGFP sequence is shown as a diagonally hatched box. (B) Wt M53 and mutants M53-∆16-106 
and M53-∆16-106NLS were reinserted into ∆M53-BAC. BAC DNA was isolated and transfected 
into MEF cells and screened for plaque formation and the rescue result is indicated (+, -, N.a.-
not applicable). (C) Sub-cellular localization of expressed proteins with N-terminal deletions. 
NIH 3T3 fibroblasts were transfected with the indicated constructs. The localization of the 
expressed proteins were visualized by indirect immunofluorescence for the wt M53, M53-∆16-
106 and M53-∆16-106NLS. Endogenous fluorescence was recorded for EGFP and mutant 
s106EGFP. 
 
Finally, also the mutant M53-∆16-106NLS, lacking aa 16 to aa 106 but carrying 
the SV40 NLS, but not M53-∆16-106 rescued the null phenotype of 
m16/17FRT-∆M53-BAC. Thus, nuclear targeting of the protein is the only 
essential function of the N-terminal part of M53/p38. 
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6. The M50/p35 binding site of M53/p38
 
6.1 Using M53-stop and N-terminal deletion mutants the M50/p35 binding 
site of M53/p38 can be located to CR1 of M53/p38 
 
We predicted that binding of M53/p38 to M50/p35 should represent an essential 
function. Therefore, the pool of lethal M53 mutants should contain mutants 
which have lost the ability to bind to M50/p35. For a first rough mapping of the 
binding region the selected set of M53/p38 truncation mutants was analyzed. To 
this end, NIH 3T3 fibroblasts were transfected either with wt M53/p38 or 
M53/p38 mutants in the presence or absence of M50/p35 co-expression. Sub-
cellular localization of wt and mutated M53/p38 was analyzed by confocal 
microscopy after indirect immunofluorescence staining with specific antisera 
(Fig. 23A). After isolated expression all truncation mutants as well as the wt 
M53/p38 (M53) showed the typical diffuse nuclear staining pattern (Fig. 23A, 
first vertical row). 
After co-transfection with M50/p35 the diffuse nuclear staining and no co-
localization with M50/p35 was observed only for the stop mutant s106 lacking 
all four conserved regions (Fig. 23A, second horizontal row). All other stop 
mutants, s137, lacking CR 2-4 and the C-terminal part of CR1 and s168, lacking 
CR 2-4 (Fig. 23A, third and fourth horizontal rows), co-localized with M50/p35 at 
the nuclear rim. In addition, M53∆16-106, lacking the NLS, lost the ability to be 
transported to the nucleus (see Fig. 22) and therefore did not co-localize with 
M50/p35, whereas functional M53∆16-106NLS did (Fig. 23B). 
 
 
 
 
 
 
 
 
 
 
 
 - 87 - 
 
 D. Results 
 
 A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23A. Analysis of the interaction of M53 stop mutants with M50/p35. Localization of 
M53 stop mutants. NIH 3T3 cells were transfected with M53 stop mutants s106, s137 or s168 
alone (first vertical row) or together with wt M50/p35 (second to fourth vertical rows). Single 
transfected cells were stained with rat specific antiserum against M53/p38. For detection a 
fluorescein-conjugated secondary antibody was used (green). Co-transfected cells were treated 
as described above and co-stained with an M50/p35-specific rabbit serum, which was detected 
by Texas red coupled secondary antibody (red). As control wt M53/p38 was used (first 
horizontal row). 
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Figure 23B and C. Analysis of the interaction of M53 stop- and N-terminal deletion 
mutants with M50/p35. (B) Localization of M53 N-terminal deletion mutant M53∆16-106NLS. 
NIH 3T3 cells were transfected with M53∆16-106NLS alone (first vertical row) or together with 
wt M50/p35 (second to fourth vertical rows). Single transfected cells were stained with rat 
specific antiserum against M53/p38. For detection a fluorescein-conjugated secondary antibody 
was used (green). Co-transfected cells were treated as described above and co-stained with an 
M50/p35-specific rabbit serum, which was detected by Texas red coupled secondary antibody 
(red). (C) Localization of M53-stop mutants fused to EGFP. NIH3T3 cells were transfected with 
wt M53 or mutant M53 fused to EGFP (first vertical row) or co-transfected with wt M50/p35 
(second to fourth vertical row). Co-transfected cells were stained with rabbit specific antiserum, 
which was detected by Texas red coupled secondary antibody (red). 
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Furthermore, NIH 3T3 cells expressing wtM53-EGFP fusion construct or fusion 
constructs of M53 truncation mutants and EGFP in presence of M50/p35 co-
expression were analyzed. Sub-cellular localization of wt and mutated M53/p38 
was investigated by confocal microscopy after indirect immunofluorescence 
staining with specific antisera. In isolated expression wtM53- and mutant EGFP 
fusion constructs were diffusely distributed in the nucleus, as described for 
wtM53 (Fig. 23C, first vertical row). After co-expression with M50/p35 the 
wtM53-or s137- and s168-EGFP fusion constructs co-localized together with 
M50/p35 to the nuclear envelope but showed a more punctuated staining than 
wtM53/p38 (Fig. 23C, first, third and fourth horizontal rows). Fusion construct 
s106-EGFP was present in the nucleus but lost the ability to co-localize with 
M50/p35 (Fig. 23C, second horizontal row). 
These co-localization experiments indicated a critical role of M53/p38 aa 1-137 
for interaction with M50/p35. To confirm the results obtained by sub-cellular 
localization of the M53 truncation mutants, we performed co-
immunoprecipitation experiments with the stop mutants. 293 cells were co-
transfected with expression plasmids containing mutant M53 constructs and 
pM50 expressing wt M50/p35. Controls were transfected with plasmids 
expressing wt M50, wt M53 or M53 truncation mutants alone. Cell lysates were 
precipitated by specific antisera. The wt M53/p38 was co-precipitated in the 
presence of M50/p35 when M50 specific antiserum was used (Fig. 24A, lane 3). 
The M53s106 stop mutant was unable to bind to M50/p35 (lane 5). All other 
stop mutants M53s137, M53s168, and M53s185 bound M50/p35 as shown by 
the specific bands corresponding to the expected molar masses after co-
precipitation with anti-M50/p35 (lanes 7, 9 and 11). 
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Figure 24A. Co-immunoprecipitation of M53 stop mutants and M50/p35. Plasmids 
expressing wt M53/p38 (lane 1), wt M50/p35 (lane 2) and M53 stop mutants (lanes 4, 6, 8, 10) 
were transfected into 293 cells. In parallel wt M53/p38 and M53 stop mutants were co-
transfected with wt M50/p35 (lanes 3, 5, 7, 9, 11). Cells were radioactively labeled and single 
transfected probes were precipitated with anti-M53/p38 specific rat serum on Protein-G 
Sepharose. Protein complexes with wt M50 were precipitated with Protein-A Sepharose using 
anti-M50/p35 specific rabbit serum (lanes 3, 5, 7, 9, 11; black arrowheads). Samples were 
analyzed by SDS-PAGE followed by autoradiography. 
 
Furthermore, also the M53∆16-106NLS mutant, containing 9 aa of the SV40 
NLS and lacking the N-terminal part of the protein till aa 106, but not M53∆16-
106, lacking the same N-terminal aa but also the SV40 NLS, co-precipitated 
with M50/p35 (Fig. 24B). 
The binding pattern was further tested in pull down assays after co-transfection 
of pM50ST expressing Strep-II tagged M50/p35 with wt and mutant M53 
constructs. From the lysates of co-transfected 293 cells proteins bound to 
M50ST were recovered by Strep-Tactin Sepharose beads. The M50ST 
complexes were eluted from the beads by desthiobiotin and separated by SDS-
PAGE and subjected to Western-blot analysis using M53/p38 specific 
antiserum. The data were in full agreement with the results obtained by co-
immunoprecipitation with wt M50/p35 (Fig. 24C). 
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Figure 24B and C. (B) Co-immunoprecipitation of M53 N-terminal deletion mutants and 
M50/p35. Plasmids expressing M53∆1-106 (lane 1) or M53D1-106N (lane 3) were transfected 
into 293 cells. In parallel both M53 mutants were co-transfected with wt M50/p35 (lanes 2 and 
4). Cells were radioactively labeled and single transfected probes were precipitated with anti-
M53/p38 specific rat serum on Protein-G Sepharose. Protein complexes with wt M50 were 
precipitated with Protein-A Sepharose using anti-M50/p35 specific rabbit serum. Samples were 
analyzed by SDS-PAGE followed by autoradiography. (C) Pull down assay of M53 stop 
mutants with Strep tagged M50/p35. Wt M53/p38 and M53 stop mutants were co-transfected 
with M50ST into 293 cells. Total cell lysates were analyzed to test the protein expression by 
Western blot using specific antiserum against M53/p38 (upper panel, total protein-T). Proteins 
complexed with M50ST were precipitated by Strep-Tactin Sepharose. Desthiobiotin eluates 
were analyzed by SDS-PAGE and blotted on membranes. Wt M53/p38 and mutant proteins 
were detected by Western blot with M53/p38 specific antiserum (lower panel, bound protein-B). 
 
These data, together with the functionality of M53∆16-106NLS mutant in virus 
context suggested that a short sequence of M53/p38 CR1 is required for 
M50/p35 binding. 
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6.2 Using M53 insertion mutants the M50/p35 binding can be located to 
the beginning of CR1 and the most important residues are probably 
represented by aa 115 to 131 of the M53/p38 protein 
 
To describe the contribution of specific residues involved in M50/p35-M53/p38 
interaction we analyzed M53/p38 mutants with insertions in the region between 
aa 106 and aa 138 by confocal microscopy and by the M50ST mediated protein 
pull down assay. NIH 3T3 cells were transfected with different M53/p38 
insertion mutants alone or together with pM50. As expected, all analyzed M53 
insertion mutants showed a diffuse nuclear staining after isolated expression 
(Fig. 25A, first vertical row). After co-transfection with pM50 only mutant 
M53i128 was not able to co-localize with M50/p35 at the nuclear rim (Fig. 25A, 
third horizontal row). All other insertion mutants tested, i.e. i104, i115, i131 and 
i138 tolerated the 5 aa insertion in as much as they were recruited to the NE by 
M50/p35 co-expression. 
 A 
Figure 25A. Analysis of the 
interaction of M53 insertion 
mutants with M50/p35. 
Localization of M53 insertion 
mutants. NIH 3T3 cells were 
transfected with M53 insertion 
mutants i104, i115, i128, i131 or 
i138 alone (first vertical row) or 
together with wt M50 (second to 
fourth vertical rows). Single 
transfected cells were stained 
with rat specific antiserum 
against M53/p38. For detection 
a fluorescein-conjugated 
secondary antibody was used 
(green). Co-transfected cells 
were treated as described above 
and co-stained with an M50/p35 
specific rabbit serum, which was 
detected by Texas red coupled 
secondary antibody (red). 
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In addition, 293 cells were co-transfected with pM50ST and the same set of 
M53/p38 insertion mutants which was used in the co-localization experiments. 
In parallel, the total cell lysates were analyzed to determine the expression of 
the M53/p38 mutants by Western-blot. Furthermore, for Strep II-tag pull down 
experiments instead of standard cell lysates nuclear extracts were processed to 
enrich the nuclear M53/p38. Among the mutants tested, only the insertion 
mutant M53i128 was not pulled down by M50ST (Fig. 25B, lane 3), which is in 
line with the results of the co-localization studies shown above. 
 
B  
 
 
 
 
 
 
 
Figure 25B. Pull down analysis of M53 insertion mutants with Strep tagged M50/p35. 293 
cells were co-transfected with M53 insertion mutants and M50ST. Total cell lysates were 
analyzed by SDS-PAGE and Western blot using specific M53/p38 antiserum (upper panel, T). 
Proteins complexed with M50ST were precipitated with Strep-Tactin Sepharose and 
desthiobiotin eluted proteins were separated by SDS-PAGE. Signals for M53/p38 insertion 
mutants were visualized by Western blot using specific antiserum against M53/p38 (lower 
panel, B). 
 
Taken together, co-localization- and protein-protein interaction assays using 
several C-terminal truncation and insertion mutants indicated that the region of 
M53/p38 which is necessary for M50/p35 binding is located at the start of CR1 
and the most important residues are probably represented by aa 115 to 131 of 
the M53/p38 protein. 
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7. Characterization of the M50/p35 binding site of M53/p38 
 
7.1 Distinct M53-point mutants lost to some extent the ability to localize to 
M50/p35 
 
Insertions of five amino acids helped to identify a binding motif but the 
contribution of the inserted amino acids that differ between the different 
insertion mutants is difficult to evaluate. In order to define the relative role of 
individual amino acids with respect to M50/p35 binding the 12 amino acids 
which are conserved in beta-herpesviruses within the N-terminal half of CR1 (aa 
112-137) were one by one replaced by alanine. After transfection of NIH 3T3 
cells with the M53/p38 point mutants alone or co-transfection with M50/p35, 
respectively, the sub-cellular localization of the M53/p38 mutants was analyzed. 
All M53/p38 point mutants showed a diffuse nuclear staining when expressed 
alone (Fig. 26, first vertical row). After co-expression with M50/p35, the intra-
nuclear distribution of M53 point mutants fell into three classes of phenotypes:  
 
i. Mutants that redistributed to the nuclear rim and recruited M50/p35 
similar to wt M53/p38 (M53P123A, M53D124A, and M53E126A). 
ii. Mutants that had apparently lost the ability to redistribute to the nuclear 
rim in presence of M50/p35 (M53Y129A (Fig. 26), M53L130A and M53I133A). 
iii. Mutants with intermediate phenotypes. Several mutants fell into this 
class and their phenotypic appearance was variable. One subset showed 
abundant diffuse intra-nuclear staining in addition to co-localization with 
M50/p35 at the nuclear rim (M53L112A (Fig. 26), M53H116A, M53F119A, 
M53I137A). The second type of mutants co-localized with M50/p35 at least to 
some extent. 
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Figure 26. Functional analysis 
of M53 point mutants. Sub-
cellular localization of M53 point 
mutants. NIH 3T3 cells were 
transfected alone with M53 point 
mutants L112A, L125A, K128A 
and Y129A (first vertical row) or 
co-transfected with wt M50/p35 
(second to fourth vertical rows). 
Single transfected cells were 
stained with rat specific 
antiserum against M53/p38. For 
detection a fluorescein-
conjugated secondary antibody 
was used (green). Co-
transfected cells were treated as 
described above and co-stained 
with an M50/p35 specific rabbit 
serum, which was detected by 
Texas red coupled secondary 
antibody (red). 
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The remarkable phenotype, however, was a new distribution of M53/p38 
mutants upon co-expression of M50/p35 resulting in the formation of discrete 
intra-nuclear aggregates (M53L125A) and fibrous structures (M53K128A, Fig. 
26) which did not co-localize with M50/p35. In the absence of M50/p35 the intra-
nuclear distribution of the mutants was indistinguishable from that of wt 
M53/p38. 
 
 
7.2 Distinct M53/p38 point mutants showed reduced binding to M50/p35 and 
resulting viruses were strongly attenuated 
 
Next, 293 cells were co-transfected with M50ST and the set of alanine scanning 
M53/p38 mutants. Strep-Tactin Sepharose pull-down was performed to analyze 
the binding capacity of the M53 point mutants to M50ST. Remarkably, despite 
the different distribution phenotypes, all M53 point mutants could still be 
retrieved by M50ST pull-down, including those that did not show a detectable 
interaction in the co-localization assay (Fig. 27A). Notably, the binding was 
found significantly reduced for the mutants M53L112A, M53L125A, M53Y129A 
and M53M133A. 
 
A  
 
 
 
 
 
 
 
Figure 27A. Pull down analysis of 12 M53 point mutants with Strep-tagged M50/p35. 293 
cells were co-transfected with the indicated M53 point mutants and M50ST. Total cell lysates 
were analyzed to test the protein expression by Western blot using specific antiserum against 
M53/p38 (upper panel, T). Proteins complexed with M50ST were precipitated by Strep-Tactin 
Sepharose. Desthiobiotin eluates were analyzed by SDS-PAGE and blotted on membranes. 
Signals for M53 point mutants were visualized by Western blot with M53/p38 specific antiserum 
(lower panel, B). As positive control for precipitation functional insertion mutant M53i104 was 
used (lane 1) and M53 insertion mutant M53i128 served as negative control (lane 2). 
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Since there was a substantial degree of variability in the co-localization assay 
and certain heterogeneity of interactions detectable by the pull-down assay, we 
tested the M53 point mutants for functionality in the viral context. Interestingly, 
the null phenotype of ∆M53FRT-BAC could be reverted by all M53 point 
mutants. Usually about 11 days are required to detect the first virus plaques 
after transfection of the ectopically complemented deletion genome. 
Remarkably, virus reconstitution time and plaque formation was significantly 
delayed to three weeks for mutants M53K128A and M53L130A. Virus 
reconstitution from the BAC carrying M53Y129A required even six weeks. 
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 Bure 27B. Rescue of ∆M53-BAC by M53 point mutants K128A, Y129A and L130A. Growth 
etics of the viruses derived from pM53E or pM53K128AE, pM53Y129AE and pM53L130AE. 
H 3T3 cells were infected with the respective viruses. Supernatants of the infected cells were 
rvested on the indicated days, and virus titers were determined by plaque assay. 
cordingly, the growth of mutants M53K128A and M53L130A was reduced by 
e order and M53Y129A was attenuated more than 3 orders of magnitude in 
mparison with a genome complemented by wt M53 ORF (Fig. 27B). These 
ta show that already the exchange of a single aa within the binding region of 
53/p38 can strongly affect M50/p35 binding but cannot completely abolish a 
nctional M50/p35-M53/p38 interaction. 
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7.3 Exchange of only two aminoacids abolishes M50-M53 interaction and 
rescue of the M53 null phenotype 
 
To rigorously test the binding site we replaced either two adjacent critical amino 
acids (M53YL129-130A) or three adjacent amino acids by alanine 
(M53KYL128-130A). In addition, we deleted the sequences aa 108-136 of M53 
(M53∆106-136). As expected, each of these mutants completely failed to co-
localize with M50/p35 (Fig. 28A), failed to interact with M50ST in the pull-down 
assay (Fig. 28B) and also failed to rescue the M53 null phenotype. 
 
A  
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Figure 28A. Functional analysis of M53 point-and deletion mutants. Sub-cellular 
localization of M53 point-and deletion mutants. NIH 3T3 cells were transfected alone with M53 
point- and deletion mutants M53YL129-130A, M53KYL128-130A, ∆16-136A, ∆16-106N and 
∆16-136N (first vertical row) or co-transfected with wt M50/p35 (second to fourth vertical rows). 
Single transfected cells were stained with rat specific antiserum against M53/p38. For detection 
a fluorescein-conjugated secondary antibody was used (green). Co-transfected cells were 
treated as described above and co-stained with an M50/p35 specific rabbit serum, which was 
detected by Texas red coupled secondary antibody (red). 
 
 B C 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28B and C. Analysis of the interaction of M50/p35 with M53 point- and N-terminal 
deletion mutants. (B) Pull down analysis of M53 point mutants YL129,130A, KYL 128-130A 
and M53-∆108-136 with Strep-tagged M50. 293 cells were co-transfected with M53 point 
mutants and M50ST. Expression of the constructs was tested by SDS-PAGE of total cell lysates 
and Western blot using specific M53/p38 antiserum (upper panel, T). Proteins complexed with 
M50ST were precipitated by Strep-Tactin Sepharose. Desthiobiotin eluates were analyzed by 
SDS-PAGE and blotted on membranes. Signals for M53 point mutants were visualized by 
Western blot with M53/p38 specific antiserum (lower panel, B). As a positive control a functional 
insertion mutant, M53i104, was used (lane 1) and M53i128, which failed to bind to M50/p35 
served as negative control (lane 2). (C) Pull down analysis of N-terminal deletion mutants of 
M53/p38. 293 cells were co-transfected with M53 N-terminal deletion mutants M53-∆16-
106NLS or M53-∆16-136NLS and M50ST. Analysis of total cell lysates (upper panel, T) and 
protein complex formation (lower panel, B) was performed as described above. 
 
The N-terminal deletion mutant of M53-∆16-106NLS carrying deletions of aa 16 
to aa 106 and an artificial NLS rescued the M53 deletion after ectopic re-
insertion into the mutant MCMV-BAC indicating that this mutant can interact 
with the M50/p35. To confirm the M50/p35 interaction site mapping data, the N-
terminal deletion was increased to aa 16 to aa 136 (M53-∆16-136NLS). As 
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expected, the M53-∆16-106NLS did interact with M50ST in the pull-down assay 
whereas M53-∆16-136NLS did not (Fig. 28C). Also, in contrast to M53-∆16-
106NLS the N-terminal deletion mutant M53-∆16-136NLS was not able to 
rescue the M53 null phenotype upon insertion into the deletion BAC. 
 
 
8. Homo-oligomerization of M53/p38 
 
So far we could show, that the N-terminal domain of M53/p38 possesses a 
nuclear targeting sequence as functional element. The N-terminal 1/3 of the 
protein is crucial for M50/p35 interaction. Next, we wanted to investigate, if 
M53/p38 is able to interact with itself. Therefore, 293 cells were co-transfected 
with expression plasmids containing Ig-tagged M53 construct and pM53 
expressing wt M53/p38. Controls were mock transfected or transfected with 
plasmids expressing wt M53 or Ig-tagged M53 alone. In total cell lysates the 
M53/p38 specific signal at 38 kDa or at 62 kDa for Ig-tagged M53/p38 became 
detectable for all analyzed probes but was missing for mock transfected 293 
cells (Fig. 29, T, lanes 1-4). 
 
Figure 29. Analysis of oligomerization of 
M53/p38. Pull down analysis of wt M53 with Ig-
tagged M53. 293 cells were transfected with wt 
M53 or Ig-tagged M53 or co-transfected with 
wt M53 and IgM53. Expression of the 
constructs was tested by SDS-PAGE of total 
cell lysates and Western blot using specific 
M53/p38 antiserum (upper panel, T). Proteins 
complexed with Ig M53 were precipitated by 
protein-A sepharose. Eluates were analyzed 
by SDS-PAGE and blotted on membranes. 
Signals for M53 were visualized by Western 
blot with M53/p38 specific antiserum (lower 
panel, B). 
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Next, cell lysates were precipitated by addition of protein G-sepharose 
(Pharmacia). M53/p38 signals were visualized by Western-blot using rat 
antiserum specific to the N-terminal 15 amino acids (aa) of the M53/p38 ORF 
(Bubeck, 2004). As expected, the Ig-tagged M53/p38, could be precipitated 
directly by the G-sepharose beads as indicated by presence of the specific 62 
kDa band (Fig. 29, B, lane 3), whereas the wt M53/p38 did not bind when 
expressed alone (Fig.29, B, lane 2). However, the wt M53/p38 could be co-
precipitated in the presence of Ig-tagged M53/p38, indicated by an additional 
specific signal at 38 kDa (Fig. 29, B, lane 4). Therefore, beside interaction with 
M50/p35, M53/p38 is able to oligomerize. 
 
 
9. Cellular interaction partners of M53/p38 and M50/p35
 
Next, we wanted to target functions that can be assigned to the C-terminal 2/3 
of M53/p38. For the α-herpesvirus herpes simplex virus type 1 (HSV-1) it has 
been described recently that the M53/p38- and M50/p35 homologues UL31 and 
UL34 can induce conformational changes in the nuclear lamina (Reynolds, 
2004). Both gene products have been assumed to bind to lamin A/C thereby 
promoting the late maturation of viral replication compartments to the nuclear 
periphery (Simpson-Holley, 2004). Furthermore, UL34- and UL31-gene 
products from HSV-1 seem to be involved in alteration of the nuclear 
architecture (Simpson-Holley, 2005). The M53/p38- and M50/p35 homologues 
BFLF2 and BFRF1 of γ-herpesvirus EBV were shown to interact as complex 
with lamin B (Farina, 2005; Gonnella, 2005). Moreover, for human 
cytomegalovirus (HCMV) it has been described that the viral kinase pUL97 is 
recruited to the nuclear lamina by the cellular protein p32, thereby inducing 
conformational changes there (Marschall, 2005). Herpesvirus nucleocapsid 
formation is followed by a complex process of nucleocapsid transitions through 
cellular membranes. Most interestingly, co-transfected UL31 and UL34 of the α-
herpesvirus pseudorabies virus (PrV) seem to be sufficient for formation of 
budding membrane vesicles from the inner nuclear membrane in absence of 
any other viral proteins (Klupp, 2006). These data indicate that a number of host 
cell proteins might be involved in function of the NEC either as a target or as a 
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partner for function. Therefore, we wanted to analyze, which cellular proteins 
can be found that are associated with the NEC of MCMV. 
 
 
9.1 Identification of the M50/p35-M53/p38 complex in post nuclear 
fractions 
 
The nuclear lamina is on the one hand connected with integral membrane 
proteins of the INM and on the other hand connected with the chromatin 
(Östlund, 2006, Foisner, 2001, Gruenbaum, 2005). This makes the nuclear 
matrix components difficult to analyze. In order to study interaction of matrix 
components with M53/p38 or M50/p35, the NEC, extraction conditions had to 
be set up in a fashion that the matrix is disrupted but that NEC formation is 
maintained. Matrix proteins can be solubilized using mild detergents and high 
salt conditions (salt out effect; Montes de Oca, 2005). Therefore, first we tested 
the effect of increasing salt concentration on complex formation by M53/p38 
and M50p35. To that end, 293 cells were either mock transfected, transfected 
with pM53 or pM50, expressing wtM53 or wtM50, or co-transfected with pM53 
and pM50. 
 
 
 
 
 
 
 
 
 
 
Figure 30. Co-immunoprecipitation of M53/p38 and M50/p35 under increasing salt 
conditions. Plasmids expressing wt M53/p38 (lane 2), wt M50/p35 (lane 3 were transfected 
into 293 cells. In parallel wt M53/p38 was co-transfected with wt M50/p35 (lanes 4-10). Cells 
were radioactively labeled, lysed at NaCl concentrations 150 mM, 300 mM, 400 mM, 600 mM, 
750 mM and 900 mM and single transfected probes were precipitated with anti-M53/p38 
specific rat serum on protein-G sepharose or with anti-M50/p35 specific sera from rabbit on 
protein-A sepharose. Protein complexes with wt M50 were precipitated with protein-A 
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sepharose using anti-M50/p35 specific rabbit serum. Samples were analyzed by SDS-PAGE 
followed by autoradiography. 
Cell lysates were prepared at different salt concentrations and co-
immunoprecipitation was performed. Lysates of mock and pM50 transfected 
cells or lysates of cells co-transfected with M50/p35 and M53/p38 were 
precipitated with specific rabbit anti-M50/p35 sera and protein A-sepharose 
(Fig. 30, lanes 1,2 and 4-10). M53/p38 was precipitated with specific rat anti-
M53/p38 sera (Fig. 30, lane 2). As described previously, using anti-M50/p35 
sera M50/p35 was precipitated indicated by a specific band at 35 kDa (Fig. 30, 
lanes 1,2 and 4-10). M53/p38 could be precipitated and co-precipitated at all 
tested salt concentrations indicated by a specific band at 38 kDa (Fig. 30, lane 2 
and 4-10). The amount of co-precipitated M53/p38 increased by addition of 300 
mM NaCl to the lysis buffer and reached its maximum at 400 mM NaCl (Fig. 30, 
lanes 5 and 6). M53/p38 co-precipitation at higher salt concentrations was 
slightly less efficient than at 400 mM NaCl (Fig. 30, lanes 8-10). Therefore, to 
guarantee complex stability of M53/p38 and M50/p35 in further experiments for 
protein extraction the NaCl concentration was limited to 400 mM. 
 
 
9.2 Cellular lamins and M53/p38 are retained in a salt resistant 
compartment of the cell: the nuclear matrix 
 
Next, we determined the effect of different salt concentrations on solubilization 
of nuclear matrix proteins such as lamin B and A/C and M53/p38 after MCMV-
infection. To that end, NIH 3T3 fibroblasts were infected with wt MCMV at an 
MOI of 0.5 and cells were lysed at different salt concentrations 24 hours after 
infection and separated by SDS-PAGE. Proteins retained in the pelleted cellular 
debris were re-solubilized and analyzed, too. The M53/p38 signals in different 
fractions were visualized by Western-blot using rat antiserum specific to the N-
terminal 15 amino acids (aa) of the M53/p38 ORF at a dilution of 1:2000 
(Bubeck, 2004). 
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Figure 31. Cellular lamins and 
M53/p38 are retained in a salt 
resistant compartment of the 
cell. 3T3 cells were infected with 
wt MCMV at an MOI of 0.5. 24 
hours post infection cells were 
lysed at different salt 
concentrations. Pelleted debris 
from cell lysates (lanes 1-3) and 
supernatants (lanes 4-6) were 
analyzed by Western blot using 
specific antiserum against 
M53/p38, lamin B or lamin A/C. 
Control cell lysates from 
uninfected NIH3T3 cells were 
probed for lamin B. 
 
 
 
 
 
 
 
The specific M53/p38 band at 38 kDa was detectable for all analyzed probes of 
the pelleted cellular debris after low-, moderate- and high salt protein extraction, 
indicating that the majority of M53/p38 was still retained in the matrix (Fig. 31, 
lanes 1-3). At high salt extraction the M53/p38 signal strength was slightly 
reduced for the pelleted cellular debris (Fig. 31, lane 3). Accordingly, the 
M53/p38 signal intensity in the supernatant increased after high salt protein 
extraction (Fig. 31, lanes 6). In contrast low-or moderate salt extraction did not 
increase the M53/p38-signal intensity in the supernatants. Here, using low-or 
moderate salt protein extraction M53/p38 was hardly solubilized (Fig. 31, lanes 
4, 5). High salt protein extraction could improve M53/p38 solubilization after 
infection (Fig. 31, lane 6). 
The same conditions were applied for lamins B and A/C which were visualized 
by Western-blot using specific antibodies at a dilution of 1:300. Interestingly, in 
contrast to lamin C the lamin A was not efficiently solubilized after low- or high 
salt protein extraction. Control cell lysates from uninfected NIH 3T3 cells were 
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processed as described above and probed for lamin B. Also lamin B could be 
detected only after high salt protein extraction. Therefore, M53/p38 and cellular 
proteins lamin B and A/C are retained in the same salt resistant nuclear 
compartment of the cell designated as nuclear matrix. Proteins can be efficiently 
solubilized using high salt conditions for extraction. Apparently, in contrast to 
uninfected cells after MCMV infection some lamin B is already solubilized using 
low salt extraction conditions. 
 
 
10. The lamin B receptor complex (LBR) interacts with STM50 alone or 
STM50 complexed with M53/p38
 
Next, we wanted to analyze interactions between nuclear matrix proteins and 
the viral NEC. There are two main matrix residents of the INM: The lamin B 
receptor complex (LBR) and the LEM domain proteins (LEMs), such as emerin, 
MAN1 or LAPs (see introduction: 4.2.1 and 4.2.2). First, we tested the lamin B 
receptor complex (LBR) for interaction with the MCMV NEC proteins. 
Binding was tested by pull down assay after isolated expression of pM50ST 
expressing Strep-II tagged M50/p35 or after co-expression with wt M53. As 
control for specificity of the assay 293 cells were either mock transfected or 
transfected with pM53, expressing wt M53 alone. As control for protein load- 
and expression total cell lysates were separated by SDS-PAGE and subjected 
to Western-blot analysis using LBR specific antibody at a dilution of 1:300. 
 
 
 
 
 
 
 
Figure 32. Pull down of LBR with Strep tagged M50/p35. 293 cells were transfected with wt 
M53/p38 and M50ST. Furthermore 293 cells were co-transfected with M50ST and wt M53.Total 
cell lysates were analyzed to test the protein expression by Western blot using specific 
antiserum against LBR (T, lanes 1-4). Proteins complexed with M50ST were precipitated by 
Strep-Tactin sepharose. Desthiobiotin eluates were analyzed by SDS-PAGE and blotted on 
membranes. LBR was detected by Western blot with LBR specific antiserum (B, lanes 5-8). 
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The specific LBR-band at 58 kDa became detectable in total cell lysates of all 
probes (Fig. 32, T, lanes 1-4). Proteins bound to M50ST were recovered by 
Strep-Tactin sepharose beads from cell lysates of 293 cells transfected with 
pM50ST or cell lysates after co-expression of pM50ST and pM53. 
Bound proteins were eluted from the beads by desthiobiotin, separated by SDS-
PAGE and subjected to Western-blot analysis using LBR specific antibody. The 
LBR specific band at 58 kDa was missing in mock-, M53- and M50ST 
transfected cells. But there was a LBR specific band detectable after co-
expression of M50ST and wt M53 (Fig. 32, B, lane 8). Thus, the LBR complex 
p58 interacts with the NEC. 
However, the efficiency of the Strep-tag pull down was poor for the LBR. 
Moreover, interaction of M53/p38 with cellular proteins could only be addressed 
in complex with M50ST and not in isolation. Therefore, new pull down assays 
needed to be established for further analysis of cellular interaction partners of 
M53 and M50. 
 
 
11. Both, Flag-tagged M53/p38 and HA-tagged M50/p35 can efficiently pull 
down LBR 
 
In order to further improve the efficiency of the pull down assay to identify 
cellular interaction partners of M50/p35 and M53/p38 additional pull down 
systems were established: The HA-tag pull down and the Flag-tag pull down. 
To test the specificity of HA-pull down 293 cells were either mock transfected, 
transfected with pM53, expressing wt M53, transfected with pHAM50, 
expressing HA-tagged M50 or co-transfected with pHAM50 and pM53. As 
controls for protein load- and expression total cell lysates were separated by 
SDS-PAGE and subjected to Western-blot analysis using M53- and M50-
specific antisera at dilutions of 1:2000 (Fig. 33A, T, upper- and middle panel). 
The specific M53-band at 38 kDa became detectable for total cell lysates after 
isolated expression of M53/p38 and after co-expression of wt M53 and HA-
tagged M50 (Fig. 33A, upper panel, T, lanes 2, 4). The specific M50-band at 35 
kDa was present in total cell lysates after isolated expression of HAM50 and 
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after co-expression of wt M53 and HA-tagged M50 (Fig. 33A, middle panel, T, 
lanes 3, 4). 
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Figure 33A. HA-pull down analysis. 
293 cells were mock transfected, 
transfected with HAM50, transfected with 
wt M53 or co-transfected with HAM50 
and wt M53. Total cell lysates were 
analyzed by SDS-PAGE and Western 
blot using specific M53/p38 antiserum 
(upper panel, M53, T) or specific 
M50/p35 antiserum (middle panel, M50, 
T). Proteins complexed with HAM50 
were precipitated with HA-matrix 
sepharose beads and eluted by specific 
IP loading buffer. Next, proteins were 
separated by SDS-PAGE and signals for 
M53/p38 were visualized by Western 
blot using specific antiserum against 
M53/p38 (lower panel, M53, B). 
 the HA- tag pull down assay only proteins bound to M50 should be recovered 
 HA-matrix sepharose beads from lysates of 293 cells transfected with 
AM50 or lysates of co-expressed pHAM50 and pM53. Bound proteins were 
ted from the HA-matrix by SDS-sample buffer, separated by SDS-PAGE and 
bjected to Western-blot analysis using M53-specific antisera. The M53/p38 
ecific band at 38 kDa was clearly detectable only after co-expression of M53 
th HA-tagged M50, but was missing for the other controls (Fig. 33A, B, lanes 
8). No signals for unspecific bound proteins were detectable, indicating the 
h specificity of this assay. 
xt, the Flag-tag pull down assay was tested. To test the specificity of the 
ag-tag pull down 293 cells were either mock transfected, transfected with 
lagM53, expressing Flag-tagged M53 or co-transfected with pFlagM53 and 
50. To control protein load- and expression the total cell lysates were 
parated by SDS-PAGE and subjected to Western-blot analysis using M50-
ecific antisera at a dilution of 1:2000. Here, the specific M50-band at 35 kDa 
d signals for M50-processing products became detectable in total cell lysates 
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after co-expression of wt M50 and Flag-tagged M53 (Fig. 33B, upper panel, T, 
lane 3). As a further control for protein load- and expression total cell lysates 
were separated by SDS-PAGE and subjected to Western-blot analysis using 
M53-specific antisera at a dilution of 1:2000. The specific M53-band at 38 kDa 
was seen only in total cell lysates after isolated expression of Flag-tagged M53 
or after co-expression of wt M50 and Flag-tagged M53 (Fig. 33B, middle panel, 
T, lanes 2, 3). 
 
B Figure 33B. Flag-tag pull down 
analysis. 293 cells were mock 
transfected, transfected with FlagM53, or 
co-transfected with FlagM53 and wt 
M50. Total cell lysates were analyzed by 
SDS-PAGE and Western blot using 
specific M50/p35 antiserum (upper 
panel, M50, T) or specific M53/p38 
antiserum (middle panel, M53, T). 
Proteins complexed with FlagM53 were 
precipitated with Flag-matrix sepharose 
beads and eluted by specific IP loading 
buffer. Next, proteins were separated by 
SDS-PAGE and signals for M50/p35 
were visualized by Western blot using 
specific antiserum against M50/p35 
(lower panel, M50, B). 
 
 
 
 
 
 
 
Flag-tag pull down should only reveal proteins bound to Flag-tagged M53. 
Bound proteins were eluted from the Flag-matrix by SDS-sample buffer, 
separated by SDS-PAGE and subjected to Western-blot analysis using M50-
specific antisera. M50/p35 and processing products were only detectable after 
co-expression with Flag-tagged M53/p38, indicating the high specificity of the 
assay (Fig. 33B, lower panel, B, lane 3). 
Next, the interaction of LBR with M50/p35 or M53/p38 alone or with the 
M50/p35-M53/p38 complex was re-analyzed. For the HA-tag pull down 293 
cells were mock transfected, transfected with pHAM50 or co-transfected with 
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pHAM50 and pM53. For Flag-tag pull down 293 cells were mock transfected, 
transfected with pFlagM53 or co-transfected with pM50 and pFlagM53. As 
control for protein load- and expression total cell lysates were separated by 
SDS-PAGE and subjected to Western-blot analysis using LBR- specific 
antibody at a dilution of 1:300. 
 
C 
 
 
 
 
 
 
 
Figure 33C. LBR pull down using HA-tagged M50/p35. 293 cells were mock transfected, 
transfected with HAM50 or co-transfected with HAM50 and wt M53. Total cell lysates were 
analyzed by SDS-PAGE (12% SDS-gel) and Western blot using specific LBR antibody (T; lanes 
1-3). Proteins complexed with HAM50 were precipitated with HA-matrix sepharose beads and 
eluted proteins were separated by SDS-PAGE (12% SDS-gel). Signals for LBR were visualized 
by Western blot using specific antibody against LBR (B; lanes 4-8). 
 
The LBR band at 58 kDa was present in all total cell lysates of both sets (Fig. 
33C, D, lanes 1-3). Due to a higher resolution of the SDS-PAGE for total cell 
lysates of the Flag set an additional LBR band was detectable (Fig. 33D, lanes 
1-3). Proteins bound to Flag-or HA-matrix were eluted from the respective 
sepharose beads by SDS-sample buffer, separated by SDS-PAGE and 
subjected to Western-blot analysis using LBR-specific antibody at a dilution of 
1:300. 
The signal at 58 kDa, characteristic for the LBR complex major component p58, 
was detectable after Flag-pull down assay with the lysate of isolated expressed 
Flag-tagged M53. Due to the higher efficiency compared to the Strep-tag pull 
down assay p58 was also detectable after HA-pull down with the lysate of 
isolated expressed HA-tagged M50, indicating direct interaction with both NEC 
proteins (Fig. 33C, D, lanes 5). The lower LBR complex band was not 
detectable after Flag-pull down, suggesting two LBR isoforms. 
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 Dure 33D. LBR pull down using Flag-tagged M53/p38. 293 cells were mock transfected, 
nsfected with FlagM53 or co-transfected with FlagM53 and wt M50. Total cell lysates were 
alyzed by SDS-PAGE (15% SDS-gel) and Western blot using specific LBR antibody (T; lanes 
). Proteins complexed with FlagM53 were precipitated with Flag-matrix sepharose beads and 
ted proteins were separated by SDS-PAGE (15% SDS-gel). Signals for LBR were visualized 
 Western blot using specific antibody against LBR (B; lanes 4-8). 
 the HA-pull down, the intensity of the LBR signal was increased for co-
pressed HAM50 and wt M53 (Fig. 33C, lane 6). The LBR signal intensity was 
t increased after pull down with co-expressed FlagM53 and wt M50, 
ggesting a more prominent role of M50/p35 in LBR interaction (Fig. 33D, lane 
. 
. Both M53/p38 and M50/p35 specifically interact with nuclear matrix 
oteins 
xt, we tested other nuclear matrix proteins for interaction with M53/p38 and 
50/p35. Total lysates were separated by SDS-PAGE and subjected to 
estern-blot analysis using specific antibodies for cellular matrix proteins at a 
ution of 1:300 to control protein load and expression (Fig. 34A and B, T, lanes 
3). All tested cellular proteins were expressed and protein load was 
mparable for all analyzed samples. After pull down p32, a component of the 
R, binds to M53/p38 and M50/p35 and can be detected by a doubled band at 
/34 kDa (Fig. 34A and B, lanes 5). Interestingly, after pull down with isolated 
pressed FlagM53 or HAM50 only the lower p32 band is detectable. 
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Figure 34A. Pull down analysis of cellular interaction partners using HA-tagged M50/p35. 
293 cells were mock transfected, transfected with HAM50, transfected with wt M53 or co-
transfected with HAM50 and wt M53. Total cell lysates were analyzed by SDS-PAGE and 
Western blot using antibodies specific for the tested Cellular proteins. (T; lanes 1-3). Proteins 
complexed with HAM50 were precipitated with HA-matrix sepharose beads and eluted by 2x 
SDS sample buffer. Next, proteins were separated by SDS-PAGE and signals for cellular 
interaction partners were visualized by Western blot using specific antibodies (B; lanes 4-6). 
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Figure 34B. Pull down analysis of cellular interaction partners using Flag-tagged 
M53/p38. 293 cells were mock transfected, transfected with FlagM53 or co-transfected with 
FlagM53 and wt M50. Total cell lysates were analyzed by SDS-PAGE and Western blot using 
antibodies specific for the tested proteins (T; lanes 1-3). Proteins complexed with FlagM53 were 
precipitated with Flag-matrix sepharose beads and eluted proteins were separated by SDS-
PAGE. Signals for cellular proteins were visualized by Western blot using specific antibodies (B; 
lanes 4-8). 
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The upper p32 band was only detectable to some extent, suggesting two 
modified p32 isoforms of which one is bound preferentially to isolated 
expressed M50/p35 or M53/p38. Both p32 bands were equally induced in 
lysates after co-expression of HAM50 and wt M53. This was not the case after 
Flag-tag pull down with lysates from co-expressed FlagM53 and wt M50 (Fig. 
34A and B, lanes 6), suggesting a more prominent role of M50/p35 in binding 
p32 isoforms. 
Linker histone 1 (H1) and histone 3 (H3) are connected with the LBR and the 
lamina (Gruenbaum, 2005; Montes de Oca, 2005; Bártová, 2005; Poliodaki, 
2001). They were seen in pull downs only after isolated expression of FlagM53, 
co-expression of FlagM53 and wt M50 or co-expression of HAM50 and wt M53, 
indicating that histone interaction is a function of M53/p38 (Fig. 34A and B, 
lanes 5, 6). Furthermore, interaction of M53/p38 and M50/p35 with HP1α, which 
bridges LBR and chromatin, with the LEM-domain protein MAN1 and with 
lamins B and A/C was analyzed by pull down assays. Neither after pull down of 
isolated expressed M53/p38 or M50/p35 nor after pull down of co-expressed 
M53/p38 and M50/p35 specific signals for these cellular proteins were 
detectable, indicating no specific interaction (Fig. 34A and B, lanes 4-6). 
In conclusion, after isolated expression both M53/p38 and M50/p35 react very 
specific with cellular residents of the inner nuclear membrane. Only M53/p38 
binds to histone 1 and- 3, whereas M50/p35 does not. Using HA-tag sepharose 
beads for pull down of LBR and p32 after co-expression of the viral proteins 
additive effects could be observed which may be linked to different specificity of 
the respective matrix or may be due to conformational changes of the cellular 
matrix. 
 
 
13. Proteomics on the MCMV NEC 
 
To verify the pull down results we analyzed isolated proteins by mass-
spectrometry. 
To that end, two sets of 293 cells were mock transfected, transfected with 
pHAM50, transfected with pFlagM53 or co-transfected with pHAM50 and 
pFlagM53. Cell lysates were prepared 24 hours post transfection. Next, HA-tag 
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pull down was performed with one set, and proteins bound to the HA-matrix 
sepharose beads were eluted from the beads by IP-sample buffer. With the 
second set of lysates Flag-tag pull down was performed and proteins bound to 
Flag-matrix sepharose beads were recovered by SDS-sample buffer. Eluted 
proteins were separated by SDS-PAGE on a gradient gel and silver staining 
was performed. Using both Flag- or HA-matrices for pull down distinct bands 
became visible after isolated expression of HAM50, FlagM53 and co-expression 
of FlagM53 and HAM50 that were missing in mock controls (Fig. 35, black 
arrowheads).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Analysis of cellular interaction partners of M53/p38 and M50/p35 by silver 
staining and mass-spectrometry. 293 cells were transfected with pHAM50, pFlagM53 or co-
transfected with pHAM50 and pFlagM53. Cells were lysed and either HA-and Flag-tag pull 
down was performed. Eluated proteins were analyzed by SDS-PAGE on an 8-16% gradient gel. 
Silver staining was performed and protein bands (arrowheads) were isolated from the gel and 
analyzed by mass-spectrometry. Silver staining indicates numerous putative interactors (black 
arrowheads) of M53 (green arrowheads), M50 (red arrowheads) or the complex of M53 and 
M50.  
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Furthermore, the pattern was different to some extent between isolated 
expressed HAM50 and FlagM53 and the co-expressed viral NEC proteins. At 
15 kDa, 25 kDa, 35 kDa, 38 kDa, 40 kDa and 65 kDa bands became visible 
using both matrices for pull-down of co-expressed HAM50 and FlagM53. 
Using the Flag-tag pull down after transfection with FlagM53, bands at around 
15 kDa, 25 kDa, 38 kDa and 40 kDa became visible. Using the HA-tag pull 
down after transfection with HAM50 only an additional band at around 35 kDa 
became visible that differed from the mock control. Therefore we suggested, 
that either M53 and M50 or complexed M53-M50 share cellular interaction 
partners but may also have unique ones. Next, a set of bands was isolated from 
the gel and analyzed by mass-spectrometry, that only appeared after pull down 
of lysates from isolated expressed FlagM53 or HAM50 or from lysates of co-
expressed FlagM53 and HAM50 but were missing for mock control. Mass-
spectrometry was performed in cooperation with Arnd Kieser and Thomas 
Knöfel (GSF, Hämatologikum, München). We could identify both viral interaction 
partners. Unfortunately the amount of recovered protein was too low for further 
identification of cellular interaction partners. To increase recovery proteins 
bound to Flag-matrix or HA-matrix were competed out by specific Flag-or HA-
peptide. The advantage of this elution strategy is, that eluted proteins can be 
analyzed as a pool and that proteins can be eluted under native conditions. The 
specificity of this assay is shown in figure 36 A and B. 
For the identification of cellular interaction partners of M53/p38 and M50/p35 by 
mass-spectrometry in the future the system needs to be up-scaled, since mass-
spectrometry is less sensitive than Western-blot analysis and proteins are often 
expressed only at low levels. 
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Figure 36A. Peptide elution after pull down analysis using HA-tagged M50/p35. 293 cells 
were mock transfected, transfected with HAM50 or co-transfected with HAM50 and wt M53. 
Total cell lysates and pelleted debris from the lysates were analyzed by SDS-PAGE and 
Western blot using specific M53/p38 antiserum (T, P; lanes 1-6). Proteins complexed with 
HAM50 were precipitated with HA-matrix sepharose beads and proteins eluted by specific HA-
peptide were separated by SDS-PAGE. Signals for M53/p38 were visualized by Western blot 
using specific antiserum against M53/p38 (B; lanes 7, 8). 
 
 
 
B 
 
 
 
 
 
 
 
 
 
Figure 36B. Peptide elution after pull down analysis using Flag-tagged M53. 293 cells 
were mock transfected, transfected with FlagM53 or co-transfected with FlagM53 and wt M50. 
Total cell lysates and debris from the lysates were analyzed by SDS-PAGE and Western blot 
using specific M50/p35 antiserum (T, P; lanes 1-6). Proteins complexed with FlagM53 were 
precipitated with Flag-matrix sepharose beads and proteins eluted by specific Flag-peptide were 
separated by SDS-PAGE. Signals for M50/p35 were visualized by Western blot using specific 
antiserum against M50/p35 (B; lanes 7, 8). 
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1. The UL31- and UL34 homologues and their function during virus 
replication 
 
We owe our basic knowledge on the herpes-common proteins governing the 
egress of the herpesvirus nucleocapsid from the cell nucleus to pioneering 
studies in alpha-herpesviruses. To achieve nucleocapsid egress the UL31- and 
UL34-proteins need to form a complex at the nuclear membrane. Deletion of 
either protein severely compromises virus replication but still gives rise to 
progeny (Bubic, 2004; Fuchs, 2002; Liang, 2004; Reynolds, 2001, 2002; Ye, 
2000). For beta- and gamma-herpesviruses the conditions are even more 
stringent. The lack of either protein abolishes virus replication (Bubeck, 2004, 
Farina, 2005; Gonella, 2005). Therefore, these studies could only be initiated 
after cloning and mutagenesis of complete infectious herpesvirus genomes as 
BAC in E. coli (Messerle, 1997; Wagner, 2002). Published work and data 
presented in this study converge to the conclusion that UL31- and UL34-
homologues of alpha-, beta- and gamma-herpesviruses have to interact at the 
inner nuclear membrane to execute their function as nuclear egress complex 
(NEC) (Bubeck, 2004; Chang, 1997; Reynolds, 2004; Gonnella, 2005; Lake, 
2004, Liang, 2004; Muranyi, 2002; Reynolds, 2002; Simpson-Holley, 2004; Ye, 
2000). This must involve contacts with several other unknown cellular and viral 
proteins. The mutual binding sites need to be determined to address the 
question, which functions of these proteins are conducted in isolation and which 
are executed subsequent to NEC formation. 
 
 
2. M53/p38, an essential MCMV protein, which is expressed by late 
kinetics 
 
M50 is an essential MCMV gene. The M50 gene product p35 is expressed by 
early late kinetics upon MCMV infection and is involved in the egress of the 
 
 - 118 - 
 
 E. Discussion
 
MCMV capsid from the nucleus. M53/p35 can be co-precipitated with M50/p35, 
indicating functional interaction between both gene products (Bubeck, 2004). 
When the M53 ORF is deleted from the MCMV-BAC reconstitution of infectious 
virus in cell culture is not possible. The null-phenotype is reverted by re-
insertion of the M53 ORF at an ectopic position of the ∆M53-MCMV-BAC. Thus, 
the inability to gain infectious virus is solely due to the deletion of the M53 gene 
and not an effect of neighboring genes. Growth of the reconstituted virus is 
slightly attenuated. Probably this attenuation is connected to altered expression 
kinetics of the ectopic M53/p38, which is controlled by the immediate early (ie) 
promoter of HCMV and not by its endogenous promoter. These findings were 
also confirmed by a trans-complementation assay. Here, a trans-complemented 
M53 deletion virus was unable to produce viral progeny under non-
complementing conditions (Lötzerich, 2006). 
M53/p38 is detectable after 18 hours and accumulated gradually over time in 
MCMV infected cells. The accumulation of M53/p38 after 24 hours can be 
related to a second replication cycle of MCMV. PAA treatment, which blocks 
DNA replication, could prevent gene expression of late MCMV major capsid 
protein (M86) and also of M53/p38. Therefore M53/p38 expression is following 
true late kinetics. We showed recently that M50/p35 follows early-late 
expression kinetics upon MCMV infection (Bubeck, 2004). Like M53/p38, 
expression of UL31 homologues of α-herpesviruses follows late kinetics (Liang, 
2004; Fuchs, 2002). Interestingly, the M53/p38- and M50/p35- homologues 
BFLF2 and BFRF1 of γ-herpesvirus EBV are already expressed at the early late 
stage of infection (Farina, 2005; Gonnella, 2005). Although M53/p38 and 
M50/p35 can be co-precipitated and therefore assumingly functionally interact, 
expression of M50/p35 follows early late kinetics. One can speculate whether 
M50/p35 has an M53/p38 independent function early in infection. 
 
 
3. Exploring M53/p38 by transposon mutagenesis of the M53 ORF 
 
Viral functions that are involved in morphogenesis are preferably studied in the 
context of viral replication where the relevant genes are expressed in 
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operational conditions. Random transposon mutagenesis procedures described 
so far for herpesviruses create null-mutants of the respective gene in order to 
analyze non-essential genes or to define essentiality (Brune, 2001; Hobom, 
2000; Menard, 2003; Smith, 1999). These insertion libraries cannot be used for 
a detailed functional characterization of a gene. The type of transposon cannot 
be removed from the genome and most of the insertions destroy the target gene 
completely. Furthermore, the number of insertions within a given gene in these 
libraries is far below the requirements of a comprehensive or even saturating 
analysis. Comprehensive mutant pools for cloned viral genes can be obtained 
through random mutagenesis procedures creating small insertions or deletions 
(Biery, 2000). Due to the genome size of large DNA viruses, simple approaches 
using traditional molecular cloning techniques are not feasible. In a previous 
paper we reported on the comprehensive mutagenesis of M50/p35, the UL34 
homologue of beta-herpesvirus MCMV (Bubeck, 2004). After mutagenesis the 
mutated M50-gene was re-introduced into the viral genome (Menard, 2003). 
However, due to frequent insertions into the rescue vector backbone the 
efficiency of random insertion mutagenesis of the M50 ORF was less than 20% 
and required laborious screening. 
In this study we improved the transposon mediated random mutagenesis 
technique. Several transposon- donor and- acceptor combinations were 
analyzed. To that end, we excluded vector insertions by sub-cloning the primary 
pool of transposon labeled M53-ORFs into the rescue vector. Furthermore, 
background signals originating from the transposon donor vector were 
minimized by means of a temperature sensitive transposon donor. Both, sub-
cloning of the primary pool of transposon labeled M53-ORFs and selection 
against the transposon donor after transposition at non-permissive temperature 
raised the successful insertion frequency to 55%, which was almost five times 
more efficient than the method we published earlier. Actually, we had expected 
a higher insertion frequency. It turned out that by sub-cloning of the M53 ORF 
also sequences originating from the multiple cloning sites were transferred to 
the new rescue vector. Since the transposon preferentially inserts to GC-rich 
sequences the multiple cloning sites with inserted transposons led to insertion 
frequency numbers that are far below 100 %. In the future the efficiency could 
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be improved by selection of adequate multiple cloning sites with a low GC 
content. Altogether, we created a library of about 28,000 insertion/stop mutants 
in the M53-ORF, screened 986 by PCR and sequenced 498 PCR-positive 
clones. A total of 54 random mutants (46 M53-insertion- and 8 truncation-
mutants) were tested both at the level of isolated expression and for 
complementation of the M53 null phenotype in the viral context. In addition, a 
total of 18 targeted mutants were tested also in the genomic context.  
 
 
4. Analysis of M53/p38 mutants 
 
The analysis of M53/p38 transposon- and targeted mutants lead to the following 
conclusions: 
 
i) Sequence comparison of 36 known members of the UL31 family of 
herpesvirus proteins revealed an N-terminal variable region and 4 conserved 
regions (CR) located within the C-terminal 2/3 of the sequences.  
ii) For the less conserved N-terminal part of M53/p38 a bi-parted nuclear 
localization signal (NLS) was predicted. We could confirm this by co-
localization- and co-precipitation experiments and also by testing functionality of 
the respective N-terminal deletion mutants.  
iii) Within CR1 (aa 115-174 in MCMV M53/p38) we found the binding 
motif for M50/p35. This motif is represented by aa 115-137 which is necessary 
for binding to M50/p35.  
iv) Mutation of all conserved amino acids of this region into alanines 
resulted in different phenotypes with regard to NEC formation, revealing a 
prominent role for the residues K128, Y129, and L130. Nevertheless, all single 
point mutants were able to bind to M50/p35 and to rescue the M53 null 
phenotype of the genome. Only when two or three of the critical residues were 
replaced the mutants failed to bind to M50/p35 and did not rescue the M53 null 
phenotype. 
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v.) The C-terminal conserved regions two to four (CR2-4) bear yet 
unidentified essential function(s). Insertion mutants in these regions could bind 
to M50/p35 but lack functionality. 
 
 
4.1. The N-terminal part of M53/p38 harbors a NLS as functional element 
 
Alignment of M53 to members of the UL31 family demonstrated a conserved 
central and C-terminal region whereas the N-terminal region was variable. The 
results of the functional analysis of the M53-insertion mutants were in line with 
the in silico prediction. Non-functional insertion mutants accumulated only within 
the conserved regions of the M53 ORF. Within the N-terminal variable region of 
M53/p38 two overlapping nuclear localization signals (NLS) were predicted 
between aa 24 and 42. The deletion mutant of M53/p38 lacking the region from 
aa 16 to 106 failed to rescue the virus growth in absence of the wt M53 gene, 
however, introduction of an artificial 9 aa SV40 NLS rescued the functionality of 
the mutant. Thus, the variable N-terminal domain of M53/p38 contains an NLS 
as functional element. The consensus sequence for a nuclear targeting signal 
(Dingwall, 1991) is present only in 14 out of 36 members of UL31 family. For 
instance, the type bi-parted NLS is not predicted for the N-terminal part of 
HCMV UL53. However, if an NLS is predicted it is always located within the N-
terminal variable region. All analyzed members of the UL31 protein family are 
localized exclusively in the nucleus upon isolated expression indicating that they 
possess an active NLS and we believe that this is the function of the N-terminal 
variable domain. The presence of one N-terminal NLS for UL53 or other UL31 
family members remains to be elucidated. 
 
 
4.2. The interaction of M50/p35 and M53/p38 
 
Binding between M50/p35 homologues (UL34) and M53/p38 homologues 
(UL31) is a conserved feature in all herpesviruses. A stop mutant suggested 
that the N-terminal 136 aa of M53/p38 are sufficient for M50/p35 binding. The 
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N-terminal sequences aa16 to aa106 could be replaced without loss of 
functionality, which placed the M50/p35 binding region between aa 106 and 
136. The non-functional insertion mutants M53i115 and i131 further located 
sequences necessary for M50/p35 binding within aa 115-131 of M53/p38. The 
alanine scanning mutagenesis for the 12 conserved aa of this essential region 
confirmed and extended these observations. All point mutants showed wt 
nuclear distribution upon isolated expression. No difference in protein stability 
compared to wild type M53/p38 was traceable. Analysis of total lysates by 
western blot displayed no degradation of the produced proteins. However, a 
variety of phenotypes occurred in the presence of M50/p35, including those 
which formed intranuclear aggregates (M53L125A) or filamentous structures 
(M53K128A). Since these structures were only seen in the presence of the 
M50/p35 we assume that at least a transient M50/p35-M53/p38 interaction is 
responsible for the observed phenotypic changes. M50/p35 binding may initiate 
M53/p38 processing, thereby inducing conformational changes in different 
mutants. Furthermore, this transient interaction was apparently sufficient to 
cause aggregation of M53/p38 alone or in complex with so far unknown cellular 
partners. Surprisingly, all tested point mutants could bind to M50/p35 to some 
extent in the pull-down assay and more importantly all rescued the M53 null 
phenotype in the viral context including those without apparent co-localization. 
This indicates that using only one assay to study a protein-protein interaction 
might not be sufficient to define a function. Co-localization studies show only the 
major steady state phenotype. Residual low affinity interactions may be 
overlooked and protein-protein interaction or functionality of the virus are not 
addressed. Co-IP reveals the potential to bind. But a confirmed protein-protein 
interaction does not implicate functionality. Furthermore, testing M53-mutants 
for functionality enables to map essential domains of the protein but not to 
identify protein-protein interaction domains. Thus, to produce reliable results, 
the application of various assays was indicated. 
The growth of reconstituted viruses was poor for mutants M53K128A, 
M53Y129A and M53L130A. These data imply that wt M50/p35-M53/p38 
complexes are required for efficient productive infection, and that a small 
number of complexes or transient complex formations suffice for virus 
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production. However, if two or more aa within the predicted binding region were 
exchanged the mutants neither co-localized with nor bound to M50/p35 and 
were not able to rescue the M53 null phenotype. Loss of M53/p38-binding to 
M50/p35 is associated with the inability to replicate. However, M50/p35-binding 
is not the only function of CR1. Notably there are M53-insertion mutants within 
the identified binding motif (i115 and i131) which bind to M50/p35 but are 
nevertheless lethal. Interestingly, the M50/p35 binding region of M53/p38 is 
strictly conserved only in beta-herpesviruses. The homology of alpha- or 
gamma-herpesvirus UL31 family members to the beta-herpesvirus sequence 
(aa 115-136) is lower than the average similarity of the conserved regions and 
is presumably determined more by the character of the amino acids than by 
sequence. Only within sub-families the sequence conservation is considerably 
high. We could show that M53 can be replaced by its HCMV homologue UL53. 
UL53, expressed at an ectopic position of the ∆M53-MCMV-BAC could rescue 
the M53-null phenotype, implicating that M50/p35 can interact with M53/p38 
homologues from different species within β-herpesviruses. The same 
phenomenon could be observed within other subfamilies (Schnee, 2006). The 
divergence is already experimentally proven for the binding region for UL34 
members from the alpha- and beta-herpesvirus subfamilies. In MCMV M50/p35 
aa 53-57 and aa 114 are important for M53/p38 binding (Bubeck, 2004). Using 
a set of 9 HSV-1 UL34 mutants, one of which was introduced into the genomic 
context, the binding region was located to a different region, namely to aa 137-
181 of UL34 (which corresponds to region aa 129-173 of M50/p35) (Liang, 
2004). Therefore, it can be expected that sequences in the conserved regions 
but not necessarily the same sequences in CR1 functionally define the binding 
region in alpha- and gamma-herpesvirus homologues. 
 
 
4.3. The C-terminal 2/3 of M53/p38 bears essential MCMV functions 
 
The C-terminal regions CR2 to CR4 are conserved in the UL31-family and 
several insertion mutants have a null phenotype, although they bind to 
M50/p35. This indicates that the C-terminal half of M53/p38 bears yet 
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unidentified essential functions. Under certain conditions HSV-1 UL31 interacts 
with lamins A/C and is involved in chromatin reorganization (Reynolds, 2001; 
Scott, 2001; Simpson-Holley, 2004). M50/p35 and BFRF1 have indirect effects 
on the nuclear lamina (Farina, 2005; Muranyi, 2002) and in EBV the complex of 
BFLF2 and BFRF1 interacts with lamin B (Gonnella, 2005). These features but 
also oligomerization, capsid recruitment and regulation of the subsequent 
budding event may involve the CR2-4 of the UL31 family proteins. Experimental 
approaches, such as testing mutants for dominant negative effects (Rupp, 
2005) or protein pull-downs using a functional or a non-functional NEC may 
pave the way to the elucidation of the other herpesvirus NEC functions. 
 
 
5. Homo-oligomerization of M53/p38 
 
In this study we could show, that at least after isolated expression M53/p38 is 
able to form homo-dimer or –oligomers. It may be that M53/p38 dimers are built 
by interaction within the same binding region of CR1 as M50/p35. 
Oligomerization may contribute to stabilization of NEC formation and therefore 
could be an essential process. As suggested for lamins, BAF and certain LEM 
domain proteins (e.g. LAP2α) M53/p38 oligomers may also exhibit a scaffolding 
function for multi-protein complexes (Gruenbaum, 2005). However, whether the 
oligomerization is required for a function of the MCMV NEC remains to be 
determined. But at the moment no suitable technique is available to address 
this question. 
 
 
6. Interaction of M53/p38 and M50/p35 with nuclear matrix proteins 
 
A a critical step of herpesvirus morphogenesis is the nucleocapsid egress from 
the nucleus. A well accepted model suggests that nucleocapsid penetration of 
the nuclear envelope involves a budding process through the inner nuclear 
membrane (INM) (Mettenleiter, 2002, 2004, 2006). This is not simply 
accessible, since the INM is stabilized by a filamentous nuclear lamina layer. 
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The lamina represents a physical barrier for capsid budding and is only 
dissolved during mitotic events due to phosphorylation of lamins by cellular 
protein kinase C (PKC) (Gerace, 1980; Ottaviano, 1985; Otto, 2001; Peter, 
1990; Dessev, 1988; Buenida, 2001; Muranyi, 2002). Also upon infection with β-
herpesvirus MCMV- or  α-herpesvirus HSV-1- cellular PKC is recruited to the 
nuclear envelope. This is accompanied by lamin B phosphorylation (Muranyi, 
2002; Park, 2006). The HCMV kinase UL97, which is not essential but critical 
for viral replication also was shown to be involved in lamin phosphorylation. 
(Prichard, 1999, 2005; Krosky, 2003; Azzeh, 2006; Marschall, 2005). 
The M53/p38- and M50/p35 homologues UL31 and UL34 of α-
herpesvirus HSV-1 are involved in nuclear egress processes of viral 
nucleocapsids. Both proteins induce alterations of the nuclear architecture. 
Under certain conditions UL31 interacts with lamins A and C and is suggested 
to be involved in chromatin reorganization (Simpson-Holley, 2004, 2005; 
Reynolds, 2004; Scott, 2001). Also, in γ-herpesvirus EBV the UL31- and UL34 
homologues BFLF2 and BFRF1 interact with lamin B (Gonella, 2005). 
Furthermore, BFRF1 is presumably involved in transport of nucleocapsids 
across the nuclear membrane (Farina, 2005). 
M53/p38 and/ or M50/p35 probably have similar functions. As a first hint here 
we showed that M53/p38 and M50/p35 are retained with lamin B in the same 
salt resistant compartment of the nucleus, the nuclear matrix. To maintain the 
M50/p35-M53/p38 complex stability the NaCl concentration was limited to a 
maximum of 400 mM. Only at these high-salt conditions for extraction also 
several matrix proteins became soluble. Interestingly, although the majority of 
lamin B but also of M53/p38 was found soluble under high salt extraction 
conditions, upon MCMV infection already a small amount of lamin B and 
M53/p38 was already detectable under low salt protein extraction conditions. 
We therefore assumed, that MCMV infection increases the solubility of lamin B. 
In contrast, lamin A/C was not solubilized under low salt protein extraction 
conditions upon MCMV infection. Moreover, high salt protein extraction upon 
infection with MCMV only solubilized lamin C but had no effect on lamin A 
extraction. We therefore concluded that MCMV infection has no effect on A-type 
lamin solubilization. 
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Next, we studied interactions of M50/p35 and M53/p38 with proteins residing in 
the inner nuclear matrix. For HCMV capsid egress from the nucleus an 
involvement of cellular lamin B receptor-complex (LBR) and p32 is indicated. 
Viral UL97 kinase phosphorylates p32 in vitro. The UL97-p32 complex is 
recruited to the nuclear envelope and interacts with the LBR complex. In vitro 
this is accompanied by lamin phosphorylation (Marschall, 2005). Moreover, LBR 
was suggested to be involved in disruption of the nuclear lamina after α-
herpesvirus HSV-1 infection (Scott, 2001). The lamin B receptor (LBR) is one of 
the best characterized lamin- but also chromatin- binding membrane proteins. It 
is widely expressed in cells of higher eukaryotes and the human gene is already 
characterized (Schuler, 1994). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. Schematic diagram of possible cellular interaction partners of M50/p35 and 
M53/p38. INM protein complexes LBR and LEM domain proteins with associated cellular and 
viral proteins, nuclear envelope (NE), nuclear lamina and chromatin structures (Ch) are 
depicted: Lamin B receptor (LBR/ p58) as complex with SR-kinase (SRK), p18, p32, lamin B 
(LaB), heterochromatin protein-1 (HP1), histone 1 (H1), histone 3 (H3) and histone 4 (H4); 
LEMs with barrier to autointegration factor (BAF), lamin A/C (LaA) and histones H3 and H4. 
 
The human LBR or p58 comprises of an amino-terminal nucleoplasmic domain 
and a hydrophobic C-terminal domain with eight putative transmembrane 
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segments that integrate the protein into the INM (Chu, 1998; Worman, 1990; 
Ye, 1994; Fig. 37). LBR forms a multimeric-protein complex with p32, a 
polypeptide p18 of yet unknown function, a LBR kinase that phosphorylates 
LBR and associated proteins and with nuclear A- and B-type lamins (Simos, 
1996; Nikolakaki, 1997, Deb, 1996). LBR also binds to lamin B. Furthermore, 
LBR was shown to interact with (ds) DNA, histone H3-H4 tetramers, HA95 and 
heterochromatin protein-1 (HP1) (for review: Chu, 1998; Foisner, 2001; 
Gruenbaum, 2005). 
By Strep-II tag pull down assay we showed that the major component of the 
LBR complex p58 interacts with the NEC. In presence of M53/p38 this 
interaction was intensified, indicating that p58 may also interact with M53/p38. 
Since this interaction was hardly detectable we assumed that the Strep-II tag 
pull down assay is not recommended for a reliable screen of cellular interaction 
partners of M50/p35 and M53/p38. Furthermore, interaction of M53/p38 with 
cellular proteins only could be analyzed in complex with M50ST. Therefore, two 
efficient pull down assays were established: the HA-tag- and the Flag-tag pull 
down assay. 
We showed after isolated expression of Flag-tagged M53 or HA-tagged M50 
that both NEC proteins directly interact with the LBR complex major component 
p58. In the HA-pull down, the intensity of the LBR signal was increased for co-
expressed HAM50 and wt M53. This was not the case after pull down with co-
expressed FlagM53 and wt M50. Although there may be differences in 
efficiency of the two pull down systems a more prominent role of M50/p35 in the 
LBR interaction can be suggested. 
Furthermore, similar results for interaction of M50/p35 and M53/p38 were 
obtained with LBR complex component p32 (Fig. 37). The p32 protein localizes 
to the mitochondrial matrix as well as to the nucleus and forms homo-trimers. It 
was shown to be involved in different cellular-but also viral processes and 
therefore may have multifunctional properties (Simos, 1994, Jiang, 1999; 
Sunayama, 2004; Muta 1997; Krainer, 1991; Luo, 1994; Matthews, 1998; Hall, 
2002). A phosphorylation of p32 by cellular and viral kinases is indicated 
(Simos, 1994; Marschall, 2005). Interestingly, we detected for p32 after pull 
down with Flag-tagged M53 or HA-tagged M50 a doubled band at 32/34 kDa for 
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p32. The lower p32-band was strongly induced using both pull down systems 
after isolated expression of the tagged viral MCMV egress proteins or co-
expression with the respective non-tagged partner. In contrast, the upper p32-
band was detectable only to some extent and remained uninduced in both 
assays after isolated expression of HAM50- or FlagM53 constructs. Moreover, 
HA-pull down after co-expression of HA-tagged M50 and wt M53 revealed an 
equal and strong induction of both p32-bands. After Flag-tag pull down of co-
expressed FlagM53 and wt M50 an induction of the upper p32 band could not 
be observed. Perhaps two modified isoforms of p32 exist that are able to 
interact with M53/p38 or M50/p35. As already mentioned, p32 can be 
phosphorylated. We therefore suggest that the induced upper p32-band 
represents the phosphorylated p32-isoform, which may interact with the NEC 
proteins M53/p38 and M50/p35 preferentially by binding to M50/p35. However, 
phosphorylation of p32 and its involvement in NEC formation need to be 
addressed in further experiments. 
In addition, several other cellular matrix proteins were tested for interaction with 
M50/p35 and M53/p38. Recently, it was shown that the human polyomavirus 
agnoprotein interacts with HP1 and presumably is responsible for HP1 
dissociation from the LBR and perturbation of the NE. This enables 
polyomavirus virions to egress from the nucleus (Okada, 2005). Like MCMV, 
the polyomavirus is a DNA virus. Therefore a similar nuclear egress mechanism 
for DNA viruses may exist. HP1 links LBR complex and chromatin by H3-H4 
interaction (Bartova, 2005; Gruenbaum, 2005). Furthermore, HP1 interacts with 
subtypes of linker-histone H1 (Daujat, 2005). But here we could show that 
HP1α neither binds to M50/p35 or M53/p38 nor to the M50-M53 complex. 
Therefore both MCMV proteins fulfill functions different from that of 
polyomavirus agnoprotein during nuclear egress. 
Next we tested the interaction of M50/35 or M50-M53 complex with the LEM 
domain protein MAN1. All yet identified LEM domain proteins in vertebrates 
exhibit direct interaction with A- and/or B-type lamins and are important for 
nuclear integrity (Fig. 37). Therefore, like the LBR complex, LEM domain 
proteins are possible targets of the MCMV egress machinery. They are variable 
in length and the majority is anchored in the INM. Besides binding to lamins all 
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LEM domain proteins directly bind to BAF dimers (barrier to autointegration 
factor) (Lee, 2001; Shumaker, 2001; Lin, 2000; Furukawa, 1999; Chu, 1998; 
Mansharamani, 2005; Dechat, 2004). Furthermore, LEM domain proteins 
exhibit binding to chromatin, which is mediated by BAF (Margalit, 2005; Tifft, 
2006, Haraguchi, 2001; Segura-Totten, 2002). BAF was shown to interact with 
histone H3 and linkerhistone H1 (Bengtsson, 2006; Montes De Oca, 2005). 
Therefore, an inter-connection of LBR complex and LEM domain proteins can 
be assumed. But to that end, using both pull down systems after isolated 
expression of HAM50 and FlagM53 or co-expression of the tagged proteins with 
the corresponding partners no interaction of MAN1 with the viral proteins was 
detectable. Other LEM domain- or LEM associated proteins, e.g. emerin, 
LAP2α, LAP2β and BAF are of further interest and need to be analyzed. 
For HSV-1 it was shown, that under certain conditions the M53/p38 homologue 
UL31 interacts with A-type lamins A and C (Simpson-Holley, 2004, 2005; 
Reynolds, 2004; Scott, 2001). Also for γ-herpesvirus EBV the UL31- and UL34 
homologues BFLF2 and BFRF1 were shown to interact with lamin B (Gonnella, 
2005). Therefore, the interaction of M53/p38 and M50/p35 with A-and B-type 
lamins was tested. In both pull down systems no direct interaction of lamin B or 
lamin A/C with the MCMV-NEC proteins was detectable. Thus, the results for 
the MCMV-NEC proteins could not confirm the lamin interactions described for 
α-herpesvirus HSV-1 and of γ-herpesvirus EBV. A divergent development of 
herpesviruses during evolution might be the reason for the variable results. We 
presume technical reasons since insufficient solubilization of matrix proteins can 
easily result in a non specific interaction. 
Next, the interaction of M53/p38 and M50/p35 with linker-histone H1 and 
histone H3 was tested. We could show that both histones are unable to bind to 
HAM50. In contrast, both, H3 and H1, directly interacted with FlagM53 and 
furthermore bound to the M53-M50 complex using both pull down systems. 
Moreover, in presence of the M53-M50 complex or isolated expressed 
pFlagM53 an additional protein co-precipitated with H1, which was missing for 
the controls. Histones H1 and H3 both interact via HP1 with the LBR complex 
and via BAF with the LEM domain proteins. Therefore, a critical role of M53/p38 
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or M53/p38 in complex with M50/p35 in chromatin re-organization can be 
assumed. 
The interaction of M53/p38 or M50/p35 with nuclear matrix proteins was only 
tested upon isolated expression of the NEC proteins. For the M53/p38- and 
M50/p35- homologues UL31 and UL34 of α-herpesvirus pseudorabies virus 
(PrV) it has been demonstrated that the expression of only the PrV-NEC 
proteins is apparently sufficient for formation of primary envelopment structures 
(Klupp, 2006). Nevertheless, the interactions of M53/p38 and M50/p35 with 
cellular matrix proteins need to be analyzed upon MCMV infection to confirm 
the results during infection conditions. 
Altogether, we could identify for the first time four interaction partners of the 
MCMV-NEC proteins: LBR, p32, H3 and H1. The complex of M53/p38 and 
M50/p35 was able to bind the listed cellular proteins, whereas in isolation only 
FlagM53 bound to H1 and H3. Therefore, as described for UL31 from HSV-1, 
also M53/p38 might be involved in chromatin reorganization (Reynolds, 2004). 
 
 
7. Basic proteomics to identify MCMV- and cellular NEC proteins 
 
We tried to confirm indicated cellular interaction partners of M53/p38 and 
M50/p35 by mass-spectrometric analysis. Therefore, cells transfected with 
pHAM50, pFlagM53 or co-transfected with HAM50 and FlagM53 were lysed 
and Flag-tag- or HA-tag pull down assay was performed. Proteins bound to the 
two matrices were eluted, separated by SDS-PAGE and analyzed by silver 
staining. Numerous interaction partners of M53/p38 and M50/p35 were 
indicated. Protein bands were isolated from the gel and analyzed by mass-
spectrometry, which was performed in cooperation with Arnd Kieser and 
Thomas Knöfel (GSF, Hämatologikum, München). We could identify both viral 
interaction partners. However, the amount of recovered protein was too low for 
a more detailed and specific analysis and reliable identification of the less 
prominent members of the protein complexes. The system needs to be 
improved and to be scaled up in future experiments. 
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EBV      Epstein-Barr virus 
EDTA ethylenediamine tetraacetic acid 
EGFP enhanced green fluorescent protein 
ER      endoplasmic reticulum 
et al.      Et alii (Lat.=and others) 
EtOH      ethanol 
FCS      fetal calf serum 
Fig      figure 
FITC      fluoresceinisocyanat 
FLP      flippase 
FRT FLP recognition target 
G guanine 
GFP      green fluorescent protein 
gp      glycoprotein 
h      hour(s) 
HA      hemagglutinin-tag 
HCMV     human CMV 
HSV      herpes simplex virus 
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kb      kilo bases 
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l      liter 
LB      Luria-Bertani medium 
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MCMV     mouse CMV 
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n.a.      not applicable 
NE      nuclear envelope 
NEC      nuclear egress complex 
NLS nuclear localization signal 
N nanometer 
OD      optical density 
ON      over night 
ONM      outer nuclear membrane 
ORF      open reading frame 
p.i.      post infection 
PAA      phoshonoacetic acid 
PAGE      polyacrylamide-gel electrophoresis 
PBS      phosphate buffered saline 
PCR      polymerase chain reaction 
Pen./ Strep.     penicillin/ streptomycin 
PFU      plaque forming unit 
PrV      pseudorabies virus 
RNA      ribonucleic acid 
rpm      rounds per minute 
RPMI    Roswell Park Memorial Institute 
RT      room temperature 
s      stop mutant(s) 
SDS      sodiumdodecylsulfate 
ST      strep-II-tag 
SV40      simian virus 40 
T      thymine 
tab.      Table 
TAE      Tris-acetate-EDTA 
TBST    Tris buffered saline with Tween 20 
TE      Tris/EDTA 
TEMED     N, N, N´, N´-tetramethylenediamine 
TCID tissue culture infective dose 
TM      transmembrane region 
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TR      texas red 
Tris      Tris(hydroxymethyl)aminomethan 
U      unit(s), enzyme activity 
V      volt 
v/v      volume/ volume 
VZV      Varicella Zoster virus 
w/v      weight/ volume 
wt      wild type 
µ      micro (10-6) 
µg      microgram 
µl      microliter 
µm      micrometer 
zeo      zeocin 
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A, Ala     alanine 
C, Cys     cysteine 
D, Asp     aspartic acid 
E, Glu     glutamic acid 
F, Phe     phenylalanine 
G, Gly      glycine 
H, His     histidine 
I, Ile     isoleucine 
K, Lys     lysine 
L, Leu     leucine 
M, Met     methionine 
N, Asn     asparagine 
P, Pro      proline 
Q, Gln     glutamine 
R, Arg     arginine 
S, Ser     serine 
T, Thr     threonine 
V, Val     valine 
W, Trp     tryptophan 
Y, Tyr     tyrosine 
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4. Primers used in this study
 
aThe recognition sequences of restriction endonuclease are underlined. 
 
Primer name 5´to 3´ sequencea
ieST1 TCGAGCGCTTGGTCCCACCCCCAGTTCGAGAAGTAGGG
GCC 
ieST2 CCTACTTCTCGAACTGGGGGTGGGACCAAGCGC 
M50Strep GTGTGCTCGAGGGATGACCCGCCGAACG 
5´-M53del  AGCCCGGAGGGAGAGGAACGGGACGCCGCCGACCGAG
AAGAGGACGATTTATTCAACAAAGCCACG 
3´-M53del  TATCAATAAAATACAACGTTGAACGACAGTCTCACACTGT
GTGCCTCGTCAGCCAGTGTTACAACCAATTAACC 
5´-AB6-02  CGCGGTACCATGTTTAGGAGC 
3´-AB7-02 CGCGGATCCTCACAACGAGTA 
5´-SapI-delN TCTCGCTCTTCCTTCTTCTTGGGCACACCGGTTCGGTCG
GCGGCGTCCCGT 
3´-Ndel-SapI GTGTGGCTCTTCAGAAGAGGAAAGTCTCCACCGGTGAGT
ATCTGAACGTGAAGC 
Flag1 CATGGATTACAAGGATGACGACGATAAGTTTAGGAGCCC
GGAGGGAGAGGAACGGGACGCCGCCGA 
Flag2 CGGTCGGCGGCGTCCCGTTCCTCTCCCTCCGGGCTCCT
AAACTTATCGTCGTCATCCTTGTAATCCATGGTAC 
NLS21 CCGGTGTGCCCAAGAAGAAGAGGAAAGTCTCCACCGGC
AT 
NLS22 CATGATGCCGGTGGAGACTTTCCTCTTCTTCTTGGGCAC
A 
Mutfor-  
-5´L112A GGGGGCTCTTCCGCCCATGACGTGTTTCAGAGACAT 
-5´H116A GGGGGCTCTTCCCGCCGACGTGTTTCAGAGACA 
-5´F119A GGGGGCTCTTCCGCTCAGAGACATCCCGACCTC 
-5´P123A GGGGGCTCTTCCGCCGACCTCGAACAGAAGTAC 
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Primer name 5´to 3´ sequencea
-5´D124A GGGGGCTCTTCCGCTCTCGAACAGAAGTACCTC 
-5´L125A GGGGGCTCTTCCGCCGAACAGAAGTACCTCAAG 
-5´E126A GGGGGCTCTTCCGCGCAGAAGTACCTCAAGATC 
-5´K128A GGGGGCTCTTCCGCCTACCTCAAGATCATGAAG 
-5´Y129A GGGGGCTCTTCCAGCGCTCAAGATCATGAAGCT 
-5´L130A GGGGGCTCTTCCGCCAAGATCATGAAGCTAC 
-5´YL129,130A GGGGGCTCTTCCGCCAAGATCATGAAGCTACCG 
-5´KYL128-130A GGGGGCTCTTCCGCGGCCAAGATCATGAAGCTACCG 
-5´ Delmo108-136 GGGGGCTCTTCCGCCAAGATCATGAAGCTACCG 
-5´M133A GGGGGCTCTTCCGCCAAGCTACCGATCACGGGC 
-5´I137A GGGGGCTCTTCCACCGGTAAGGAGTCGATCCGACTC 
Mutrev-  
-3´L112A GGGGGCTCTTCCGGCCTCAGAGAGCTTCACGTT 
-3´H116A GGGGGCTCTTCCGCGAGCTCAGAGAGCTTCACG 
-3´F119A GGGGGCTCTTCCAGCCACGTCGTGAAGCTCAGA 
-3´P123A GGGGGCTCTTCCGGCATGTCTCTGAAACACGTC 
-3´D124A GGGGGCTCTTCCAGCGGGATGTCTCTGAAACAC 
-3´L125A GGGGGCTCTTCCGGCGTCCGGATGTCTCTGAAACACG 
-3´E126A GGGGGCTCTTCCCGCAAGGTCGGGATGTCTCTG 
-3´K128A GGGGGCTCTTCCGGCCTGTTCGAGGTCGGGATG 
-3´Y129A GGGGGCTCTTCCGCTTTCTGTTCGAGGTCGGGA 
-3´L130A GGGGGCTCTTCCGGCGTACTTCTGTTCGAGGTC 
-3´YL129,130A GGGGGCTCTTCCGGCCGCTTTCTGTTCGAGGTC 
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Primer name 5´to 3´ sequencea
-3´KYL128-130A GGGGGCTCTTCCCGCGGCCTGTTCGAGGTCGGGATG 
-3´ Delmo108-136 GGGGGCTCTTCCGGCCTCAGAGAGCTTCACGTT 
-3´M133A GGGGGCTCTTCCGGCGATCTTGAGGTACTTCTG 
-3´I137A GGGGGCTCTTCCGGTGGCCGGTAGCTTCATGATCTT 
AB6-SpAs GGGACTAGTGGCGCGCCGGTACCATGTTTAGGAGC 
M53rev AGAGGTCCAGGCACGTGTG 
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